<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001951" GROUP_ID="SCHIZ" ID="663799082509322342" MERGED_FROM="" MODIFIED="2013-08-07 14:36:11 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="1" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2013-08-07 14:36:11 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Haloperidol dose for the acute phase of schizophrenia</TITLE>
<CONTACT MODIFIED="2013-08-07 14:36:11 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="95363346650509472274091208101902" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lorna</FIRST_NAME><LAST_NAME>Donnelly</LAST_NAME><POSITION>Consultant Psychiatrist</POSITION><EMAIL_1>lornadonnelly@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cambridge Street House</DEPARTMENT><ORGANISATION>NHS Lothian</ORGANISATION><ADDRESS_1>5-7 Cambridge Street</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH1</ZIP><REGION>Lothian</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>07861291789</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-08-07 14:36:11 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="95363346650509472274091208101902" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lorna</FIRST_NAME><LAST_NAME>Donnelly</LAST_NAME><POSITION>Consultant Psychiatrist</POSITION><EMAIL_1>lornadonnelly@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cambridge Street House</DEPARTMENT><ORGANISATION>NHS Lothian</ORGANISATION><ADDRESS_1>5-7 Cambridge Street</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH1</ZIP><REGION>Lothian</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>07861291789</PHONE_1></ADDRESS></PERSON><PERSON ID="BDA7003182E26AA2004D2786DC8C695A" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>Rathbone</LAST_NAME><POSITION>Systematic Reviewer</POSITION><EMAIL_1>J.Rathbone@sheffield.ac.uk</EMAIL_1><EMAIL_2>John.Rathbone@nottingham.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>HEDS, ScHARR</DEPARTMENT><ORGANISATION>The University of Sheffield</ORGANISATION><ADDRESS_1>Regent Court</ADDRESS_1><ADDRESS_2>30 Regent Street</ADDRESS_2><CITY>Sheffield</CITY><ZIP>S1 4DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 114 222 0890</PHONE_1><PHONE_2>+44 114 272 4095</PHONE_2></ADDRESS></PERSON><PERSON ID="8746" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Clive</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Adams</LAST_NAME><POSITION>Co-ordinating Editor</POSITION><EMAIL_1>clive.adams@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road,</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 8231274</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-01-29 12:22:56 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="2" MONTH="2" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="2" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2013-04-03 14:03:51 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-04-03 14:03:51 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>Conclusions changed after results from new trials assessed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-03 14:02:53 +0100" MODIFIED_BY="Clive E Adams">
<DATE DAY="7" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Substantial update with new trials and summary of findings.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-04-03 14:02:34 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-04-03 14:02:34 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="5" YEAR="2002"/>
<DESCRIPTION>
<P>Minor update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-04-03 14:02:31 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="9" YEAR="1999"/>
<DESCRIPTION>
<P>Reformatted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-06-05 10:34:49 +0100" MODIFIED_BY="Clive E Adams">
<INTERNAL_SOURCES MODIFIED="2013-01-29 12:29:51 +0000" MODIFIED_BY="Clive E Adams">
<SOURCE MODIFIED="2012-10-02 13:24:01 +0100" MODIFIED_BY="Clive E Adams">
<NAME>Norfolk and Suffolk Foundation Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-10-02 13:24:01 +0100" MODIFIED_BY="Clive E Adams">
<NAME>MHECCU, Department of Psychiatry, University of British Columbia</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-10-02 13:24:00 +0100" MODIFIED_BY="Clive E Adams">
<NAME>Iberoamerican Cochrane Centre</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-01-29 12:29:51 +0000" MODIFIED_BY="[Empty name]">
<NAME>University of Nottingham</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-06-05 10:34:49 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-06-05 10:34:49 +0100" MODIFIED_BY="[Empty name]">
<NAME>No external sources of support provided</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-08-07 14:33:13 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-08-07 14:29:55 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-06-20 13:45:33 +0100" MODIFIED_BY="[Empty name]">Haloperidol dose for the acute phase of schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2013-08-07 14:29:55 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a mental illness where the person often experiences both positive symptoms (such as hearing voices, seeing things and having strange beliefs) and negative symptoms (such as tiredness, apathy and loss of emotion). Antipsychotic drugs are used to treat schizophrenia. The antipsychotic drug, haloperidol, is one of the most frequently used drugs worldwide for people with schizophrenia.</P>
<P>The benefits of antipsychotic drugs, such as haloperidol, need to be weighed against their tendency for causing debilitating side effects (such as movement disorders, weight gain, lack of drive) and in some cases an increased likelihood of physical illnesses such as diabetes and heart disease. These debilitating side effects may mean that people stop taking their medication, which can lead to relapse and going into hospital. It is, therefore, important to find a tolerable and effective dose of haloperidol, which helps control the symptoms of schizophrenia but with fewer side effects.</P>
<P>The main aim of this review was to determine the best range of doses of haloperidol for the treatment of schizophrenia. Nineteen trials were included that compared varying doses of haloperidol. Despite over 30 years of trials, data on the effects of differing doses of haloperidol are sparse and poorly reported. This is especially so for the lower dose ranges generally used for the treatment of schizophrenia today. However, lower doses of haloperidol may be just as effective as higher doses but result in fewer side effects. This review also suggests that an important bias against haloperidol may exist in modern trials comparing new drugs with haloperidol. Results are not conclusive and are based on small, short studies of limited quality.</P>
<P>The authors of the review note that it would be understandable if psychiatrists were cautious about prescribing doses above 7.5 mg a day and if people with schizophrenia did not want to take higher dosages. Further research is needed to assess the tolerability and effectiveness of lower doses. Low doses of haloperidol may be just as good as higher doses, but with fewer side effects.</P>
<P>This plain language summary was written by a consumer, Benjamin Gray, Service User and Service User Expert. Rethink Mental Illness. Email: <A HREF="mailto:ben.gray@rethink.org">ben.gray@rethink.org</A>.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-08-07 14:28:11 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-06-26 10:59:08 +0100" MODIFIED_BY="Anne Lawson">
<P>Haloperidol is a benchmark, accessible antipsychotic drug against which the effects of newer treatments are gauged.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-08-07 14:26:32 +0100" MODIFIED_BY="Anne Lawson">
<P>To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-06-26 10:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Trials Register (February 2010), which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-06-26 10:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>We selected studies if they involved people being treated for acute schizophrenia, randomised to two or more dose ranges of non-depot haloperidol, and if they reported clinically meaningful outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-06-26 10:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we inspected all citations and independently re-inspected a sample of citations in order to ensure reliable selection. We resolved any disagreement by discussion, and where doubt remained, we acquired the full-text article for further inspection. We then ordered papers, and reliably re-inspected and quality assessed the full reports, and extracted data. For homogeneous dichotomous data, we calculated the risk ratio (RR) with 95% confidence intervals (CI) on an intention-to-treat (ITT) basis. We assumed that people who left the study early or were lost to follow-up had a negative outcome. We calculated mean differences (MD) for continuous outcomes that reported ITT, last observation carried forward (LOCF) data. We excluded data if loss to follow-up was greater than 50%.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-08-07 14:28:11 +0100" MODIFIED_BY="[Empty name]">
<P>We included 19 trials with 19 different randomised dose comparisons. No studies reported data on relapse rates or quality of life and only one compared low dose (&gt; 1.5 to 3 mg/day) haloperidol to higher dose ranges. Using standard lower dose (&gt; 3 to 7.5 mg/day) did not result in loss of efficacy (no clinically important improvement in global state, versus standard higher dose (&gt; 7.5 to 15 mg/day, n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.8, <I>very-low-quality evidence</I>); versus high dose (&gt; 15 to 35 mg/day, n = 81, 2 RCTs, RR 0.95, 95% CI 0.8 to 1.2, <I>very-low-quality evidence</I>). Doses of haloperidol in the range of &gt; 3 to 7.5 mg/day had a lower rate of development of clinically significant extrapyramidal adverse effects than higher doses (clinically significant extrapyramidal adverse effects, versus standard higher dose, n = 64, 2 RCTs, RR 0.12, 95% CI 0.01 to 2.1, <I>very-low-quality evidence</I>); versus high dose, n = 144, 3 RCTs, RR 0.59, 95% CI 0.5 to 0.8, very-low-quality evidence; versus very high dose (&gt; 35 mg/day, n = 86, 2 RCTs, RR 0.70, 95% CI 0.5 to 1.1, <I>very-low-quality evidence</I>). None of the other comparisons between dose ranges yielded statistically significant differences, but several, particularly with lower dose ranges, were underpowered to detect clinically meaningful differences.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-06-26 10:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>Noresults were conclusive and all were based on small, short studies of limited quality. However, it would be understandable if clinicians were cautious in prescribing doses in excess of 7.5 mg/day of haloperidol to a person with uncomplicated acute schizophrenia, and if people with schizophrenia were equally reticent to take greater doses. Further research is needed regarding the efficacy and tolerability of the lower dose ranges, especially &gt; 1.5 to 3 mg/day.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-08-07 14:33:13 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Antipsychotic medications are a mainstay of treatment for people with acute schizophrenia. These compounds are beneficial in the short to medium term course of the illness. For example, in a review of 45 randomised studies involving the oldest neuroleptic, chlorpromazine, there was a clinically significant reduction in a person's symptoms over placebo after six months of treatment (10 RCTs, n = 1123, RR 0.76, 95% CI 0.7 to 0.8) (<LINK REF="REF-Thornley--2002" TYPE="REFERENCE">Thornley 2002</LINK>). When haloperidol was compared with placebo, the findings were similar (8 RCTs, n = 313, RR 0.65, 95% CI 0.6 to 0.8) (<LINK REF="REF-Joy-2002" TYPE="REFERENCE">Joy 2002</LINK>). The value of these drugs for treating people with acute psychoses needs to be weighed against their tendency to induce significant adverse effects. In one chlorpromazine review, the risk of medication-related parkinsonism, such as tremor and stiffness, was significantly higher than placebo (10 RCTs, n = 1265, RR 2.0, 95% CI 1.5 to 2.7, NNTH 10, 95% CI 8 to 16) (<LINK REF="REF-Thornley--2002" TYPE="REFERENCE">Thornley 2002</LINK>). This was also the case in one haloperidol review (4 RCTs, n = 165, RR 8.9, 95% CI 2.6 to 31, NNTH 3, 95% CI 2 to 5) (<LINK REF="REF-Joy-2002" TYPE="REFERENCE">Joy 2002</LINK>). Such adverse effects are a cause for concern to people with schizophrenia and their clinicians.</P>
<P>Intolerable effects can lead to the premature discontinuation of drugs and result in an increase in potentially damaging relapses of acute symptoms of schizophrenia (<LINK REF="REF-Hansen-1997" TYPE="REFERENCE">Hansen 1997</LINK>; <LINK REF="REF-Marder-1998" TYPE="REFERENCE">Marder 1998</LINK>). Therefore, various means of minimising adverse effects have been sought (<LINK REF="REF-Bezchlibnyk-1994" TYPE="REFERENCE">Bezchlibnyk 1994</LINK>; <LINK REF="REF-De-Oliveira-1996" TYPE="REFERENCE">De Oliveira 1996</LINK>; <LINK REF="REF-Leucht-1999" TYPE="REFERENCE">Leucht 1999</LINK>; <LINK REF="STD-McEvoy-1991" TYPE="STUDY">McEvoy 1991</LINK>). The focus of this review will be one specific means of avoiding adverse effects, the determination of a tolerable yet effective dose range of a specific drug. This is often termed the dose-response relationship (<LINK REF="REF-Miller-1997" TYPE="REFERENCE">Miller 1997</LINK>). We have also chosen to focus this review on a specific antipsychotic agent, haloperidol, which continues to be among the most frequently used drugs for people with schizophrenia worldwide (<LINK REF="REF-Baldessarini-1995" TYPE="REFERENCE">Baldessarini 1995</LINK>; <LINK REF="REF-Johnson-1993" TYPE="REFERENCE">Johnson 1993</LINK>; <LINK REF="REF-Kiivet-1995" TYPE="REFERENCE">Kiivet 1995</LINK>; <LINK REF="REF-Raschetti-1993" TYPE="REFERENCE">Raschetti 1993</LINK>; <LINK REF="REF-Williams-1999" TYPE="REFERENCE">Williams 1999</LINK>) and haloperidol remains a comparison agent of choice for clinical drug trials of novel agents (<LINK REF="REF-Awad-1993" TYPE="REFERENCE">Awad 1993</LINK>; <LINK REF="REF-Thornley-1998" TYPE="REFERENCE">Thornley 1998</LINK>).</P>
<P>The development of the so-called second-generation antipsychotics has changed how schizophrenia is treated. Studies have shown these drugs to be a heterogeneous group (<LINK REF="REF-Davis-2003" TYPE="REFERENCE">Davis 2003</LINK>; <LINK REF="REF-Gardner-2005" TYPE="REFERENCE">Gardner 2005</LINK>). Clozapine, amisulpride, risperidone and olanzapine antipsychotics are more efficacious than first-generation antipsychotics and produce a better functional recovery making them cost effective (<LINK REF="REF-Davis-2003" TYPE="REFERENCE">Davis 2003</LINK>). A lesser propensity to cause extrapyramidal side effects is another benefit of second-generation over first-generation drugs, but this must be balanced against metabolic, endocrine and cardiovascular effects (<LINK REF="REF-Gardner-2005" TYPE="REFERENCE">Gardner 2005</LINK>).</P>
<CONDITION MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a chronic, relapsing mental illness and has a worldwide lifetime prevalence of about 1% irrespective of culture, social class and race. The acute phase of schizophrenia is the florid psychotic phase, during which the patient exhibits acute symptoms that can include positive symptoms (such as delusions, hallucinations, disorganised thinking and speech), or more profound negative symptoms (such as flattened affect, alogia and avolition), or both positive and negative symptoms. Twenty-five per cent of those who have experienced an episode of schizophrenia recover and the illness does not recur. Another 25% experience an unremitting illness. Fifty per cent do have a recurrent illness but with long episodes of considerable recovery from the positive symptoms. Current medication is effective in reducing positive symptoms, but negative symptoms are fairly resistant to treatment. In addition, drug treatments are associated with adverse effects and the overall cost of the illness to the individual, their carers and the community is considerable.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Haloperidol is a 'typical' or 'older-generation' antipsychotic. It is a butyrophenone derivative. It was discovered by Paul Janssen and developed by Janssen Pharmaceuticals in Belgium in 1958; however, it was not approved for use in the US until 1967. Haloperidol remains a widely used antipsychotic although the development of 'atypical' antipsychotic agents has seen a decrease in its use in developed countries. It is only one of three antipsychotic drugs on the World Health Organizations Essential Drug List (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>The mechanism of action of haloperidol is not entirely understood but it is thought that its high affinity for the D<SUB>2</SUB> subtype of dopamine receptor in the mesocortex and limbic systems of the brain is responsible for its efficacy in treating positive symptoms of schizophrenia. There is a marked tendency to produce extrapyramidal effects, which is thought to be due to its antidopaminergic action in the nigrostriatal pathways.</P>
<P>Haloperidol has relatively minor antihistamine and anticholinergic properties. It has strong sedative properties. The peripheral actions of haloperidol are thought to be responsible for its antiemetic properties and its potential to cause hyperprolactinaemia.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>There are already important reviews that pool data on the combined dose-response relationship of various typical antipsychotic agents and that incorporate some data on haloperidol. One review proposed an optimum dosage range of 10 to 15 mg/day haloperidol or the equivalent of such a dose when using other antipsychotics (<LINK REF="REF-Baldessarini-1988" TYPE="REFERENCE">Baldessarini 1988</LINK>). This review summarised randomised controlled trial data combined with information from studies using other methodologies. Another systematic review looking at antipsychotic neuroleptic dose for maintenance management of people with schizophrenia employed systematic review techniques and examined data from randomised controlled trials up to June 1989 (<LINK REF="REF-Bollini-1994" TYPE="REFERENCE">Bollini 1994</LINK>). The conclusion reached was that there was no benefit from using doses higher than 375 mg/day of chlorpromazine or the equivalent of such a dose when using other antipsychotics (about 7.5 mg/day of haloperidol).</P>
<P>There are several reasons for a study to complement this previous work. First, previous reviews need to be updated with data from more recent trials. Second, the use of conversion factors to pool data from studies of different antipsychotics is not based on rigorous evidence and different means of comparing drugs are currently in evolution (<LINK REF="REF-Awad-1993" TYPE="REFERENCE">Awad 1993</LINK>; <LINK REF="REF-Kane-1996" TYPE="REFERENCE">Kane 1996</LINK>; <LINK REF="REF-Kapur-1998" TYPE="REFERENCE">Kapur 1998</LINK>). Thus, this review summarises data from trials investigating the dose-response relationship of haloperidol alone. Third, several new agents have been developed that are not significantly different from placebo with regard to important adverse effects such as parkinsonism (<LINK REF="REF-Leucht-1999" TYPE="REFERENCE">Leucht 1999</LINK>). This has led to the recommendation of these agents as first-line treatments for acute schizophrenia (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>; <LINK REF="REF-CPA-1998" TYPE="REFERENCE">CPA 1998</LINK>). Using the cost of mean clinical doses as a basis for comparison, these novel drugs have the drawback of being significantly more expensive than agents such as haloperidol (<LINK REF="REF-Awad-1999" TYPE="REFERENCE">Awad 1999</LINK>; <LINK REF="REF-Glazer-1998" TYPE="REFERENCE">Glazer 1998</LINK>; <LINK REF="REF-Zito-1998" TYPE="REFERENCE">Zito 1998</LINK>). There is need for a systematic review to determine whether an optimum dosage of the less costly drugs may minimise adverse effects with no significant decrease in clinical efficacy. Finally, many trials of novel agents do not report a clear justification for the dose of reference drug that they choose. They have frequently used doses well in excess of the maximum levels recommended by <LINK REF="REF-Bollini-1994" TYPE="REFERENCE">Bollini 1994</LINK> and <LINK REF="REF-Baldessarini-1995" TYPE="REFERENCE">Baldessarini 1995</LINK>. Using a higher dose of the reference drug, frequently haloperidol, may have biased results in favour of the novel agent due to differential attrition or the promotion of adverse effects in the control arm of the study (<LINK REF="REF-Awad-1993" TYPE="REFERENCE">Awad 1993</LINK>; <LINK REF="REF-Jadad-1999" TYPE="REFERENCE">Jadad 1999</LINK>). An accurate estimate of a dose range for specific reference drugs that defines an optimum balance between adverse effects and efficacy is urgently needed to serve as a 'gold standard' for future comparative studies. Haloperidol continues to be used as a comparative agent in trials of novel antipsychotics such as lurasidone (<LINK REF="REF-Citrome-2011" TYPE="REFERENCE">Citrome 2011</LINK>).</P>
<P>Once a decision had been made to undertake a review focusing on the dose-response of haloperidol, it was important for the review authors to define specific dose ranges to be used. The review authors selected dose ranges (&gt; 0.25 to 1.5 mg/day, &gt; 1.5 to 3 mg/day, &gt; 3 to 7.5 mg/day, &gt; 7.5 to 15 mg/day, &gt; 15 to 35 mg/day and &gt; 35 mg/day) that were considered to reflect patterns of clinical use (<LINK REF="REF-Baldessarini-1984" TYPE="REFERENCE">Baldessarini 1984</LINK>; <LINK REF="REF-Reardon-1989" TYPE="REFERENCE">Reardon 1989</LINK>), research using positron emission tomography (PET) studies (<LINK REF="REF-Kapur-1996" TYPE="REFERENCE">Kapur 1996</LINK>; <LINK REF="REF-Kapur-1997" TYPE="REFERENCE">Kapur 1997</LINK>; <LINK REF="REF-Kapur-1998" TYPE="REFERENCE">Kapur 1998</LINK>), the findings of previous reviews (<LINK REF="REF-Baldessarini-1988" TYPE="REFERENCE">Baldessarini 1988</LINK>; <LINK REF="REF-Bollini-1994" TYPE="REFERENCE">Bollini 1994</LINK>; <LINK REF="REF-Leucht-1999" TYPE="REFERENCE">Leucht 1999</LINK>), and the recommendations of treatment guidelines (<LINK REF="REF-Geddes-1999" TYPE="REFERENCE">Geddes 1999</LINK>). This review also investigates only within-study comparisons - where one group of participants has been randomised to two or more dose ranges - and not cross-study comparisons. In cross-study comparisons, many variables, such as participant group or clinical setting, may be so radically different as to make comparison fraught with difficulty.</P>
<P>Having underlined the need to review a specific drug in predefined dose ranges using multiple dose studies only, the final major factor to discuss was duration of treatment. The review authors did not consider that pooling data where treatment can vary from less than 24 hours' duration to more than six months' duration was justifiable. It has been well established that the efficacy and rate of adverse effects with antipsychotic drugs vary depending on the treatment duration (<LINK REF="REF-Conley-1997" TYPE="REFERENCE">Conley 1997</LINK>; <LINK REF="REF-Kane-1996" TYPE="REFERENCE">Kane 1996</LINK>). Therefore, the review authors defined four treatment durations (3 days to &lt; 2 weeks, 2 weeks to 10 weeks, &gt; 10 weeks to 6 months, &gt; 6 months) to reflect various findings on the course of treatment response (<LINK REF="STD-Garver-1984" TYPE="STUDY">Garver 1984</LINK>; <LINK REF="REF-Hogarty-1973" TYPE="REFERENCE">Hogarty 1973</LINK>; <LINK REF="REF-Hogarty-1974" TYPE="REFERENCE">Hogarty 1974</LINK>; <LINK REF="REF-Levy-1996" TYPE="REFERENCE">Levy 1996</LINK>; <LINK REF="REF-Lieberman-1993" TYPE="REFERENCE">Lieberman 1993</LINK>; <LINK REF="REF-Milton-1995" TYPE="REFERENCE">Milton 1995</LINK>).</P>
<P>Several factors may affect results of a review that uses data from trials conducted across a wide time span in many different settings. Variables such as participant age, sex and phase of illness, may substantially differ between studies and affect the size or even direction of outcomes. As diagnostic criteria for schizophrenia have varied over the years (<LINK REF="REF-Awad-1993" TYPE="REFERENCE">Awad 1993</LINK>), a sensitivity analysis for only the primary outcomes (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) was performed for whether formal diagnostic criteria were used or not. The review authors also performed sensitivity analysis for studies whose participants had schizophrenia defined as first episode or treatment resistant to determine if they differed in their treatment response from other people with schizophrenia.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="Anne Lawson">
<P>To determine the dose-response relationships for haloperidol, at a range of treatment durations, in the treatment of people with schizophrenia experiencing an acute phase of their illness.</P>
<P>It was also proposed to see if:<BR/>1. people whose illnesses were diagnosed using operational criteria, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD), differed in their treatment response from people with informally derived diagnoses;</P>
<P>2. people whose illness was defined as first episode or treatment resistant differed in their treatment response from other people with schizophrenia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-06-26 12:05:27 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>We included all relevant randomised controlled trials. We included any trials that were described as 'double-blind' where it was implied that the studies were randomised and the demographic details of each group were similar. We excluded quasi-randomised studies, such as those allocated by using alternate days of the week. The duration of studies included in this review needed to be a minimum of three days.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>We included people with schizophrenia or similar serious, non-affective psychosis diagnosed by any criteria irrespective of gender, age, or race. If a trial included people with other mental illnesses, we accepted it for inclusion if greater than 50% of participants had serious functional psychotic illnesses such as schizophrenia, but we excluded studies if greater than 33% of people were experiencing an affective psychosis. We considered people to be in the acute phase of schizophrenia if they were experiencing an exacerbation in their baseline level of symptoms, or if they had active symptoms and were currently hospitalised. We excluded studies where greater than 50% of people were considered to be healthy, or were described as undergoing maintenance, or dose reduction treatment.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Drug dosages</HEADING>
<P>1. Haloperidol: dose greater than 0.25 mg/day to 1.5 mg/day (ultra low dose).<BR/>2. Haloperidol: dose greater than 1.5 mg/day to 3 mg/day (low dose).<BR/>3. Haloperidol: dose greater than 3 mg/day to 7.5 mg/day (standard lower dose).<BR/>4. Haloperidol: dose greater than 7.5 mg/day to 15 mg/day (standard higher dose).<BR/>5. Haloperidol: dose greater than 15 mg/day to 35 mg/day (high dose).<BR/>6. Haloperidol: dose greater than 35 mg/day (very high dose).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Plasma levels</HEADING>
<P>1. Haloperidol: plasma level greater than 1.4 to 3.5 ng/mL (very low plasma levels).<BR/>2. Haloperidol: plasma level greater than 3.5 to 7 ng/mL (low plasma levels).<BR/>3. Haloperidol: plasma level greater than 7.0 to 16.5 ng/mL (medium plasma levels).<BR/>4. Haloperidol: plasma level greater than 16.5 ng/mL (high plasma levels).</P>
<P>We included any means of administration with the exception of depot.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>We divided outcomes into the following time periods:</P>
<UL>
<LI>three days to less than two weeks;</LI>
<LI>two weeks to 10 weeks * </LI>
<LI>greater than 10 weeks to six months;</LI>
<LI>greater than six months.</LI>
</UL>
<P>* (timescale for primary outcomes of interest)</P>
<P>If data on more than one time point within these time periods were available, we used the duration closest to the middle of the time period. For the greater than six months period, we used the longest available time period.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-06-20 14:56:20 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Leaving the study early</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Clinical response</HEADING>
<P>2.1 No clinically significant response in global state</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Extrapyramidal adverse effects</HEADING>
<P>3.1 No clinically significant extrapyramidal adverse effects</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Behaviour</HEADING>
<P>4.1 Clinically significant agitation</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Mortality, any cause</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Clinical response</HEADING>
<P>2.1 Mean score/change in global state<BR/>2.2 Clinically significant change in mental state<BR/>2.3 No clinically significant response in psychotic symptoms<BR/>2.4 Mean score/change in psychotic symptoms<BR/>2.5 No clinically significant response in positive symptoms<BR/>2.6 Mean score/change in positive symptoms<BR/>2.7 No clinically significant response in negative symptoms<BR/>2.8 Mean score/change in negative symptoms<BR/>2.9 Relapse</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Extrapyramidal adverse effects</HEADING>
<P>3.1 Use of any antiparkinsonism drugs<BR/>3.2 Mean score/change in extrapyramidal adverse effects<BR/>3.3 Tardive dyskinesia<BR/>3.4 Acute dystonia<BR/>3.5 Akathisia</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Other adverse effects, general and specific</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Hospital and service utilisation outcomes</HEADING>
<P>5.1 Hospital admission<BR/>5.2 Mean change in days in hospital<BR/>5.3 Improvement in hospital status (e.g. change from formal to informal admission status, use of seclusion, level of observation)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Economic outcomes</HEADING>
<P>6.1 Mean change in total cost of medical and mental health care<BR/>6.2 Total indirect and direct costs</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Quality of life/satisfaction with care for either recipients of care or carers</HEADING>
<P>7.1. No significant change in quality of life/satisfaction<BR/>7.2 Mean score/change in quality of life/satisfaction</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Behaviour</HEADING>
<P>8.1 Use of adjunctive medication for sedation<BR/>8.2 Aggression to self or others</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Cognitive response</HEADING>
<P>9.1 No clinically important change<BR/>9.2 No change, general and specific</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cochrane Schizophrenia Group Trials Register</HEADING>
<P>The Trials Search Co-ordinator of the Cochrane Schizophrenia Group searched the Cochrane Schizophrenia Group Trials Register (February 2010) with the phrase:<BR/>
<BR/>[(*dosage-effect* or *dose-activity* or *dose-dependence* or *dose-effect* or *dose-rate* or *dose-response* or *dosage-scheme* or *drug-response* or *effective-dose* or *dose-finding* or *dose-calculation* or *therapeutic-equivalency* or *blood-level* or *blood-drug* or *serum-level* or *serum-drug* or *plasma-level* or *plasma-drug* or *high-dos* or *low-dos* or *medium-dos* or *standard-dos* or *middle-dos* or *maximum-dos* or *minimum-dos* or *threshold-dos*) AND (*haloperi* or *R-1625* or *haldol* or *alased* or *aloperidi* or *bioperido* or *buterid* or *ceree* or *dozic* or *duraperido* or *fortuna* or *serena* or *serenel* or *seviu* or *sigaperid* or *sylad* or *zafri*) in title abstract and index terms of reference) OR (*haloperidol* and dosage*) in intervention of STUDY]</P>
<P>Previous search strategies are shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cited reference searching</HEADING>
<P>We inspected the references of all identified trials for more studies. Each of the included studies was sought as a citation on the SCISEARCH database. We inspected reports of articles that had cited these studies in order to identify further trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Search of other Cochrane reviews</HEADING>
<P>We reviewed the included studies of other Cochrane reviews involving haloperidol for potential inclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Personal contact</HEADING>
<P>We contacted the primary authors of all studies initially selected for inclusion, as well as the authors of Cochrane haloperidol reviews, in order to identify further relevant trials. We also contacted companies producing relevant compounds for copies of published, unpublished, and archived trials.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-06-26 12:05:27 +0100" MODIFIED_BY="[Empty name]">
<P>For details of previous data collection and analysis methods see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<STUDY_SELECTION MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, one review author (LD) inspected all abstracts. LD used a random number generator program to select a sample of 10% of all abstracts. CEA then re-inspected this sample in order to allow selection to be reliable. We resolved any disagreement by discussion, or where there was still doubt, we acquired the full-text article for further inspection. We obtained full-text articles of relevant reports and two review authors (LD and CEA) independently decided whether they met the review criteria. We resolved any disagreement by discussion, and, when this was not possible, we sought further information from the study authors. We excluded studies that appeared to meet all inclusion criteria but had no extractable outcomes pending further information from the study authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-06-26 12:05:27 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>LD extracted data from all included studies. CEA independently extracted data from a sample to ensure reliability. Again, we resolved any disagreements by discussion. We extracted data presented in graphs and figures whenever possible, as well as that reported clearly in text.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, and are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore, we included continuous data from rating scales only if the measuring instrument had been described in a peer-reviewed journal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>Where both final endpoint data and change data were available for the same outcome category, we presented only final endpoint data. We acknowledge that by doing this, much of the published change data may be excluded, but argue that endpoint data are more clinically relevant and that if change data were to be presented along with endpoint data, it would be given undeserved equal prominence. We have contacted authors of studies reporting only change data and requested endpoint figures.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on outcomes in mental health trials are often not normally distributed. To avoid applying parametric tests to non-parametric data, we applied the following standards to all endpoint data derived from continuous measures. The criteria were used before inclusion: (a) standard deviations (SD) and means had to be obtainable; and, for finite scores, such as endpoint measures on rating scales, (b) the SD, when multiplied by two had to be less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution) (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). If a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210), the calculation described above in (b) should be modified to take the scale starting point into account. In these cases, skew is present if 2 SD &gt; (S - Smin), where S is the mean score and Smin is the minimum score.</P>
<P>Skewed endpoint data from studies with fewer than 200 participants were not shown graphically, but were added to 'Other data' tables and briefly commented on in the text. However, skewed endpoint data from larger studies (&#8805; 200 participants) pose less of a problem and we entered the data for analysis.</P>
<P>For continuous mean change data (endpoint minus baseline), the situation is even more problematic. In the absence of individual patient data, it is impossible to know if change data are skewed. The Review Manager 5 meta-analyses of continuous data are based on the assumption that the data are, at least to a reasonable degree, normally distributed (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). Therefore, we included such data, unless endpoint data from the same scale were also reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Conversion of continuous to binary</HEADING>
<P>Where possible, we attempted to convert outcome measures into binary data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS) (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>; <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). For many people, especially those with chronic or severe illness, a less rigorous definition of important improvement (e.g. 25% on the BPRS) would be equally valid. If individual patient data were available, we used the 50% cut-off point for non-chronically ill people and a 25% cut-off point for those with chronic illness. If data based on these thresholds were not available, we used the primary cut-off presented by the original study authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Management of dose-response studies other than fixed-dose studies</HEADING>
<P>We gave careful consideration to determining a methodology on how to combine studies that used alternate methods of dose allocation, for example plasma studies, neuroleptic threshold studies. We converted the thresholds for dosage groups into plasma thresholds using data from PET research (<LINK REF="REF-Kapur-1996" TYPE="REFERENCE">Kapur 1996</LINK>). These indicated that a 2.1 mg oral dose was approximately equivalent to a 1 ng/mL plasma level. The thresholds for plasma dose ranges in nanograms per millilitre are outlined in <LINK TAG="CRIT_INTERVENTIONS" TYPE="SECTION">Types of interventions</LINK>. This approach was affirmed using data from another study (<LINK REF="STD-Volavka-1995" TYPE="STUDY">Volavka 1995</LINK>), which reported both oral dose and plasma levels, and there was 100% correspondence between oral dose range allocation and plasma dose allocation using this method.</P>
<P>We classified treatment arms from neuroleptic threshold and other flexible-dose range studies in the same dose ranges as fixed-dose studies. The criteria used were the following: if the mean dose plus or minus the 50% confidence interval (CI) fell within the predefined fixed-dose range, or if at least 50% of people in a dose arm had received doses within the prespecified ranges, the flexible treatment arm was considered equivalent to the corresponding fixed-dose treatment arm. If the dose range from a treatment arm met none of the criteria, then data related to that arm of the study were not extracted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Management of co-interventions</HEADING>
<P>We excluded studies that involved randomisation to combined treatments of neuroleptic with additional known psychoactive treatments. We did not exclude studies that allowed for use of other forms of intervention on an 'as needed' basis, or as part of routine clinical practice.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.8 Management of multiple time periods</HEADING>
<P>If data on more than one time point within prespecified time periods were available, we used the duration closest to the middle of the time period. For the greater than six-month period, we used the longest available time period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.9. Management of multiple doses</HEADING>
<P>If data were available for more than one dose within the prespecified dosage ranges, we pooled the data from these two doses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.10 Clinically significant outcomes</HEADING>
<P>Several outcomes were prefixed by the term 'clinically significant'. Wherever possible, we utilised the definition of the authors of the study to define this concept. Where the authors were not specific, we determined that any circumstance that would have led to a significant change in clinical management (e.g. intolerable adverse effects, use of adjunctive medication) was considered clinically significant. For continuous outcomes, we considered a 40% change to be clinically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.11 'Summary of findings' table</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>), and used GRADE profiler (<A HREF="http://www.ims.cochrane.org/revman/gradepro">GRADEPRO</A>), to import data from Review Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision making. We considered treatment with a standard lower dose (&gt; 3 to 7.5 mg/day) versus other doses and selected the following main outcomes for inclusion in the 'Summary of findings' table:</P>
<P>1. Leaving the study early;<BR/>2. Clinical response;<BR/>2.1 No clinically significant response in global state;<BR/>3. Extrapyramidal adverse effects;<BR/>3.1 No clinically significant extrapyramidal adverse effects;<BR/>4. Behaviour;<BR/>4.1 Clinically significant agitation.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-06-26 10:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed risk of bias using the tool described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases.</P>
<P>If disputes arose as to which category a trial had to be allocated, we resolved them by discussion, after working with a third review author.</P>
<P>Earlier versions of this review used a different, less well-developed, means of categorising risk of bias (<LINK REF="REF-Waraich-2002" TYPE="REFERENCE">Waraich 2002</LINK>; see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1 Binary data</HEADING>
<P>For binary outcomes, we calculated the risk ratio (RR) and its 95% CI based on the fixed-effect model. RR is more intuitive than odds ratios (OR) (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>), and ORs tend to be interpreted as RRs by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. The number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH) with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and interpretation (<LINK REF="REF-Hutton-2009" TYPE="REFERENCE">Hutton 2009</LINK>). For binary data presented in the 'Summary of findings' tables, where possible, we calculated illustrative comparative risks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes, estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of considerable similarity are used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ cluster randomisation (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. First, authors often do not account for intraclass correlation (ICC) in clustered studies, leading to a unit-of-analysis error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>), whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes Type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering had not been accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will contact first authors of studies to obtain ICCs of their clustered data and to adjust for this using standard methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a design effect. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1 + (m - 1) *ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported, we assumed it to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>). If cluster studies had been appropriately analysed taking into account ICCs and relevant data documented in the report, we combined these with other studies using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over design</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a washout phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are likely in schizophrenia, we only used data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, we did not reproduce these data.<BR/>
</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Leaving the study early</HEADING>
<P>We excluded data from studies where more than 50% of participants in any group were lost to follow-up (this did not include the outcome of 'leaving the study early'), as such data were considered to be too prone to bias. In studies with less than 50% dropout rate, people leaving early were considered to have had a negative outcome, except for the event of death, and dropouts that were clearly attributable to clinical improvement. We analysed the impact of including studies with high attrition rates (25% to 50%) in a sensitivity analysis. If inclusion of data from this latter group resulted in a substantive change in the estimate of effect, we did not add their data to trials with less attrition, but presented them separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management of deaths</HEADING>
<P>When analysing loss of contacts in studies where deaths had occurred, the 'type' of death affected analysis. Deaths as a result of 'natural causes' were not counted as losses of contact and the number of deaths reduced the size of treatment or control groups. However, we counted suicides or suspicious deaths as loss to follow-up and their data were incorporated into the analysis.</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>First, we considered all the included studies within any comparison to judge for clinical heterogeneity. Then we visually inspected graphs to investigate the possibility of statistical heterogeneity. We supplemented this by using primarily the I<SUP>2</SUP> statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I<SUP>2</SUP> estimate was greater than or equal to 50%, we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If inconsistency remained high, and substantially altered the results, we did not add those studies responsible for heterogeneity to the main body of homogeneous trials. We summated the heterogeneous studies and presented them separately and reasons for heterogeneity investigated.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in Section 10.1 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.<BR/>
</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible we used a fixed-effect model for analyses. We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. However, this seems true to us, as random effects put added weight onto the smaller studies - those trials that are most vulnerable to bias.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>When we found heterogeneous results, we investigated the reasons for this. Where heterogeneous data substantially altered the results and the reasons for the heterogeneity were identified, we did not summate these studies in the meta-analysis, but presented them separately and discussed them in the text.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>LD and CEA selected trials that involved people whose illnesses were diagnosed using operational criteria. We also selected trials that involved people whose illnesses were defined as first episode or treatment resistant at the data extraction stage of the review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-06-26 12:45:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of studies see: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>In this update, we identified 1494 citations in the search, and excluded 1421 because they were not controlled, not randomised or quasi-randomised, did not primarily involve people with schizophrenia, did not include acutely ill people, were not studies of antipsychotics, involved only one dose of medication, were comparing two doses of an antipsychotic drug but not haloperidol or were duplicate reports of the same trial. Thus, 73 studies remained for the final stage of inclusion/exclusion (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). CEA independently assessed a 10% random sample of the original 1494 citations for inclusion/exclusion. LD and CEA agreed on inclusion/exclusion for this 10% sample.</P>
<P>Details of citations identified and subsequent processing in the original <LINK REF="REF-Waraich-2002" TYPE="REFERENCE">Waraich 2002</LINK> review are shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> for results of the original 2002 review.</P>
<P>We included three further studies following this update (<LINK REF="STD-Curtis-1995" TYPE="STUDY">Curtis 1995</LINK>; <LINK REF="STD-Khanna-1997" TYPE="STUDY">Khanna 1997</LINK>; <LINK REF="STD-Oosthuizen-2004" TYPE="STUDY">Oosthuizen 2004</LINK>), giving 19 studies in the review. The included studies dated between 1967 and 2004.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Length of studies</HEADING>
<P>The longest study was 10 weeks (<LINK REF="STD-Liang-1987" TYPE="STUDY">Liang 1987</LINK>), the shortest was six days (<LINK REF="STD-Neborsky-1981" TYPE="STUDY">Neborsky 1981</LINK>). Most studies were between three and six weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Participants</HEADING>
<P>The largest study involved 132 people (<LINK REF="STD-Volavka-1992" TYPE="STUDY">Volavka 1992</LINK>), the smallest (<LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK>) only 16 people. Only three of the included trials did not report stringent criteria for the diagnosis of schizophrenia (<LINK REF="STD-Curtis-1995" TYPE="STUDY">Curtis 1995</LINK>; <LINK REF="STD-Donlon-1980" TYPE="STUDY">Donlon 1980</LINK>; <LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK>). In the other studies, diagnoses were established by structured interviews or clinical examination by a psychiatrist and the diagnostic criteria applied included Research Diagnostic Criteria (RDC), ICD and DSM.</P>
<P>Although sometimes demographic data were missing, participants tended to be acutely ill men or women in their 20s or 30s. People had often been recently admitted to hospital, although some studies included acutely ill people who had been in hospital for months or years. Most studies involved people who had been ill before and for some time. One study used subjects with a first episode of psychosis (<LINK REF="STD-Oosthuizen-2004" TYPE="STUDY">Oosthuizen 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Interventions</HEADING>
<P>Doses of haloperidol varied from a low of 1 mg/day (<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK>) to a high of up to 100 mg/day (<LINK REF="STD-Donlon-1980" TYPE="STUDY">Donlon 1980</LINK>). Doses were commonly fixed, perhaps preceded by a titration up to the final dose, and were given orally. The most common comparison (5/13) was standard higher dose (&gt; 7.5 to 15 mg/day) versus high dose (&gt; 15 to 35 mg/day).</P>
<P>One study had grouped participants in such a way that the control group straddled both our standard higher and high intervention group (<LINK REF="STD-Louza-1988" TYPE="STUDY">Louza 1988</LINK>). Four out of 19 randomised trials focused on plasma levels rather than dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Outcomes</HEADING>
<P>All included studies, with the exception of <LINK REF="STD-Curtis-1995" TYPE="STUDY">Curtis 1995</LINK>, reported 'leaving the study early' and most reported usable data on global state. Definitions of 'no clinically significant improvement' differed across studies. It was difficult to decide whether the results concerning clinical improvement were comparable. It seemed unlikely, however, that those judging improvement would have applied such dramatically differing criteria as to make summation inappropriate, especially given that analysis was restricted to randomised comparisons only. Further, if convergence of effects occurs despite differing methods, this may enhance the applicability of findings.</P>
<P>Mental state was reported in a form that was useful for this review in 11 of the included studies, and some adverse effects were clearly reported in 12 studies. All scale-derived data that we were able to present were from two studies (<LINK REF="STD-Oosthuizen-2004" TYPE="STUDY">Oosthuizen 2004</LINK>; <LINK REF="STD-Rifkin-1991" TYPE="STUDY">Rifkin 1991</LINK>).</P>
<P>We describe scales used by included studies to collect data.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Clinical Global Impression</HEADING>
<P>Clinical Global Impression (CGI) is a rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. Generally, a seven-point scoring system is used, with low scores indicating decreased severity or greater recovery, or both (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 Schedule for Affective Disorders and Schizophrenia</HEADING>
<P>Schedule for Affective Disorders and Schizophrenia (SADS) makes use of collateral information and past history. It rates symptoms at their highest level of severity over the previous week. Used serially, it provides a detailed record of the individual's progress. Greater scores indicate more severe symptoms (<LINK REF="REF-Endicott-1978" TYPE="REFERENCE">Endicott 1978</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3 Simpson and Angus Scale</HEADING>
<P>Simpson and Angus Scale is a standard physical examination that measures parkinsonism. This scale is comprised of a 10-item rating scale, each item rated on a five-point scale with zero indicating the complete absence of condition and four indicating the presence of condition in extreme. Adding the items and dividing by 10 obtains the total score (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4 Calgary Depression Rating Scale</HEADING>
<P>The Calgary Depression Rating Scale is the standard rating scale for measuring depression in people with schizophrenia. This is a semi-structured interview that scores nine items on a scale of absent, mild, moderate and severe (<LINK REF="REF-Addington-1990" TYPE="REFERENCE">Addington 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5 Positive and Negative Symptoms of Schizophrenia</HEADING>
<P>PANSS is a relatively brief structured interview commonly used in the study of antipsychotic therapy. It rates positive and negative symptoms as defined by the American Psychiatric Association scoring one to seven on 30 different items. It constitutes four scales measuring positive and negative symptoms, their differential and general severity of illness (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>We added a further six studies to the excluded studies section of the review following this update giving 22 studies. Several reported outcomes in such a way that made inclusion impossible. Either data did not have clear clinical implications, for example EEG recordings, or relevant clinical data were inadequately reported. Frequently, the numbers of participants in each group were not specified, means or SDs were not reported, or data were not reported from individual arms of cross-over studies.</P>
<SUBSECTION>
<HEADING LEVEL="4">Awaiting assessment</HEADING>
<P>There are no studies currently awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing</HEADING>
<P>The review authors know of no ongoing studies.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>We used the tool for assessment of bias described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and a graphical overview can be seen in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
<ALLOCATION MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of randomisation in the studies was generally unclear. All studies were described as 'randomised'. Only one study described using random number tables to achieve randomisation (<LINK REF="STD-Liang-1987" TYPE="STUDY">Liang 1987</LINK>). Most studies simply reported randomisation and presented baseline data that were equivalent for the different comparator groups.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>All studies were reported as 'double-blind' with the exception of <LINK REF="STD-Curtis-1995" TYPE="STUDY">Curtis 1995</LINK>. Several trials described using identical methods of dose delivery between groups. Only <LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK> tested this by asking ward staff to guess the allocated treatment (91% of doctors and 89.5% of nurses were able to guess correctly).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>The majority of studies described the numbers of people leaving early and reasons for leaving. Of the 19 studies, six described intention-to-treat analysis, nine described a 'per protocol' analysis and four did not report if dropout data were included in the analyses.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-06-26 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>The majority of the studies report a wide range of both statistically significant and non-significant outcomes but few reported all outcome measures. One paper presented only highly significant results (<LINK REF="STD-McEvoy-1991" TYPE="STUDY">McEvoy 1991</LINK>), and another did not report results from one treatment group (<LINK REF="STD-Curtis-1995" TYPE="STUDY">Curtis 1995</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>We noted no obvious other sources of bias for this update.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-06-26 12:45:51 +0100" MODIFIED_BY="[Empty name]">
<P>All the studies included in the review so far had outcomes assessed before 10 weeks, so no data could be presented for longer periods (greater than 10 weeks to six months, greater than six months). For several of the comparisons, the same data from a specific study were re-presented several times. For example, one study may have compared low-dose and high-dose haloperidol. Therefore, we considered it was appropriate to present these data in both comparison number 2, where low dose is the 'experimental intervention' and high the 'control' and comparison number 6, where the opposite applies.</P>
<P>We are aware that presenting the findings in this way does, at times, result in the repeating of results - but in reverse, for example the low dose versus high dose is listed twice as it appears later as high dose versus low dose. This makes results long and repetitive - although because we are using the RR rather than OR the figures do change. It is feasible to restructure the review but to not repeat listings would have asked more of the reader. For this version we have left the structure of the review as it was originally (<LINK REF="REF-Waraich-2002" TYPE="REFERENCE">Waraich 2002</LINK>), with each comparison containing all available data for that particular question (see <LINK TAG="IMPLICATIONS_RESEARCH" TYPE="SECTION">Implications for research</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">1. DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES</HEADING>
<P>We found one small (n = 26) study comparing ultra low dose with low dose (&gt; 1.5 to 3 mg/day) (<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Leaving the study early</HEADING>
<P>We found no significant difference between study groups in rates of people leaving the study early (n = 26, 1 RCT, RR 0.29, 95% CI 0.03 to 2.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Global state</HEADING>
<P>We found no significant difference between study groups (n = 26, 1 RCT, RR 1.89, 95% CI 0.9 to 3.9) though numerically there were more people who showed no significant response in the ultra low group (11/14 versus 5/12). Again, there was no significant difference between groups in use of adjunctive medication for sedation (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Mental state/behaviour</HEADING>
<P>There was no significant difference in frequency of clinically significant agitation between groups (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Adverse effects</HEADING>
<P>We found no significant difference in extrapyramidal side effect (EPSE) rates between groups (n = 26, 1 RCT, RR 0.51, 95% CI 0.15 to 1.7). We also found no significant difference in use of antiparkinsonism drugs between groups (n = 26, 1 RCT, RR 0.5, 95% CI 0.15 to 1.7).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. DOSES: 2. LOW DOSE (&gt; 1.5 to 3 mg/day) versus OTHER DOSES</HEADING>
<P>We found one small study (n = 26) comparing low dose with ultra low dose (&gt; 0.25 to 1.5 mg/day) (<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK>). A further small study compared low dose with standard higher dose (&gt; 7.5 to 15 mg/day) (<LINK REF="STD-Oosthuizen-2004" TYPE="STUDY">Oosthuizen 2004</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Leaving the study early</HEADING>
<P>We found few participants left before completion with no clear difference in acceptability between low dose and ultra low dose (n = 26, 1 RCT, RR 3.5, 95% CI 0.4 to 29).<BR/>We found there were numerically more dropouts in the standard higher dose (8/20) than the low dose (3/20) groups, but this difference was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Global state</HEADING>
<P>More people in the ultra low dose group showed no significant response during the study than in the low dose group. This did not reach conventional levels of statistical significance (n = 26, 1 RCT, RR 0.53, 95% CI 0.3 to 1.1). Use of adjunctive medication for sedation occurred less frequently in the ultra low dose group compared with low dose group, but again not to a statistically significant degree (n = 26, 1 RCT, RR 1.75, 95% CI 0.4 to 9). Mean dose of lorazepam was also similar between low and standard higher dose groups (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), as was endpoint CGI scores (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Mental state/behaviour</HEADING>
<P>Clinically significant agitation was infrequent and no different in either low or ultra low groups (n = 26, 1 RCT, RR 1.75, 95% CI 0.4 to 9). Data comparing low dose with standard higher doses was presented as endpoint PANSS differential scores (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>), CGI scores (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), and Calgary Depression Rating Scale scores (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>), which were all highly skewed with the exception of the PANSS positive subscale, which showed no significant difference between groups (n = 40, 1 RCT, MD 0.8, 95% CI -4.1 to 5.7).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Adverse effects</HEADING>
<P>EPAEs were less frequent for people allocated the ultra low dose compared to low dose, but not to a statistically significant degree (n = 26, 1 RCT, RR 1.94, 95% CI 0.6 to 6.5), as did use of antiparkinsonism drugs (n = 26, 1 RCT, RR 1.94, 95% CI 0.6 to 6.5).</P>
<P>Dystonic reactions (n = 40, 1 RCT, RR 0.33, 95% CI 0.1 to 1.5), dyskinesia (n = 40, 1 RCT, RR 0.2, 95% CI 0.01 to 3.9) and akathisia (n = 40, 1 RCT, RR 0.38, 95% CI 0.1 to 1.2) occurred more commonly in the standard higher dose group compared to the low dose group but the differences were not statistically significant. Mean dose of orphenadrine used in the standard higher dose group was significantly higher than in the low dose range, though data were skewed (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>). Similarly, prolactin levels at endpoint were significantly higher in the standard higher dose group though data were again skewed (<LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. DOSES: 3. STANDARD LOWER DOSE (&gt; 3 mg to 7.5 mg/day) versus OTHER DOSES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Leaving the study early</HEADING>
<P>Standard lower dose was more acceptable than standard higher dose (&gt; 7.5 to 15 mg/day) (n = 64, 2 RCTs, RR 0.1, 95% CI 0.01 to 2.1). When the standard lower dose was compared with high dose (&gt; 15 to 35 mg/day) the results did not conclusively show that the lower of the two doses was more acceptable. This did not reach a statistically significant level (n = 191, 4 RCTs, RR 0.78, 95% CI 0.5 to 1.3). There also was no discernible difference in the numbers leaving the groups early when the standard lower dose was compared with very high dose (&gt; 35 mg/day) (n = 86, 2 RCTs, RR 0.7, 95% CI 0.3 to 1.6).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Global state</HEADING>
<P>About the same numbers of people allocated to the standard lower dose group showed no clinically important improvement in global state compared with standard higher dose (n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.8) and with high dose (n = 81, 2 RCTs, RR 0.95, 95% CI 0.8 to 1.2). The need for sedative medication was evenly balanced between standard lower and standard higher dose groups (n = 238, 4 RCT, RR 0.99, 95% CI 0.8 to 1.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Mental state/behaviour</HEADING>
<P>One small study (n = 65) reported on agitation (<LINK REF="STD-Volavka-1995" TYPE="STUDY">Volavka 1995</LINK>). There was no difference for those allocated standard lower dose compared with high dose (RR 0.93, 95% CI 0.7 to 1.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 Adverse effects</HEADING>
<P>Adverse effects were measured by development of clinically significant EPSE and use of antiparkinsonism drugs.</P>
<P>Compared with standard higher dose, the standard lower dose was not shown to spare people clinically significant EPAEs (n = 64, 2 RCTs, RR 0.12, 95% CI 0.01 to 2.1). Compared with a high dose, people allocated the standard lower dose had fewer adverse effects (n = 144, 3 RCTs, RR 0.59, 95% CI 0.5 to 0.8, NNTH 3, 95% CI 2 to 6). When the same standard lower dose was compared with very high dose, however, this finding was not replicated (n = 86, 2 RCTs, RR 0.7, 95% CI 0.5 to 1.1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. DOSES: 4. STANDARD HIGHER DOSE (7.5 to 15 mg/day) versus OTHER DOSES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Mortality</HEADING>
<P>Only one small study (n = 20), comparing standard higher dose with very high dose (&gt; 35 mg/day), reported on death stating that none had occurred (<LINK REF="STD-Neborsky-1981" TYPE="STUDY">Neborsky 1981</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 Leaving the study early</HEADING>
<P>Two studies comparing standard higher dose with very high dose reported early study attrition (between 3 and 14 days). There was no clear difference between groups (n = 83, 2 RCTs, RR 0.72, 95% CI 0.3 to 2). One study reported one participant leaving on day one or two (<LINK REF="STD-Louza-1988" TYPE="STUDY">Louza 1988</LINK>).</P>
<P>Several studies reported attrition between two and 10 weeks. There was no difference between the standard higher dose group and low dose (&gt; 1.5 to 3 mg/day) (n = 40, 1 RCT, RR 2.67, 95% CI 0.8 to 8.6), standard lower dose (&gt; 3 to 7.5 mg/day) (n = 64, 2 RCTs, RR 8.31, 95% CI 0.5 to 146), high dose (&gt; 15 to 35 mg/day) (n = 188, 4 RCTs, RR 0.87, 95% CI 0.5 to 1.7), or very high dose (n = 74, 2 RCTs, RR 0.62, 95% CI 0.3 to 1.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3 Global state</HEADING>
<P>One study comparing standard higher dose with very high dose reported early appraisal of global state (between 3 and 14 days). There was no clear difference between groups (n = 20, 1 RCT, RR 3.0, 95% CI 0.4 to 24).</P>
<P>A series of small trials, even when combined, showed no difference for the outcome of 'no significant global improvement' when standard higher dose was compared with standard lower dose (n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.7), high dose (n = 106, 2 RCTs, RR 1.33, 95% CI 0.9 to 2.1), or very high dose (n = 58, 1 RCT, RR 1.29, 95% CI 0.8 to 2).</P>
<P>Mean change scores were also equivocal. Numbers of people needing additional sedation not significantly when standard higher dose was compared with high dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high dose (n = 58, 1 RCT, RR 1.43, 95% CI 0.6 to 3).</P>
<P>One trial reported endpoint CGI scores (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>) and mean use of lorazepam (<LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>) in standard higher and low dose groups. The results were similar between groups and skewed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4 Mental state/behaviour</HEADING>
<P>Early appraisal of psychotic symptoms (between 3 and 14 days) was undertaken in the one study that compared standard higher dose with very high dose. There was no clear difference between groups (n = 20, 1 RCT, RR 3.0, 95% CI 0.4 to 24).</P>
<P>PANSS positive subscale endpoint score was not significantly different between standard higher and low dose groups (n = 40, 1 RCT, MD -0.8, 95% CI -5.56 to 3.96). PANSS general score (<LINK REF="CMP-004.13" TYPE="ANALYSIS">Analysis 4.13</LINK>), PANSS negative subscale (<LINK REF="CMP-004.15" TYPE="ANALYSIS">Analysis 4.15</LINK>) and Calgary Depression Rating Scale (<LINK REF="CMP-004.16" TYPE="ANALYSIS">Analysis 4.16</LINK>) were all similar between groups and skewed.</P>
<P>
<LINK REF="STD-Rifkin-1991" TYPE="STUDY">Rifkin 1991</LINK> reported on agitation between 2 and 10 weeks, but showed no differences between standard higher dose and high dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high dose (n = 58, 1 RCT, RR 1.43, 95% CI 0.6 to 3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5 Adverse effects</HEADING>
<P>Acute dystonia was no more common in those allocated standard higher dose than in people given very high dose (n = 63, 1 RCT, RR 0.69, 95% CI 0.4 to 1.2). Neither were clinically significant EPAEs clearly more common for people taking standard higher dose than those given standard lower dose (n = 64, 2 RCTs, RR 8.3, 95% CI 0.5 to 146). Mean change scores for EPAEs were also equivocal. Conversely, dystonic reaction (n = 40, 1 RCT, RR 3, 95% CI 0.7 to 13.1), dyskinesia (n = 40, 1 RCT, RR 5, 95% CI 0.3 to 98) and akathisia (n = 40, 1 RCT, RR 2.7, 95% CI 0.8 to 8.6) appeared more common in the standard higher dose group than the low dose group though not to a significant level.</P>
<P>
<LINK REF="STD-Louza-1988" TYPE="STUDY">Louza 1988</LINK> compared EPSE between standard higher dose versus high and very high doses combined but again, there was no significant difference (<LINK REF="CMP-004.21" TYPE="ANALYSIS">Analysis 4.21</LINK>).</P>
<P>Mean values of orphenadrine used (<LINK REF="CMP-004.22" TYPE="ANALYSIS">Analysis 4.22</LINK>) and endpoint prolactin levels (<LINK REF="CMP-004.25" TYPE="ANALYSIS">Analysis 4.25</LINK>) were significantly higher in the standard higher dose group to the low dose group, though data were skewed.</P>
<P>Finally, only one study reported on postural hypertension (n = 63) but showed no difference between people taking standard higher dose compared with people taking very high dose (RR 0.7, 95% CI 0.03 to 16) (<LINK REF="STD-Donlon-1980" TYPE="STUDY">Donlon 1980</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. DOSES: 5. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Leaving the study early</HEADING>
<P>No differences were apparent when high dose was compared with standard lower dose (&gt; 3 to 7.5 mg/day) (n = 191, 4 RCTs, RR 1.28, 95% CI 0.8 to 2.1), standard higher dose (&gt; 7.5 to 15 mg/day) (n = 188, 4 RCTs, RR 1.16, 95% CI 0.6 to 2.2) and very high dose (&gt; 35 mg/day) (n = 312, 5 RCTs, RR 1.04, 95% CI 0.7 to 1.6).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.2 Global state</HEADING>
<P>Even combination of several studies found no differences when high dose was compared with standard lower dose (n = 81, 2 RCTs, RR 1.06, 95% CI 0.8 to 1.3) and very high dose (n = 255, 4 RCTs, RR 0.92, 95% CI 0.8 to 1.1). Change scores also found no clear differences when high dose was compared with standard higher dose and very high dose . One study used the outcome of 'no psychotic symptoms' to compare high dose and standard lower dose but no people in either group met the description.</P>
<P>The risk of needing additional sedation was greater for people given high dose compared with standard lower dose (n = 144, 3 RCTs, RR 1.40, 95% CI 1.1 to 1.8, NNTH 3, 95% CI 2 to 6). No differences were apparent when high dose was compared with standard higher dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), and very high dose (n = 115, 2 RCTs, RR 1.07, 95% CI 0.7 to 1.7). The use of sedatives at high dose compared to standard lower dose between 0 and 14 days specifically was not significant (n = 47, 1 RCT, RR 0.74, 95% CI 0.4 to 1.3), similarly between 2 and 10 weeks (n = 47, 1 RCT, RR 0.29, 95% CI 0.03 to 2.6).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3 Mental state/behaviour</HEADING>
<P>For the outcome of 'no clinically important change in psychotic symptoms' there were no differences for those given high dose compared with people allocated to very high dose (n = 92, 1 RCT, RR 1.57, 95% CI 0.8 to 3.1).</P>
<P>Agitation was equally common for people given high dose versus standard lower dose (n = 65, 1 RCT, RR 1.08, 95% CI 0.8 to 1.5), standard higher dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high doses (n = 115, 2 RCTs, RR 1.07, 95% CI 0.7 to 1.7). Mean scores were also equivocal. Although sustained high doses of haloperidol are extensively used to treat agitation in acute phases of schizophrenia (<LINK REF="REF-Baldessarini-1988" TYPE="REFERENCE">Baldessarini 1988</LINK>), there were no statistically significant differences between the dose ranges in studies that reported on this outcome. However, there are few studies that examine this outcome.</P>
<P>It should be emphasised that this review does not have any information regarding the benefits and tolerability of 'as needed' doses of antipsychotics. For this, readers should examine the findings from a complementary Cochrane review (<LINK REF="REF-Whicher-2002" TYPE="REFERENCE">Whicher 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.4 Adverse effects</HEADING>
<P>High doses resulted in more EPAEs than standard lower doses (n = 144, 3 RCTs, RR 1.7, 95% CI 1.3 to 2.2, NNTH 3, 95% CI 2 to 6), but the same levels as very high doses (n = 114, 2 RCTs, RR 1.03, 95% CI 0.7 to 1.4). Change scores in ratings of EPAEs were, compared with standard higher dose and very high doses, equivocal and uninformative. More people allocated to high dose needed drugs to counter parkinsonism compared with standard lower dose (n = 144, 3 RCTs, RR 1.7, 95% CI 1.3 to 2.2, NNTH 3, 95% CI 2 to 6). Compared with very high doses people given high dose did not need more antiparkinsonism drugs (n = 114, 2 RCTs, RR 1.13, 95% CI 0.9 to 1.4). Akathisia was as common for people allocated to high dose as people allocated to very high dose (n = 57, 1 RCT, RR 0.71, 95% CI 0.4 to 1.4).</P>
<P>One study considered blurred vision in high and standard lower dose groups, but there was no significant difference between the groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. DOSES: 6. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Mortality</HEADING>
<P>Only one small study (n = 20), comparing standard higher dose (&gt; 7.5 to 15 mg/day) with very high dose, reported on death, stating that none had occurred (<LINK REF="STD-Neborsky-1981" TYPE="STUDY">Neborsky 1981</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Leaving the study early</HEADING>
<P>Two studies comparing very high dose with standard higher dose reported early study attrition (between 3 and 14 days). There was no clear difference between groups (n = 83, 2 RCTs, RR 1.4, 95% CI 0.5 to 4).</P>
<P>Several studies reported study attrition between 2 and 10 weeks. There was no clear difference between the very high dose group and standard lower dose (&gt; 3 to 7.5 mg/day) (n = 86, 2 RCTs, RR 1.42, 95% CI 0.6 to 3.2), standard higher dose (n = 74, 2 RCTs, RR 1.62, 95% CI 0.7 to 4), or high dose (&gt; 15 to 35 mg/day) (n = 312, 5 RCTs, RR 0.96, 95% CI 0.6 to 1.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Global state</HEADING>
<P>One study comparing very high dose with standard higher dose reported early appraisal of global state (between 3 and 14 days). There was no clear difference between groups (n = 20, 1 RCT, RR 0.33, 95% CI 0.04 to 3).</P>
<P>For the outcome of 'no global improvement between 2 and 10 weeks', no clear differences were found when very high dose was compared with standard higher dose (n = 58, 1 RCT, RR 0.78, 95% CI 0.5 to 1.3), and high dose (n = 255, 4 RCTs, RR 1.09, 95% CI 0.9 to 1.3). Mean change scores comparing very high dose with standard higher dose and high dose were equally equivocal. The numbers of people needing additional sedation was not significantly different when very high dose was compared with standard higher dose (n = 58, 1 RCT, RR 0.7, 95% CI 0.3 to 1.6) or high dose (n = 115, 2 RCTs, RR 0.94, 95% CI 0.6 to 1.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4 Mental state/behaviour</HEADING>
<P>Very high doses were no different to any other doses for various measures of mental state/behaviour. For the outcome of 'no clinically important change in psychotic symptoms between three days and two weeks,' very high doses were not significantly different to standard higher doses (n = 20, 1 RCT, RR 0.33, 95% CI 0.04 to 2.7). There was also no significant difference in changes in psychotic symptoms when very high dose were compared with high dose (n = 92, 1 RCT, RR 1.18, 95% CI 0.9 to 1.5). Mean change scores on rating of mental state were also equivocal for a comparison of very high dose versus high dose. Finally, agitation was equally common for people given very high dose when compared with both standard higher dose (n = 58, 1 RCT, RR 0.7, 95% CI 0.3 to 1.6) and high dose (n = 115, 2 RCTs, RR 0.94, 95% CI 0.6 to 1.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.5 Adverse effects</HEADING>
<P>Acute dystonia was as common for people allocated very high dose as for people given standard higher dose (n = 63, 1 RCT, RR 1.45, 95% CI 0.9 to 2.5). However, when compared with standard lower dose, very high doses did not cause more clinically significant EPAEs (n = 86, 2 RCTs, RR 1.42, 95% CI 0.9 to 2.2). When very high dose was compared with high dose, studies found no difference (n = 114, 2 RCTs, RR 0.97, 95% CI 0.7 to 1.4). Mean scores where very high dose was compared with standard higher dose or high dose, were equivocal and uninformative. Use of drugs to counter parkinsonism was as common for those allocated very high dose as for people given standard lower doses (n = 70, 1 RCT, RR 1.25, 95% CI 0.8 to 2) and high dose (n = 114, 2 RCTs, RR 0.89, 95% CI 0.7 to 1.1). Akathisia was common, but no more so for people taking very high dose compared with high dose (n = 57, 1 RCT, RR 1.4, 95% CI 0.7 to 2.7).</P>
<P>Finally, postural hypotension was not common and had the same risk of occurrence for people taking very high doses and those given standard higher dose (n = 63, 1 RCT, RR 1.43, 95% CI 0.1 to 34).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. DOSES: 7. COMBINED HIGH AND VERY HIGH DOSES (&gt; 15 mg/day) versus OTHER DOSES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.1 Leaving the study early</HEADING>
<P>One study compared doses above 15 mg/day with standard higher doses (&gt; 7.5 to 15 mg/day). There was no significant difference between groups in either early attrition (1 to 2 days) or late (2 to 10 weeks) (Analysis 7.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.2 Adverse effects</HEADING>
<P>There was no significant difference in rates of EPSE between the combined high and very high group and the standard higher group (Analysis 7.1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8. PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">8.1 Leaving the study early</HEADING>
<P>Very low plasma levels (&gt; 3.5 to 7 ng/mL) resulted in fewer people leaving the studies early when compared to medium plasma levels (&gt; 7.0 to 16.5 ng/mL), but this did reach statistical significance (n = 128, 2 RCTs, RR 0.61, 95% CI 0.4 to 1.1). There was no clear difference when very low plasma levels were compared with high levels (&gt; 16.5 ng/mL) (n = 70, 1 RCT, RR 0.96, 95% CI 0.4 to 2.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.2 Global state</HEADING>
<P>One study monitored 'no clinically significant improvement in global state' (n = 65) and when very low plasma levels were compared with medium levels (&gt; 7.0 to 16.5 ng/mL), the trialists found no difference (RR 0.8, 95% CI 0.3 to 1.9) (<LINK REF="STD-Volavka-1995" TYPE="STUDY">Volavka 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.3 Mental state/behaviour</HEADING>
<P>One study looked at 'significant response in positive symptoms' between very low and medium plasma level but found no significant differences (<LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8.4 Adverse effects</HEADING>
<P>Very low plasma levels resulted in fewer clinically significant EPEAs than medium levels (n = 128, 2 RCTs, RR 0.63, 95% CI 0.5 to 0.8, NNTH 3, 95% CI 2 to 7). When the same very low levels were compared with high plasma levels, no clear differences were found (n = 70, 1 RCT, RR 0.8, 95% CI 0.5 to 1.2).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">9. PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">9.1 Leaving the study early</HEADING>
<P>Compared with very low plasma levels (&gt; 1.4 to 3.5 ng/mL), medium levels did not promote study attrition (n = 128, 2 RCTs, RR 1.63, 95% CI 0.9 to 3). This also applied to comparisons with high plasma levels (&gt; 16.5 ng/mL), although results were heterogeneous (n = 149, 2 RCTs, RR 1.1, 95% CI 0.6 to 2.1, heterogeneous P value = 0.074).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9.2 Global state</HEADING>
<P>Medium plasma levels did not result in different rates of global improvement when compared with either very low plasma levels (n = 65, 1 RCT, RR 0.80, 95% CI 0.3 to 1.9) or high plasma levels (n = 92, 1 RCT, RR 1.57, 95% CI 0.8 to 3.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9.3 Mental state/behaviour</HEADING>
<P>Two studies looked at significant response in positive symptoms between medium and low plasma levels and found no significant differences (<LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9.4 Adverse effects</HEADING>
<P>Clinically significant EPAEs were more common for those allocated to medium plasma levels compared with people in a very low plasma level group (n = 128, 2 RCTs, RR 1.59, 95% CI 1.2 to 2.1, NNTH 3, 95% CI 2 to 7). There was no clear difference for those in a medium plasma level group compared with a high level group (n = 59, 1 RCT, RR 1.28, 95% CI 0.9 to 1.8).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">10. PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">10.1 Leaving the study early</HEADING>
<P>Compared with both very low plasma levels (&gt; 1.4 to 3.5 ng/mL), high plasma levels did not affect study attrition (n = 70, 1 RCT, RR 1.04, 95% CI 0.4 to 2.6), neither did medium levels (&gt; 7 to 16.5 ng/mL) (n = 149, 2 RCTs, RR 0.91, 95% CI 0.5 to 1.7, heterogeneous P value = 0.074).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.2 Global response</HEADING>
<P>One small study (n = 92) reported that there was no difference for those allocated to high levels compared with medium plasma levels (RR 1.18, 95% CI 0.9 to 1.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10.3 Adverse effects</HEADING>
<P>Over half of people given haloperidol, irrespective of plasma level, had significant EPAEs (high levels versus very low levels: n = 70, 1 RCT, RR 1.25, 95% CI 0.8 to 2; high levels versus medium levels: n = 59, 2 RCTs, RR 0.8, 95% CI 0.5 to 1.1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">11. Sensitivity analyses</HEADING>
<P>There were no data to undertake analyses separately for people in their first episode of illness. As regards use of operational diagnostic criteria, only <LINK REF="STD-Curtis-1995" TYPE="STUDY">Curtis 1995</LINK>, <LINK REF="STD-Donlon-1980" TYPE="STUDY">Donlon 1980</LINK> and <LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK> did not use operational criteria that were clearly described. Where these trials contributed to outcomes in which meta-analysis had taken place, in no case did they alter the final result to an important extent. When these trials were the sole contributor to an outcome - for example <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK> or <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK> in the case of <LINK REF="STD-Curtis-1995" TYPE="STUDY">Curtis 1995</LINK> - removal of these data deleted the outcome as a whole. However, there is no evidence that trials using operational criteria to diagnose people with schizophrenia have substantially different results from trials that imply that such stipulated criteria were not employed. Finally we were not confident that trials specifically included people whose illness would be recognised as treatment resistant, and therefore we did not undertake a sensitivity analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">12. Publication bias</HEADING>
<P>There was an insufficient number of trials per comparison (maximum of five trials) to conduct a valid funnel plot to examine for possible publication bias.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES</HEADING>
<P>
<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK> compared ultra low dose to low dose (&gt; 1.5 to 3 mg/day) and found no differences in terms of leaving the study early (both treatments were very acceptable), global measures of outcome, mental state and adverse effects. For a study involving 26 people, it would have been surprising if any outcomes had suggested a clear difference in groups, but that several favoured the ultra low dose group, even if they did not reach conventional levels of statistical significance. This suggests that this question could be further investigated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. DOSES: 2. LOW DOSE (&gt; 1.5 to 3 mg/day) versus OTHER DOSES</HEADING>
<P>
<LINK REF="STD-Oosthuizen-2004" TYPE="STUDY">Oosthuizen 2004</LINK> compared low dose to standard higher dose (&gt; 7.5 to 15 mg/day). Measures of efficacy of intervention such as PANSS and CGI were similar between groups, the Calgary Depression Rating Scale was also unequivocal as was lorazepam use for agitation. Some of the adverse effects measures - such as mean dose of orphenadrine used and mean prolactin level - were significantly higher in the high dose group (&gt; 15 to 35 mg/day) suggesting better tolerability of low dose. Rates of attrition, dystonia, dyskinesia and akathisia all favoured use of a low dose though results for these measures were not statistically significant. This study involved 40 participants and was, therefore, underpowered to assess efficacy and tolerability in all areas adequately. No other studies investigated this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. DOSES: 3. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg/day) versus OTHER DOSES</HEADING>
<P>The standard lower dose was, generally, more acceptable than any of the higher doses, as measured in terms of leaving the study early (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). However, no findings reached conventional levels of statistical significance but all comparisons involved small numbers (maximum 191). Considering the importance of this question, it would seem that more investigation is justified.</P>
<P>Standard lower dose was as effective, in terms of global state and mental state, as standard higher dose (&gt; 7.5 to 15 mg/day) and high dose (&gt; 15 to 35 mg/day), but again, the numbers involved in these comparisons were small (maximum 126). This lack of difference is striking given the tendency in clinical practice to increase the dose of people who do not respond, or to utilise high doses from the start of treatment. The finding is probably widely applicable, given that global improvement was defined in a variety of ways across studies. Considering the potential for the introduction of bias into these outcomes, this finding should only be considered as hypothesis-generating.</P>
<P>Standard lower dose consistently resulted in fewer people experiencing EPAEs, when compared with higher doses. In the comparison involving most people (n = 144), this did reach statistical significance with an NNTB of three. This is an important finding given the frequent use of the latter dose range in comparative trials of new antipsychotic agents and in clinical practice. It is also interesting to note that this finding had some preliminary evidence as early as 1967 (<LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK>). Unfortunately, this was not re-examined in a high-quality study until 1984 (<LINK REF="STD-Garver-1984" TYPE="STUDY">Garver 1984</LINK>), and was not reported appropriately in a study until 1991 (<LINK REF="STD-McEvoy-1991" TYPE="STUDY">McEvoy 1991</LINK>). Nevertheless, despite this favourable result for the standard lower dose, nearly half of the people given standard lower dose either experienced these distressing adverse effects or left the study early.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. DOSES: 4. STANDARD HIGHER DOSE (7.5 to 15 mg/day) versus OTHER DOSES</HEADING>
<P>All relevant studies were small and, even when combined, the totals amounted to no more than 188 people.</P>
<P>Standard higher dose did not result in people leaving the short studies early, when compared with standard lower dose (&gt; 3 to 7.5 mg/day), high dose (&gt; 15 to 35 mg/day) or very high dose (&gt; 35 mg/day). There were also no clear differences for global state or mental state/behaviour. Most data were reported for the comparison of standard higher dose with high dose at 2 to 10 weeks (n = 106), for 'no clinically important improvement in global state'. Numbers in groups were evenly balanced, with more than one-third of participants not showing any important degree of improvement. The fact that there was no difference in response between dose groups may be suggestive that dose level is less important, for global state and mental state outcomes, than just taking the antipsychotic.</P>
<P>While no comparisons found differences in the few adverse effects reported, there were the suggestions, consistent with the other data in this review, that higher doses led to more adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. DOSES: 5. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES</HEADING>
<P>These set of comparisons contain some of the highest numbers of participants in this review (maximum 312).</P>
<P>High dose haloperidol seems as acceptable, in terms of leaving these short studies early, as standard lower dose (&gt; 3 to 7.5 mg/day) (n = 191), standard higher (&gt; 7.5 to 15 mg/day) (n = 188) and very high doses (&gt; 35 mg/day) (n = 312).</P>
<P>For outcomes relevant to mental state/behaviour, the numbers in each comparison were low and no differences were discernible. It does seem surprising that so little research reporting useful data has been undertaken in this key area.</P>
<P>Direct comparisons for measures of global state found no differences when high dose was compared with standard lower, standard higher dose and very high doses. The risk of needing additional sedation was greater for people given high dose compared with standard lower (n = 144, NNTH 3), but not with standard higher dose, and very high doses. This must be seen as an advantage of the standard lower dose compared with the high dose. High doses also resulted in more people experiencing EPAEs or needing drugs to counter parkinsonism compared with standard lower doses (n = 144, NNTH 3), but the same levels as very high doses (n = 134). Akathisia was as common for people allocated to high dose as people allocatedtovery high dose.</P>
<P>There is no evidence that a high dose is better than standard low for mental state/global state outcomes, and the findings favouring standard low dose for adverse effect outcomes is compelling.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. DOSES: 6. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES</HEADING>
<P>Very high doses did not disproportionately cause people to leave studies before completion. Very high doses were as clinically effective for global state/mental state outcomes as standard higher dose (&gt; 7.5 to 15 mg/day) (n = 58), and high dose (&gt; 15 to 35 mg/day) (n = 255).</P>
<P>Several movement disorder adverse effects were not significantly more common for people given very high doses compared with high dose (n = 117), standard higher dose (n = 63) and even standard lower dose (&gt; 3 to 7.5 mg/day) (n = 86). This is a somewhat surprising result considering the consistent findings thus far in this review - where higher doses of haloperidol do result in more adverse effects, and is difficult to explain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. DOSES: 7. COMBINED HIGH AND VERY HIGH DOSE (&gt; 15 mg/day) versus OTHER DOSES</HEADING>
<P>
<LINK REF="STD-Louza-1988" TYPE="STUDY">Louza 1988</LINK> found no differences in attrition rates or EPSE between more than 15 mg/day and standard higher dose (&gt; 7.5 to 15 mg/day). This was a small, single study comparison (n = 20).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8. PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS</HEADING>
<P>Very low plasma levels (&gt; 3.5 to 7 ng/mL) resulted in fewer people leaving the studies early when compared to medium plasma levels (&gt; 7.0 to 16.5 ng/mL), but this did not quite reach conventional levels of statistical significance (n = 128). When compared with medium plasma levels, very low plasma levels were not clearly different for the outcome of 'no clinically significant improvement in global state' (n = 65). As regards adverse effects, however, very low plasma levels resulted in fewer clinically significant EPAEs than medium levels (n = 128, NNTH 3). This finding was not replicated when the very low levels were compared with high plasma levels (&gt; 16.5 ng/mL), but this may have been because of the low power of this comparison (n = 70).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9. PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS</HEADING>
<P>Compared with very low plasma levels (&gt; 1.4 to 3.5 ng/mL) (n = 128), and high plasma levels (&gt; 16.5 ng/mL) (n = 149), medium levels did not clearly promote study attrition or encourage different rates of global improvement.</P>
<P>Clinically significant EPAEs were more common for those allocated to medium plasma levels compared with people in a very low plasma level group (n = 128, NNTH 3), but no different when compared with the high plasma level group (n = 59). This could have been a function of power and the consistent finding is that lower levels/doses of haloperidol do lead to fewer adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10. PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS</HEADING>
<P>Compared with both very low plasma levels (&gt; 1.4 to 3.5 ng/mL) (n = 70) high plasma levels did not clearly affect study attrition, or when compared with medium plasma levels (&gt; 7 to 16.5 ng/mL) (n = 149). There was no difference for those allocated to high levels compared with medium plasma levels (n = 92) for global state outcomes, and no differences for adverse effects. However, over half of the participants given haloperidol, irrespective of plasma level, had significant EPAEs (versus very low plasma levels, n = 70; versus medium plasma levels, n = 59).</P>
<P>Even if the global and mental state changes do not seem greatly sensitive to dose, haloperidol is a common cause of adverse effects and the latter tend to be more common with higher dose/plasma level.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>This study benefited from extensive searches of the worldwide literature regarding haloperidol dosage. Some of the non-English studies may not have been included without such extensive searches (<LINK REF="STD-Klieser-1987" TYPE="STUDY">Klieser 1987</LINK>; <LINK REF="STD-Liang-1987" TYPE="STUDY">Liang 1987</LINK>). Another major strength was that all comparisons were restricted to randomised studies of the same drug, which has not been the case with previous reviews (<LINK REF="REF-Baldessarini-1984" TYPE="REFERENCE">Baldessarini 1984</LINK>; <LINK REF="REF-Bollini-1994" TYPE="REFERENCE">Bollini 1994</LINK>). This should significantly reduce the potential for bias introduced by using differing measures for the various outcomes studied.</P>
<P>A major weakness of this study was that for several outcomes there was either minimal or no data from high-quality randomised trials. This resulted in many findings being prone to type II errors (a masking of a real effect by wide CIs), and several important hypotheses being unanswered.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of included studies was generally poor, with authors not describing the randomisation process, allocation concealment and blinding (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). This could mean that even these few results are prone to biases and an overestimate of effect. Poor reporting of the process and outcomes of the trials was common. We excluded many studies due to a lack of information about the number of people randomised to various treatment arms.</P>
<P>The number and size of trials was particularly poor for the dose range of primary interest (low dose &gt; 1.5 to 3 mg/day) and the lowest dose range (ultra low dose &gt; 0.25 to 1.5 mg/day). Only one small study (n = 26) compared the lowest two groups (<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK>), and no study compared the primary dose range of interest to the next highest dose range. One further study (n = 40) compared low dose and standard higher dose (&gt; 7.5 to 15 mg/day) (<LINK REF="STD-Oosthuizen-2004" TYPE="STUDY">Oosthuizen 2004</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>While the authors made every effort to avoid publication bias, it remains possible that not all relevant studies have been identified as yet. The Cochrane Register of studies could still represent a biased sample of trials. However, we consider that a large unpublished trial in this area is implausible and that we are more likely to have overlooked other small studies.</P>
<P>We do not think that we have biased the review process by holding prior opinions and having seen past reviews. However, we have not tested this in undertaking the work.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>A systematic review of randomised trials of the maintenance phase of schizophrenia reached a similar conclusion to that made in this review in 2002 (<LINK REF="REF-Waraich-2002" TYPE="REFERENCE">Waraich 2002</LINK>), and by others even longer ago (<LINK REF="REF-Bollini-1994" TYPE="REFERENCE">Bollini 1994</LINK>); they concluded that there is no benefit in administering doses higher than 375 mg/day of chlorpromazine or the equivalent of such a dose when using other antipsychotics (about 7.5 mg/day of haloperidol). Despite this, many studies have been conducted since using much higher doses than 7.5 mg/day of haloperidol (<LINK REF="REF-Kennedy-2002" TYPE="REFERENCE">Kennedy 2002</LINK>; <LINK REF="REF-Leucht-1999" TYPE="REFERENCE">Leucht 1999</LINK>; <LINK REF="REF-Rosenheck-2003" TYPE="REFERENCE">Rosenheck 2003</LINK>; <LINK REF="REF-Srisurapanont-2002" TYPE="REFERENCE">Srisurapanont 2002</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-08-07 14:33:13 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>Almost all data in this review were at modest to high risk of bias. All implications must be tempered with this consideration.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. For clinicians</HEADING>
<P>For people who are acutely ill, there is no evidence of an important drop off in efficacy as the dose of haloperidol declines; this is true to a dose range of &gt; 0.25 to 1.5 mg/day. There are greater numbers of studies examining higher dose ranges and these suggest no clear evidence of advantages of doses greater than the &gt; 3 to 7.5 mg/day range. There is no information on longer-term outcomes from haloperidol dose studies.</P>
<P>Doses above the &gt; 3 to 7.5 mg/day range are associated with increased risk of extrapyramidal adverse effects and probably should be avoided, especially given there is no clear evidence for added efficacy. There are, unfortunately, no data that compare the standard lower dose range (&gt; 3 to 7.5 mg/day) with the next lowest dose range (&gt; 1.5 to 3 mg/day), so it is currently impossible to determine from randomised controlled trials whether there may be added benefit in using even lower dose in terms of the reduction of adverse effects. There are no data regarding long-term adverse effects, such as rates of tardive dyskinesia, in comparative haloperidol dose trials.</P>
<P>This review does not answer the question as to whether there is a dose of haloperidol that may be no different from placebo in terms of extrapyramidal adverse effects or tardive dyskinesia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For people with schizophrenia</HEADING>
<P>Generally, there are unlikely to be major benefits from a dose of haloperidol higher than &gt; 3 to 7.5 mg/day for people with schizophrenia. This review cannot answer the question as to whether there may be modest benefits to higher doses, neither can it rule out major benefits of high doses in selected individuals. Doses higher than &gt; 3 to 7.5 mg/day are, however, associated with more extrapyramidal adverse effects. The lowest effective dose of haloperidol during the non-acute phase of illness is still unknown. People with schizophrenia should note that lack of long-term data is also a problem with newer antipsychotic agents (<LINK REF="REF-Duggan-2002" TYPE="REFERENCE">Duggan 2002</LINK>; <LINK REF="REF-Kennedy-2002" TYPE="REFERENCE">Kennedy 2002</LINK>; <LINK REF="REF-Leucht-1999" TYPE="REFERENCE">Leucht 1999</LINK>; <LINK REF="REF-Srisurapanont-2002" TYPE="REFERENCE">Srisurapanont 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For policy makers</HEADING>
<P>There are no data regarding the impact of varying dose ranges of haloperidol on health service utilisation and costs.</P>
<P>This review highlights the need for funding agencies, industry and drug regulatory authorities to collaborate to ensure that clinical trials utilise appropriate dose ranges when comparing new antipsychotic drugs to reference drugs. These agencies should commission or access existing systematic reviews that closely examine dosage issues for reference drugs. They should then ensure that this information is used in the design of clinical trials at the planning stages. Such an intervention would be likely to decrease any real or perceived bias regarding the tolerability and efficacy of new drug agents in the future. This review cannot definitively answer the question as to whether there is a highly tolerable and efficacious dose range of haloperidol that might be an inexpensive equivalent to some of the newer antipsychotic agents. However, it does highlight the possibility that much of the added tolerability attributed to newer drugs is secondary to an inappropriate dosage of haloperidol as a comparator. This issue deserves to be considered when decisions regarding coverage of the new drugs on institutional formularies are being debated.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-08-07 14:33:13 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Importance of systematic reviews</HEADING>
<P>This review clearly highlights the importance of systematic reviews for informing research activities. Had this systematic review been completed in 1991, there would have already been 16 studies (nine of these with completer data only - see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>) that reported no significant benefit in randomisation to higher doses of haloperidol for people with acute schizophrenia. Four of these studies involved the standard lower dose range (&gt; 3 to 7.5 mg/day); the earliest study was conducted in 1967. If these results had been incorporated into drug trials of new agents, we would probably have a much clearer idea of the comparative benefits of the newer agents than we do at present.</P>
<P>The issue here is not only the matter of publishing studies that address dosage issues, but is also the need for the dissemination of the results of these studies throughout clinical and research practice. Researchers need to work together with funding agencies, the pharmaceutical industry and drug regulatory authorities to ensure that future comparative trials make use of the most up-to-date and systematic dosage literature on reference antipsychotic drugs so that future trials are not prone to real or perceived bias related to inappropriate dose comparisons.</P>
<P>Cochrane systematic reviews of newer antipsychotic agents have identified six studies that compare new agents with doses of older antipsychotics equivalent to &gt; 3 to 7.5 mg/day of haloperidol, and have a dropout rate of less than 50%. Three involve risperidone (<LINK REF="REF-Emsley-1995" TYPE="REFERENCE">Emsley 1995</LINK>; <LINK REF="REF-Hoyberg-1993" TYPE="REFERENCE">Hoyberg 1993</LINK>; <LINK REF="REF-Huttunen-1995" TYPE="REFERENCE">Huttunen 1995</LINK>), and three involve quetiapine (<LINK REF="REF-Kudo-1999" TYPE="REFERENCE">Kudo 1999</LINK>; <LINK REF="REF-Murasaki-1999" TYPE="REFERENCE">Murasaki 1999</LINK>; <LINK REF="REF-Peuskens-1997" TYPE="REFERENCE">Peuskens 1997</LINK>). There are no such studies identified in Cochrane reviews involving ziprasidone or olanzapine (<LINK REF="REF-Bagnall-2002" TYPE="REFERENCE">Bagnall 2002</LINK>; <LINK REF="REF-Duggan-2002" TYPE="REFERENCE">Duggan 2002</LINK>). While the tolerability to the new agents in these studies is generally somewhat higher than to the older drugs, it is much less so than in studies that have utilised high doses of haloperidol as a comparator. In all six studies, the point estimate for the efficacy of the new agent was lower than that of the reference older drug. Thus, the hypothesis that low-dose haloperidol is an inexpensive equivalent to new antipsychotic agents remains to be excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. The next update</HEADING>
<P>We are aware that this review is repetitive and lists several sets of data twice. For the next update, we will consider only listing each set of data once and directing the reader to other comparisons when relevant. We will also consider using OR rather than RR. We would be interested in the opinion of readers on this point.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Future studies</HEADING>
<P>Future antipsychotic dose range trials should closely examine outcomes that have been neglected. These include service utilisation, quality of life, satisfaction with treatment and agitation. The latter is particularly important as behavioural agitation may have different dose-response characteristics than other dimensions of symptoms of schizophrenia. This may partially explain the use of higher doses of neuroleptic agents. We do realise that trial design is something that is to be undertaken with great care and detail, but we suggest an outline for a study that would be most informative and address some of the questions currently unanswered (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Although it would fall beyond the remit of this review, long-term data on the effects of haloperidol for relapse prevention is also needed. The question of long-term relapse rates has been given new impetus by the finding that many newer drugs dissociate very quickly from dopamine type 2 (D<SUB>2</SUB>) receptors in the brain compared to drugs such as haloperidol (<LINK REF="REF-Kapur-2001" TYPE="REFERENCE">Kapur 2001</LINK>). It would be useful to know whether treatment with low-dose haloperidol leads to lower relapse rates compared to new agents in people who take medication intermittently.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-08-07 14:00:54 +0100" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank all the staff at the Cochrane Schizophrenia Group for their support. We would also like to thank the authors of earlier versions of this review for generous sharing of their work on which this new version is based (<LINK REF="REF-Waraich-2002" TYPE="REFERENCE">Waraich 2002</LINK>).</P>
<P>In particular the contributions made by:</P>
<P>Karen Hammill - database management, blinding of studies, editing and comments on drafts of the review.</P>
<P>Joan Marti - database management, blinding of studies, editing and comments on drafts of the review.</P>
<P>Marta Roque - statistical consultant, results section and tables, editing and comments on drafts of the review.</P>
<P>Paul Waraich - lead author for original version.</P>
<P>We would also like to thank and acknowledge Marianna Purgato for peer reviewing this review and Ben Gray for writing the Plain Language Summary.</P>
<P>The Trials Search Co-ordinator of the Cochrane Schizophrenia Group, Samantha Roberts, developed the search terms for this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-07 14:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>Lorna Donnelly - formulation of protocol, conducting searches, inclusion/exclusion of studies, data extraction, results/conclusions, ongoing maintenance of review.</P>
<P>John Rathbone - help with data extraction for previous versions of the review.</P>
<P>Clive Adams - formulation of protocol, inclusion/exclusion of studies, data extraction, results/conclusions, ongoing maintenance of review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-01-29 12:24:41 +0000" MODIFIED_BY="[Empty name]">
<P>In the secondary outcome measures authors added clinically significant change in mental state as a subgroup in clinical response.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-09-11 17:32:21 +0100" MODIFIED_BY="Clive E Adams">
<P>Review original title: Haloperidol dose for exacerbation of schizophrenia</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-06-26 13:10:48 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-06-26 13:06:33 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-06-26 13:03:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Curtis-1995" MODIFIED="2013-06-26 13:02:21 +0100" MODIFIED_BY="[Empty name]" NAME="Curtis 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-06-26 13:02:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Curtis CE, Mann M, Piscani K, Burr G, Hitzemann RJ, Hirschowitz J</AU>
<TI>A neuroendocrine method of antipsychotic dose reduction in schizophrenia</TI>
<SO>Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami</SO>
<YR>1995</YR>
<IDENTIFIERS MODIFIED="2012-09-19 09:15:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donlon-1980" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Donlon 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Donlon PT, Hopkin JT, Tupin JP, Wicks JJ, Wahba M, Meadow A</AU>
<TI>Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1980</YR>
<VL>6</VL>
<PG>691-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahba M, Donlon PT, Meadow A</AU>
<TI>Cognitive changes in acute schizophrenia with brief neuroleptic treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<NO>10</NO>
<PG>1307-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janicak-1997" MODIFIED="2013-06-24 14:40:07 +0100" MODIFIED_BY="[Empty name]" NAME="Janicak 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-09-12 10:19:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM</AU>
<TI>A two-phase, double-blind randomised study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1997</YR>
<VL>4</VL>
<PG>343-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Javaid JI, Janicak PG, Hedeker D, Sharma RP, Davis JM</AU>
<TI>Steady-state plasma level prediction for haloperidol from a single test dose</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1991</YR>
<VL>27</VL>
<NO>1</NO>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Javaid JI, Janicak PG, Sharma RP, Leach AM, Davis JM, Wang Z</AU>
<TI>Prediction of haloperidol steady-state levels in plasma after a single test dose</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>1</NO>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kapur-2000" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Kapur 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kapur S, Zipursky R, Jones C, Remington G, Houle S</AU>
<TI>Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>4</VL>
<PG>514-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khanna-1997" MODIFIED="2012-09-19 09:20:07 +0100" MODIFIED_BY="[Empty name]" NAME="Khanna 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-09-19 09:20:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khanna A, Lal N, Dalal PK, Khalid A, Trivedi JK</AU>
<TI>Treatment of acute and transient psychotic disorders with low and high doses of oral haloperidol</TI>
<SO>Indian Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>39</VL>
<NO>2</NO>
<PG>136-42</PG>
<IDENTIFIERS MODIFIED="2012-09-19 09:20:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klieser-1987" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Klieser 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Lehmann E</AU>
<TI>Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol</TI>
<SO>Neuropsychobiology</SO>
<YR>1987</YR>
<VL>18</VL>
<NO>3</NO>
<PG>122-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Lehmann E</AU>
<TI>Experimental comparison of the efficacy of standardized haloperidol treatment and adequate individual dosages in acute schizophrenic states</TI>
<SO>Fortschritte der Neurologie Psychiatrie</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>126-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-1987" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Liang 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liang S</AU>
<TI>Comparison of therapeutic effects between haloperidol and insulin coma for schizophrenia and the optimal blood level of haloperidol</TI>
<SO>Chinese Journal of Neurology and Psychiatry</SO>
<YR>1987</YR>
<VL>20</VL>
<NO>1</NO>
<PG>43-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Louza-1988" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Louza 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Louza Neto MR, Muller Spahn F, Ruther E, Scherer J</AU>
<TI>Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1988</YR>
<VL>21</VL>
<NO>5</NO>
<PG>226-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3227054"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-1991" MODIFIED="2013-06-26 13:02:37 +0100" MODIFIED_BY="[Empty name]" NAME="McEvoy 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-06-26 13:02:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Hogarty GE, Steingard S</AU>
<TI>Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>8</NO>
<PG>739-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Schooler NR, Wilson WH</AU>
<TI>Predictors of therapeutic response to haloperidol in acute schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1991</YR>
<VL>27</VL>
<NO>2</NO>
<PG>97-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Modestin-1983" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Modestin 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Modestin J, Toffler G, Pia M, Greub E</AU>
<TI>Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens</TI>
<SO>Pharmacopsychiatria</SO>
<YR>1983</YR>
<VL>16</VL>
<PG>4121-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neborsky-1981" MODIFIED="2012-09-19 09:21:14 +0100" MODIFIED_BY="[Empty name]" NAME="Neborsky 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neborsky R, Depry D, Janowsky DS, Munson E, Perel J</AU>
<TI>Haloperidol plasma red blood-cell ratios and clinical efficacy</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1982</YR>
<VL>18</VL>
<NO>4</NO>
<PG>17-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:21:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10. Neborsky, R.; Janowsky, D.; Munson, E., and Depry, D. Rapid treatment of acute psychotic symptoms with high-and low-dose haloperidol. Behavioral considerations. Arch-Gen-Psychiatry. 1981 Feb; 38(2):195-9; ISSN: 0003-990X.&lt;/p&gt;" NOTES_MODIFIED="2012-09-19 09:21:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neborsky R, Janowsky D, Munson E, Depry D</AU>
<TI>Rapid treatment of acute psychotic symptoms with high-and low-dose haloperidol. Behavioral considerations</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1981</YR>
<VL>38</VL>
<NO>2</NO>
<PG>195-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neborsky R, Janowsky D, Munson E, Hornbeck C, Depry D</AU>
<TI>Behavioral prediction of response to haloperidol: a test dose strategy</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1982</YR>
<VL>43</VL>
<NO>4</NO>
<PG>157-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neborsky RJ, Janowsky DS, Perel JM, Munson E, Depry D</AU>
<TI>Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1984</YR>
<VL>45</VL>
<NO>1</NO>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neborsky RJ, Janowsky DS, Perel JM</AU>
<TI>Red-blood-cell plasma haloperidol ratios and antipsychotic efficacy</TI>
<SO>Psychiatry Research</SO>
<YR>1982</YR>
<VL>6</VL>
<NO>1</NO>
<PG>123-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosthuizen-2004" MODIFIED="2012-09-19 09:21:52 +0100" MODIFIED_BY="[Empty name]" NAME="Oosthuizen 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-09-19 09:21:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosthuizen P, Emsley R, Turner HJ, Keyter N</AU>
<TI>A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>2</NO>
<PG>125-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15003147"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palao-1994" MODIFIED="2013-06-26 13:03:06 +0100" MODIFIED_BY="[Empty name]" NAME="Palao 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-06-26 13:02:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Palao DJ, Arauxo A, Brunet M, Bernardo M, Haro JM, Ferrer J, et al</AU>
<TI>Haloperidol: therapeutic window in schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>5</NO>
<PG>303-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:02:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palao DJ, Arauxo A, Brunet M, Marquez M, Bernardo M, Ferrer J, et al</AU>
<TI>Positive versus negative symptoms in schizophrenia: response to haloperidol</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>1</NO>
<PG>155-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:03:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palao DJ, Arauxo A, Haro JM, Brunet M, Bernardo M, Volavka J, et al</AU>
<TI>The relationship between plasma haloperidol concentrations and clinical results</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>12</NO>
<PG>1167-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rifkin-1991" MODIFIED="2012-09-19 09:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Rifkin 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doddi S, Rifkin A, Karajgi B, Cooper T, Borenstein M</AU>
<TI>Blood levels of haloperidol and clinical outcome in schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>3</NO>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:23:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;7. Rifkin, A.; Doddi, S.; Karajgi, B.; Borenstein, M., and Wachspress, M. Dosage of haloperidol for schizophrenia. Arch-Gen-Psychiatry. 1991 Feb; 48(2):166-70; ISSN: 0003-990X.&lt;/p&gt;" NOTES_MODIFIED="2012-09-19 09:23:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M</AU>
<TI>Dosage of haloperidol for schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>2</NO>
<PG>166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1967" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 1967" YEAR="1967">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JWS, Edwards JG</AU>
<TI>A controlled study of haloperidol in chronic schizophrenia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1967</YR>
<VL>9</VL>
<NO>8</NO>
<PG>401-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stone-1995" MODIFIED="2013-06-26 13:03:16 +0100" MODIFIED_BY="[Empty name]" NAME="Stone 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-06-26 13:03:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garver DL, Steinberg JL, McDermott BE, Yao JK, Ramberg JE, Lewis S, et al</AU>
<TI>Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>3</NO>
<PG>191-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J</AU>
<TI>Further evidence of a dose-response threshold for haloperidol in psychosis</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>8</NO>
<PG>1210-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volavka-1992" MODIFIED="2013-06-26 13:03:43 +0100" MODIFIED_BY="[Empty name]" NAME="Volavka 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-06-26 13:03:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bitter I, Volavka J, Cooper J, Scheurer, Camus L, Bakall R</AU>
<TI>Haloperidol blood levels and clinical effects in schizophrenia</TI>
<SO>Proceedings of the 8th World Congress of Psychiatry; 1989 Oct 13-19; Athens, Greece</SO>
<YR>1989</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB</AU>
<TI>Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder</TI>
<SO>Psychiatry Research</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:25:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Convit A, Volavka J, Czobor P, De Asis J, Evangelista C</AU>
<TI>Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<NO>1</NO>
<PG>49-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper TB, Volavka J, Czobor P</AU>
<TI>Plasma drug level and clinical response</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>2</NO>
<PG>134-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:25:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Dimensions of the brief psychiatric rating scale: an examination of stability during haloperidol treatment</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>3</NO>
<PG>205-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve</TI>
<SO>Psychiatry Research</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>2</NO>
<PG>129-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:03:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Positive and negative symptoms: is their change related?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>4</NO>
<PG>577-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>5</NO>
<PG>332-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krakowski M, Czobor P, Volavka J</AU>
<TI>Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes</TI>
<SO>Psychiatry Research</SO>
<YR>1997</YR>
<VL>71</VL>
<NO>1</NO>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:03:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, et al</AU>
<TI>Haloperidol blood levels and clinical effects</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>354-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Cooper TB, Meisner M, Bitter I, Czobor P, Jaeger J</AU>
<TI>Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Douyon R, Convit A, Czobor P, Cooper TB</AU>
<TI>Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>12</NO>
<PG>999-1000</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1449388"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volavka-1995" MODIFIED="2013-06-21 16:42:21 +0100" MODIFIED_BY="[Empty name]" NAME="Volavka 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB</AU>
<TI>Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder</TI>
<SO>Psychiatry Research</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>3</NO>
<PG>205-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:26:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Positive and negative symptoms: is their change related?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>4</NO>
<PG>577-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Cooper TB, Czobor P, Meisner M</AU>
<TI>Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>1</NO>
<PG>75-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:26:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Cooper TB, Czobor P, Meisner M</AU>
<TI>Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>10</NO>
<PG>837-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-21 16:42:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Cooper TB, Czobor P, Meisner M</AU>
<TI>Haloperidol plasma levels and clinical effects</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<VL>31</VL>
<PG>536</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winter-1984" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Winter 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann E, Lienert GA</AU>
<TI>Differential improvements from haloperidol in two types of schizophrenics</TI>
<SO>Psychopharmacology</SO>
<YR>1984</YR>
<VL>84</VL>
<NO>1</NO>
<PG>96-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Winter M, Lehmann E, Scholz OB</AU>
<TI>Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder</TI>
<SO>Neuropsychobiology</SO>
<YR>1984</YR>
<VL>2-3</VL>
<PG>115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-06-26 13:06:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorndal-1980" MODIFIED="2013-06-26 13:03:55 +0100" MODIFIED_BY="[Empty name]" NAME="Bjorndal 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-06-26 13:03:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;32. Bjorndal, N.; Bjerre, M.; Gerlach, J.; Kristjansen, P.; Magelund, G.; Oestrich, I. H., and Waehrens, J. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology-Berl. 1980 Jan; 67(1):17-23.&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 13:03:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH, et al</AU>
<TI>High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin</TI>
<SO>Psychopharmacology</SO>
<YR>1980</YR>
<VL>67</VL>
<NO>1</NO>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyer-1987" MODIFIED="2013-06-21 16:43:10 +0100" MODIFIED_BY="[Empty name]" NAME="Boyer 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-06-21 16:43:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyer P, Puech AJ</AU>
<TI>Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools</TI>
<TO>Modalities d'action clinique ses neuroleptiques: substances, doses, instruments de mesure utilises</TO>
<SO>Psychiatrie and Psychobiologie</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>4</NO>
<PG>296-305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coryell-1990" MODIFIED="2012-09-19 09:29:11 +0100" MODIFIED_BY="[Empty name]" NAME="Coryell 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;21. Coryell, W.; Kelly, M.; Perry, P. J., and Miller, D. D. Haloperidol plasma levels and acute clinical change in schizophrenia. J-Clin-Psychopharmacol. 1990 Dec; 10(6):397-402; ISSN: 0271-0749.&lt;/p&gt;" NOTES_MODIFIED="2012-09-11 10:02:27 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coryell W, Kelly M, Perry PJ, Miller DD</AU>
<TI>Haloperidol plasma levels and acute clinical change in schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>6</NO>
<PG>397-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:29:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly MW, Perry PJ, Coryell WH, Miller DD, Arndt SV</AU>
<TI>Reduced haloperidol plasma-concentration and clinical-response in acute exacerbations of schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1990</YR>
<VL>102</VL>
<NO>4</NO>
<PG>514-20</PG>
<IDENTIFIERS MODIFIED="2012-09-19 09:29:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coryell-1998" MODIFIED="2013-06-21 16:43:45 +0100" MODIFIED_BY="[Empty name]" NAME="Coryell 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1. Coryell, W.; Miller, D. D., and Perry, P. J. Haloperidol plasma levels and dose optimization. Am-J-Psychiatry. 1998 Jan; 155(1):48-53; ISSN: 0002-953X.&lt;/p&gt;" NOTES_MODIFIED="2012-09-11 10:02:27 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coryell W, Miller DD, Perry PJ</AU>
<TI>Haloperidol plasma levels and dose optimization</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>1</NO>
<PG>48-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-21 16:43:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coryell WH, Miller DD, Perry PJ</AU>
<TI>The clinical utility of haloperidol plasma levels</TI>
<SO>Schizophrenia Research</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1-2</NO>
<PG>146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1985" MODIFIED="2013-06-26 13:04:06 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-06-26 13:04:06 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;33. DAVIS, J. M. ERICKSEN, S.E., HURT, S., CHANG, S.S., JAVAID, J.I., =  DEKIRMENJIAN, H., CASPER, R. BLOOD LEVELS OF HALOPERIDOL AND CLINICAL RESPONSE. PSYCHOPHARMACOLOGY BULLETIN 21 (1), P.48-51, 1985.&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 13:04:06 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, et al</AU>
<TI>Blood levels of haloperidol and clinical response</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1985</YR>
<VL>21</VL>
<NO>1</NO>
<PG>48-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:30:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ericksen SE, Hurt SW, Chang S</AU>
<TI>Haloperidol dose, plasma levels, and clinical response: a double-blind study</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1978</YR>
<VL>14</VL>
<NO>2</NO>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurt SW, Holzma PS, Davis JM</AU>
<TI>Thought disorder. The measurement of its changes</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1983</YR>
<VL>40</VL>
<PG>1281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubin-1985" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Dubin 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dubin WR, Waxman HM, Weiss KJ, Ramchandani D, Tavani-Petrone C</AU>
<TI>Rapid tranquilization: the efficacy of oral concentrate</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<NO>11</NO>
<PG>475-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dutoit-1995" MODIFIED="2013-06-26 13:04:20 +0100" MODIFIED_BY="[Empty name]" NAME="Dutoit 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-06-26 13:04:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, et al</AU>
<TI>Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses</TI>
<TO>Activite cetone reductase erythrocytaire, taux plasmatiques d'haloperidol et psychoses aigues</TO>
<SO>Encephale</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>6</NO>
<PG>417-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garver-1984" MODIFIED="2013-06-21 16:45:00 +0100" MODIFIED_BY="[Empty name]" NAME="Garver 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-06-21 16:45:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J</AU>
<TI>Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)</TI>
<SO>Psychological Medicine</SO>
<YR>1988</YR>
<VL>18</VL>
<PG>873-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mavroidis ML, Garver DL, Kanter DR, Hirschowitz J</AU>
<TI>Plasma haloperidol levels and clinical response: confounding variables</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1985</YR>
<VL>21</VL>
<NO>1</NO>
<PG>62-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3983340"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:31:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL</AU>
<TI>Clinical response and plasma haloperidol levels in schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1983</YR>
<VL>81</VL>
<NO>4</NO>
<PG>354-6</PG>
<IDENTIFIERS MODIFIED="2012-09-19 09:31:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garver-1985" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Garver 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;22. Garver, D. L.; Hirschowitz, J.; Glicksteen, G. A.; Kanter, D. R., and Mavroidis, M. L. Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J-Clin-Psychopharmacol. 1984 Jun; 4(3):133-7; ISSN: 0271-0749.&lt;/p&gt;" NOTES_MODIFIED="2012-09-11 10:02:27 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML</AU>
<TI>Haloperidol plasma and red blood cell levels and clinical antipsychotic response</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>3</NO>
<PG>133-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1985a" MODIFIED="2012-09-19 09:31:16 +0100" MODIFIED_BY="[Empty name]" NAME="Gerlach 1985a" YEAR="1985">
<REFERENCE MODIFIED="2012-09-19 09:31:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Behnke K, Heltberg J, Munk-Andersen, Nielsen H</AU>
<TI>Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross-over study of therapeutic effectiveness, side effects and plasma concentrations</TI>
<TO>Le dogmatil et l'haloperidol dans le traitement de la schizophrenie. Etude croisee en double aveugle de l'action therapeutique, des effets secondaires et des concentrations plasmatiques</TO>
<SO>Semaine des Hopitaux</SO>
<YR>1985</YR>
<VL>61</VL>
<NO>19</NO>
<PG>1309-16</PG>
<IDENTIFIERS MODIFIED="2012-09-19 09:31:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirschowitz-1997" MODIFIED="2013-06-26 13:04:31 +0100" MODIFIED_BY="[Empty name]" NAME="Hirschowitz 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-06-26 13:04:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hirschowitz J, Hitzemann R, Piscani K, Burr G, Frecska E, Culliton D, et al</AU>
<TI>The Dose Reduction in Schizophrenia (DORIS) Study: a final report</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>1</NO>
<PG>31-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-1996" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Levin 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Levin ED, Wilson W, Rose JE, McEvoy J</AU>
<TI>Nicotine-haloperidol interactions and cognitive performance in schizophrenics</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>5</NO>
<PG>429-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega_x002d_Soto-1993" MODIFIED="2013-06-26 13:04:37 +0100" MODIFIED_BY="[Empty name]" NAME="Ortega-Soto 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-06-26 13:04:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ortega-Soto HA, Fernandez AE, Pinedo H, De La Torre P, Brunner E, Apiquian R</AU>
<TI>Clinical trial of haloperidol threshold doses</TI>
<SO>Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-27; San Francisco</SO>
<YR>1993</YR>
<IDENTIFIERS MODIFIED="2012-09-19 09:31:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega_x002d_Soto-1994" MODIFIED="2013-06-26 13:05:03 +0100" MODIFIED_BY="[Empty name]" NAME="Ortega-Soto 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-06-26 13:04:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ortega-Soto HA, Brunner E, Apiquian R, De La Torre P</AU>
<TI>Therapeutic minimum dose of haloperidol in schizophrenia</TI>
<SO>Neuropsychopharmocology</SO>
<YR>1994</YR>
<VL>10</VL>
<NO>3S Pt 2</NO>
<PG>140S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:05:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ortega-Soto HA, Fernandez AE, Pinedo H, De La Torre P, Brunner E, Apiquian R</AU>
<TI>Clinical trial of haloperidol threshold doses</TI>
<SO>Patient Care for the 21st Century: Asserting Professional Values with Economic Restraints. Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993, May 22-27; San Francisco</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reschke-1974" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Reschke 1974" YEAR="1974">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reschke RW</AU>
<TI>Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1974</YR>
<VL>35</VL>
<NO>3</NO>
<PG>112-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17894080"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-1989" MODIFIED="2013-06-26 13:05:11 +0100" MODIFIED_BY="[Empty name]" NAME="Santos 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-09-19 09:32:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santos JL, Cabranes JA, Almoguera I, Ramos JA, Vazquez C, Angeles F</AU>
<TI>Clinical implications of determination of plasma haloperidol levels</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1989</YR>
<VL>79</VL>
<NO>4</NO>
<PG>348-54</PG>
<IDENTIFIERS MODIFIED="2012-09-19 09:32:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11. Santos, J. L.; Cabranes, J. A.; Vazquez, C.; Fuentenebro, F.; Almoguera, I., and Ramos, J. A. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia. Biol-Psychiatry. 1989 Aug; 26(4):381-8; ISSN: 0006-3223.&lt;/p&gt;" NOTES_MODIFIED="2012-09-11 10:02:27 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Santos JL, Cabranes JA, Vazquez C, Fuentenebro F, Almoguera I, Ramos JA</AU>
<TI>Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1989</YR>
<VL>26</VL>
<NO>4</NO>
<PG>381-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:05:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santos JL, Ramos JA, Prieto P, Almoguera I, Vazquez C, Rubio ME, et al</AU>
<TI>Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia-clinical utility</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>6</NO>
<PG>917-25</PG>
<IDENTIFIERS MODIFIED="2012-09-19 09:32:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sim-1989" MODIFIED="2013-06-26 13:05:20 +0100" MODIFIED_BY="[Empty name]" NAME="Sim 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-06-26 13:05:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Sim CB, Lee YC, Hwang JP</AU>
<TI>Haloperidol for schizophrenic inpatients with three doseage regimens</TI>
<SO>Psychiatry Today: Accomplishments and Promises; Proceedings of the 8th World Congress of Psychiatry; 1989, Oct 12-19; Athens, Greece</SO>
<YR>1989</YR>
<PG>817</PG>
<PB>Excerpta Medica International Congress Series 899</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1984" MODIFIED="2013-06-26 13:05:43 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-06-26 13:05:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Baumgartner R, Burd A, Calderon M, Largen J, Mauldin M, et al</AU>
<TI>Cortical atrophy and white matter density in the brains of schizophrenics and clinical-response to neuroleptics</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1987</YR>
<VL>75</VL>
<NO>1</NO>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:05:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9. Smith, R. C.; Baumgartner, R.; Misra, C. H.; Mauldin, M.; Shvartsburd, A.; Ho, B. T., and DeJohn, C. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Arch-Gen-Psychiatry. 1984 Nov; 41(11):1044-9; ISSN: 0003-990X.&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 13:05:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, et al</AU>
<TI>Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>11</NO>
<PG>1044-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Burd A, Baumgartner R, Ravichandran GK, Mauldin M</AU>
<TI>Haloperidol and thioridazine drug levels and clinical-response in schizophrenia-comparison of gas-liquid-chromatography and radioreceptor drug level assays</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1985</YR>
<VL>21</VL>
<NO>1</NO>
<PG>52-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:05:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Ravichandran GK, Vroulis G, Mauldin M, Baumgartner R, Gordon J, et al</AU>
<TI>Lateral ventricular enlargement and clinical-response in schizophrenia</TI>
<SO>Psychiatry Research</SO>
<YR>1985</YR>
<VL>14</VL>
<NO>3</NO>
<PG>241-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC, Shvartsburd A, Vroulis G, Ravichandran GK, Mauldin M, Baumgartner R</AU>
<TI>Comparative efficacy of red-cell and plasma haloperidol as predictors of clinical-response in schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1985</YR>
<VL>85</VL>
<NO>4</NO>
<PG>449-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-21 17:20:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC</AU>
<TI>Plasma haloperidol levels-clinical-response and fancy mathematics - reply</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1985</YR>
<VL>42</VL>
<NO>8</NO>
<PG>835-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC</AU>
<TI>The interpretation of plasma haloperidol concentrations-reply</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1985</YR>
<VL>42</VL>
<NO>8</NO>
<PG>839-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1987" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith RC</AU>
<TI>Plasma haloperidol levels and clinical response</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1987</YR>
<VL>44</VL>
<NO>12</NO>
<PG>1110-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Putten-1990" MODIFIED="2013-06-24 14:47:28 +0100" MODIFIED_BY="[Empty name]" NAME="Van Putten 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-06-24 14:47:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Putten T, Marder SR, Mintz J</AU>
<TI>A controlled dose comparison of haloperidol in newly admitted schizophrenic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>8</NO>
<PG>754-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volavka-2000" MODIFIED="2013-06-26 13:05:52 +0100" MODIFIED_BY="[Empty name]" NAME="Volavka 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-06-24 14:47:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Cooper TB, Czobor P, Lindenmayer J P, Citrome LL, Mohr P, et al</AU>
<TI>High dose treatment with haloperidol: the effect of dose reduction</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>252-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10770466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:05:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P</AU>
<TI>Haloperidol blood levels and effects in schizophrenia</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2012-09-19 09:33:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimbroff-1997" MODIFIED="2013-06-26 13:06:33 +0100" MODIFIED_BY="[Empty name]" NAME="Zimbroff 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-06-26 13:06:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Baker R, Mack R, Morris D, Sebree T, Kashkin KB</AU>
<TI>The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients</TI>
<SO>Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam, Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:06:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bark N, Mack R, Zborowski J, Morris D, Sebree T, Shook S, et al</AU>
<TI>Efficacy and safety of three doses of sertindole and haloperidol in schizophrenic patients</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>597</PG>
<PB>

</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:35:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Larson GL, Mack RJ, Zborowski J, Morris DD, Sebree TB, Wallin BA</AU>
<TI>Three doses each of sertindole and haloperidol in schizophrenics</TI>
<SO>Proceedings of the 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-19 09:36:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tamminga C, Mack R, Zborowski J, Morris D, Sebree T, Wallin B</AU>
<TI>Efficacy and safety of three doses of sertindole and haldol in schizophrenic patients</TI>
<SO>Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:06:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2. Zimbroff, D. L.; Kane, J. M.; Tamminga, C. A.; Daniel, D. G.; Mack, R. J.; Wozniak, P. J.; Sebree, T. B.; Wallin, B. A., and Kashkin, K. B. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am-J-Psychiatry. 1997 Jun; 154(6):782-91; ISSN: 0002-953X.&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 13:06:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zimbroff DL, Kane JM, Tamminga C, Daniel DG, Mack RJ, Wozniak PJ, et al</AU>
<TI>Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>6</NO>
<PG>782-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:06:26 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zimbroff DL, Mack RJ, Morris DD, Silber CJ</AU>
<TI>The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients</TI>
<SO>Schizophrenia 1996: Breaking Down the Barriers. Proceedings of the 4th International Conference; 1996 Oct 6-9; Vancouver</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 13:06:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zimbroff DL, Mack RJ, Zborowski JN, Morris DD, Sebree TB, Wallin BA</AU>
<TI>The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients</TI>
<SO>Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-05-09 14:42:45 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-06-26 13:10:48 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-06-26 13:10:32 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Addington-1990" MODIFIED="2013-06-21 17:29:06 +0100" MODIFIED_BY="[Empty name]" NAME="Addington 1990" TYPE="JOURNAL_ARTICLE">
<AU>Addington D, Addington J, Schissel B
</AU>
<TI>A depression rating scale for schizophrenics</TI>
<SO>Schizophrenia Research</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2012-09-19 09:38:57 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2012-09-19 09:38:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-1997" MODIFIED="2013-06-26 13:06:43 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Psychiatric Association</AU>
<TI>Practice guideline for the treatment of patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154 Suppl 4</VL>
<PG>1-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Awad-1993" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Awad 1993" TYPE="JOURNAL_ARTICLE">
<AU>Awad AG</AU>
<TI>Methodological and design issues in clinical trials of new neuroleptics: an overview</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>Suppl 22</VL>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Awad-1999" MODIFIED="2013-06-26 13:06:49 +0100" MODIFIED_BY="[Empty name]" NAME="Awad 1999" TYPE="JOURNAL_ARTICLE">
<AU>Awad AG, Voruganti LP</AU>
<TI>Cost-utility analysis in schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60 Suppl 3</VL>
<PG>22-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagnall-2002" MODIFIED="2012-09-19 09:39:20 +0100" MODIFIED_BY="[Empty name]" NAME="Bagnall 2002" TYPE="COCHRANE_REVIEW">
<AU>Bagnall, A-M. Lewis, RA. Leitner, ML</AU>
<TI>Ziprasidone for schizophrenia and severe mental illness</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-03 14:10:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:10:57 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001945"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baldessarini-1984" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Baldessarini 1984" TYPE="JOURNAL_ARTICLE">
<AU>Baldessarini RJ, Katz B, Cotton P</AU>
<TI>Dissimilar dosing with high-potency and low-potency neuroleptics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<NO>6</NO>
<PG>748-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baldessarini-1988" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Baldessarini 1988" TYPE="JOURNAL_ARTICLE">
<AU>Baldessarini RJ, Cohen BM, Teicher MH</AU>
<TI>Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>79-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baldessarini-1995" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Baldessarini 1995" TYPE="JOURNAL_ARTICLE">
<AU>Baldessarini RJ, Kando JC, Centorrino F</AU>
<TI>Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>7</NO>
<PG>1038-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bezchlibnyk-1994" MODIFIED="2012-09-19 09:40:13 +0100" MODIFIED_BY="[Empty name]" NAME="Bezchlibnyk 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bezchlibnyk-Butler KZ, Remington GJ</AU>
<TI>Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>39</VL>
<NO>2</NO>
<PG>74-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2009-07-17 16:20:28 +0100" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bollini-1994" MODIFIED="2012-09-12 10:19:31 +0100" MODIFIED_BY="[Empty name]" NAME="Bollini 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bollini P, Pampallona S, Orza MJ, Adamas ME, Chalmers TC</AU>
<TI>Antipsychotic drugs: is more worse? A meta-analysis of the published randomised control trials</TI>
<SO>Psychological Medicine</SO>
<YR>1994</YR>
<VL>24</VL>
<PG>307-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Citrome-2011" MODIFIED="2013-06-26 13:07:00 +0100" MODIFIED_BY="[Empty name]" NAME="Citrome 2011" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L</AU>
<TI>Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved antipsychotic</TI>
<SO>International Journal of Clinical Practise</SO>
<YR>2011</YR>
<VL>65</VL>
<NO>2</NO>
<PG>189-210</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2002" MODIFIED="2013-06-26 13:07:06 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2002" TYPE="OTHER">
<AU>Clarke M, Oxman AD (editors)</AU>
<TI>Cochrane Reviewer's Handbook</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conley-1997" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Conley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Carpenter WT Jr, Tamminga CA</AU>
<TI>Time to clozapine response in a standardized trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>9</NO>
<PG>1243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CPA-1998" MODIFIED="2013-06-26 13:07:16 +0100" MODIFIED_BY="[Empty name]" NAME="CPA 1998" TYPE="JOURNAL_ARTICLE">
<AU>Canadian Psychiatric Association</AU>
<TI>Canadian clinical practice guidelines for the treatment of schizophrenia</TI>
<SO>Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie</SO>
<YR>1998</YR>
<VL>2 Suppl 43</VL>
<PG>25-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-2003" MODIFIED="2013-06-26 13:07:22 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 2003" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM, Chen N, Glick ID</AU>
<TI>A meta-analysis of the efficacy of second-generation antipsychotics</TI>
<SO>Archives General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>6</NO>
<PG>553-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Oliveira-1996" MODIFIED="2012-09-19 09:41:32 +0100" MODIFIED_BY="[Empty name]" NAME="De Oliveira 1996" TYPE="JOURNAL_ARTICLE">
<AU>De Oliveira IR, De Sena EP, Pereira EL</AU>
<TI>Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>4</NO>
<PG>229-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2013-06-26 13:07:30 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2012-09-12 10:19:31 +0100" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomised trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2002" MODIFIED="2012-09-19 09:41:55 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2002" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-03 14:13:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:13:01 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2013-06-26 13:07:37 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: sulpiride versus placebo for schizophrenia 18/22 methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emsley-1995" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Emsley 1995" TYPE="CONFERENCE_PROC">
<AU>Emsley R, McCreadie R, Livingston M, De Smedt G, Lemmens P</AU>
<TI>Risperidone in the treatment of first-episode schizophrenic patients with schizophreniform disorder: a double blind study</TI>
<SO>Congress of the International Academy for Biomedical and Drug Research on Critical Issues in the Treatment of Schizophrenia</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Endicott-1978" MODIFIED="2013-06-26 13:07:45 +0100" MODIFIED_BY="[Empty name]" NAME="Endicott 1978" TYPE="JOURNAL_ARTICLE">
<AU>Endicott J, Spitzer RL</AU>
<TI>A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>837-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gardner-2005" MODIFIED="2013-06-26 13:07:51 +0100" MODIFIED_BY="[Empty name]" NAME="Gardner 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gardner DM, Baldessarini RJ, Waraich P</AU>
<TI>Modern antipsychotic drugs: a critical overview</TI>
<SO>CMAJ</SO>
<YR>2005</YR>
<VL>172</VL>
<NO>13</NO>
<PG>1703-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geddes-1999" MODIFIED="2012-09-19 09:43:41 +0100" MODIFIED_BY="[Empty name]" NAME="Geddes 1999" TYPE="OTHER">
<AU>Geddes J</AU>
<TI>Royal College of Psychiatrists guidelines on for the care of those with schizophrenia</TI>
<SO>The Schizophrenia Trials Meeting; 1999 May 5-7; Stratford-upon-Avon, UK</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glazer-1998" MODIFIED="2013-06-26 13:07:57 +0100" MODIFIED_BY="[Empty name]" NAME="Glazer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM</AU>
<TI>Formulary decisions and health economics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59 Suppl 19</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2013-06-26 13:08:04 +0100" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2013-06-26 13:08:12 +0100" MODIFIED_BY="Anne Lawson" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-1997" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Hansen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hansen TE, Casey DE, Hoffman WF</AU>
<TI>Neuroleptic intolerance</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>4</NO>
<PG>567-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-06-26 13:08:21 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogarty-1973" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Hogarty 1973" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Goldberg SC</AU>
<TI>Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1973</YR>
<VL>28</VL>
<NO>1</NO>
<PG>54-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogarty-1974" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Hogarty 1974" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF</AU>
<TI>Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1974</YR>
<VL>31</VL>
<NO>5</NO>
<PG>603-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoyberg-1993" MODIFIED="2013-06-21 17:52:45 +0100" MODIFIED_BY="[Empty name]" NAME="Hoyberg 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hoyberg O, Fensbo C, Remvig J, LingJaerde O, Sloth-Neilsen M, Salvesen I
</AU>
<TI>Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>88</VL>
<PG>395-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2009" MODIFIED="2013-06-26 13:08:32 +0100" MODIFIED_BY="[Empty name]" NAME="Hutton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL</AU>
<TI>Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials</TI>
<SO>British Journal of Haematology</SO>
<YR>2009</YR>
<VL>146</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huttunen-1995" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Huttunen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Huttunen M, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V</AU>
<TI>Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel group trial</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1995</YR>
<VL>91</VL>
<PG>271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2013-06-26 13:08:39 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavanagh DJ, et al</AU>
<TI>Assessing the quality of reports of randomised clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1999" MODIFIED="2013-06-26 13:08:44 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1999" TYPE="CONFERENCE_PROC">
<AU>Jadad A</AU>
<TI>Meta-analysis making the same mistakes as trials</TI>
<SO>Proceedings of the 2nd Symposium on Systematic Reviews: Beyond the Basics; 1999 Jan 5-7; Oxford, UK</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1993" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Johnson RE, McFarland BH</AU>
<TI>Antipsychotic drug exposure in a health maintenance organization</TI>
<SO>Medical Care</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>5</NO>
<PG>432-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joy-2002" MODIFIED="2012-09-19 09:48:13 +0100" MODIFIED_BY="[Empty name]" NAME="Joy 2002" TYPE="COCHRANE_REVIEW">
<AU>Joy C, Lawrie S</AU>
<TI>Haloperidol versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-03 14:11:50 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:11:50 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003082.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kane-1996" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>1</NO>
<PG>34-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kapur-1996" MODIFIED="2013-06-26 13:08:53 +0100" MODIFIED_BY="[Empty name]" NAME="Kapur 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, et al</AU>
<TI>High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>7</NO>
<PG>948-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kapur-1997" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Kapur 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S</AU>
<TI>PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>11</NO>
<PG>1525-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kapur-1998" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Kapur 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kapur S</AU>
<TI>A new framework for investigating antipsychotic action in humans: lessons from pet imaging</TI>
<SO>Molecular Psychiatry</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>2</NO>
<PG>135-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kapur-2001" MODIFIED="2013-06-26 13:09:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kapur 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kapur S, Seeman P</AU>
<TI>Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>3</NO>
<PG>360-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2013-06-26 13:09:21 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-2002" MODIFIED="2012-09-19 09:48:46 +0100" MODIFIED_BY="[Empty name]" NAME="Kennedy 2002" TYPE="COCHRANE_REVIEW">
<AU>Kennedy E, Song F, Hunter R, Clarke A, Gilbody S</AU>
<TI>Risperidone versus typical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-03 14:14:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:14:32 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000440"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kiivet-1995" MODIFIED="2013-06-26 13:09:31 +0100" MODIFIED_BY="[Empty name]" NAME="Kiivet 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kiivet RA, Llerena A, Dahl ML, Rootslane L, Sánchez Vega J, Eklundh T, et al</AU>
<TI>Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1995</YR>
<VL>40</VL>
<NO>5</NO>
<PG>467-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kudo-1999" MODIFIED="2013-06-26 13:09:37 +0100" MODIFIED_BY="[Empty name]" NAME="Kudo 1999" TYPE="CONFERENCE_PROC">
<AU>Kudo Y, Nomura J, Ikawa G, Nakajima T, Saito M, Sakai T, et al</AU>
<TI>Clinical trial of quetiapine in schizophrenia-efficacy and tolerability of quetiapine: a comparative double-blind study with mosapramine in schizophrenic patients</TI>
<SO>Proceeding of the Annual Meeting of the World Psychiatric Association; 1999 Aug; Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-1999" MODIFIED="2012-09-12 10:19:31 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 1999" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Pitschel-Walz G, Abraham D, Kissling W</AU>
<TI>Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>51-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2013-06-26 13:09:47 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-1996" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Levy 1996" TYPE="JOURNAL_ARTICLE">
<AU>Levy RH</AU>
<TI>Sedation in acute and chronic agitation</TI>
<SO>Pharmacotherapy</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>Part 2</NO>
<PG>152-9S, 166-8S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-1993" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Lieberman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman J, Jody D, Geisler S</AU>
<TI>Time course and biologic correlates of treatment response in first-episode schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1993</YR>
<VL>50</VL>
<NO>5</NO>
<PG>369-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marder-1998" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Marder 1998" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR</AU>
<TI>Facilitating compliance with antipsychotic medication</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>Suppl 3</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1997" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 1997" TYPE="JOURNAL_ARTICLE">
<AU>Miller R</AU>
<TI>Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>7</NO>
<PG>1059-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milton-1995" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Milton 1995" TYPE="JOURNAL_ARTICLE">
<AU>Milton GV, Jann MW</AU>
<TI>Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>1995</YR>
<VL>28</VL>
<NO>6</NO>
<PG>494-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murasaki-1999" MODIFIED="2012-09-19 09:51:01 +0100" MODIFIED_BY="[Empty name]" NAME="Murasaki 1999" TYPE="CONFERENCE_PROC">
<AU>Murasaki M, Koyama T, Yamauchi T, Yagi MG, Ushijima S, Kamijima K</AU>
<TI>Clinical evaluation of quetiapine in schizophrenia-efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia</TI>
<SO>Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2012-09-19 09:51:17 +0100" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peuskens-1997" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Peuskens 1997" TYPE="JOURNAL_ARTICLE">
<AU>Peuskens J, Link CGG</AU>
<TI>A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1997</YR>
<VL>96</VL>
<PG>265-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raschetti-1993" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Raschetti 1993" TYPE="JOURNAL_ARTICLE">
<AU>Raschetti R, Spila Alegiani S, Diana G, Da Cas R, Traversa G, Pasquini P</AU>
<TI>Antipsychotic drug prescription in general practice in Italy</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>5</NO>
<PG>317-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reardon-1989" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Reardon 1989" TYPE="JOURNAL_ARTICLE">
<AU>Reardon GT, Rifkin A, Schwartz A, Myerson A, Siris SG</AU>
<TI>Changing patterns of neuroleptic dosage over a decade</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>6</NO>
<PG>726-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenheck-2003" MODIFIED="2013-06-26 13:09:58 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenheck 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck MD, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al</AU>
<TI>Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>20</NO>
<PG>2693-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2013-06-26 13:10:05 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson M, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-2002" MODIFIED="2012-09-19 09:52:42 +0100" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 2002" TYPE="COCHRANE_REVIEW">
<AU>Srisurapanont M, Disayavanish C, Taimkaew K</AU>
<TI>Quetiapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-03 14:15:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:15:12 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000967.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thornley--2002" MODIFIED="2012-09-19 09:52:57 +0100" MODIFIED_BY="[Empty name]" NAME="Thornley  2002" TYPE="COCHRANE_REVIEW">
<AU>Thornley B, Adams CE, Awad G</AU>
<TI>Chlorpromazine versus placebo for those with schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-03 14:13:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:13:35 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thornley-1998" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Thornley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Thornley B, Adams CE</AU>
<TI>Content and quality of 2000 controlled trials in schizophrenia over 50 years</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7167</NO>
<PG>1181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2013-06-26 13:10:18 +0100" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whicher-2002" MODIFIED="2012-09-19 09:53:15 +0100" MODIFIED_BY="[Empty name]" NAME="Whicher 2002" TYPE="COCHRANE_REVIEW">
<AU>Whicher E, Morrison M, Douglas-Hall P</AU>
<TI>'As required' medication regimens for seriously mentally ill people in hospital</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-03 14:09:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-03 14:09:57 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003441.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2013-06-26 13:10:25 +0100" MODIFIED_BY="Anne Lawson" NAME="WHO 2011" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO Model Lists of Essential Medicines, 2011 www.who.int/medicines/publications/essentialmedicines/en/</TI>
<SO>(accessed 20 June 2013)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1999" MODIFIED="2013-06-26 13:10:32 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 1999" TYPE="JOURNAL_ARTICLE">
<AU>Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD</AU>
<TI>Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia</TI>
<SO>Medical Care</SO>
<YR>1999</YR>
<VL>37 Suppl 4</VL>
<PG>81-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zito-1998" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NAME="Zito 1998" TYPE="JOURNAL_ARTICLE">
<AU>Zito JM</AU>
<TI>Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia</TI>
<SO>Psychiatric Clinics of North America</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>1</NO>
<PG>181-202</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-06-26 13:10:48 +0100" MODIFIED_BY="Clive E Adams">
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2013-06-26 13:10:48 +0100" MODIFIED_BY="Anne Lawson" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS MODIFIED="2013-06-24 14:58:09 +0100" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<REFERENCE ID="REF-Waraich-2002" MODIFIED="2012-09-19 09:55:07 +0100" MODIFIED_BY="Clive E Adams" NAME="Waraich 2002" TYPE="COCHRANE_REVIEW">
<AU>Waraich PS, Adams CE, Roque M, Hamill KM, Marti J</AU>
<TI>Haloperidol dose for the acute phase of schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-09-19 09:55:07 +0100" MODIFIED_BY="Clive E Adams">
<IDENTIFIER MODIFIED="2012-09-19 09:55:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001951"/>
<IDENTIFIER TYPE="PUBMED" VALUE="12137638"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-09-11 11:22:02 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Curtis-1995">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details available.<BR/>Blindness: no details.<BR/>Duration: not clear (time to desired haloperidol level or putative receptor occupancy level).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-20 16:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (unclear diagnostic criteria).<BR/>N = 53.<BR/>Age: no details.<BR/>Sex: no details.<BR/>History: no details.<BR/>Setting: no details.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose to 50% Bromocriptine Growth Hormone Test* blockade level (mean plasma level &lt; 0 ng/mL). N = 5.</P>
<P>2. Haloperidol: dose to 100% Bromocriptine Growth Hormone Test blockade level (mean plasma level 1.5 ng/mL). N = 19.**</P>
<P>3. Haloperidol: plasma level 10 ng/mL (mean 9 ng/mL). N = 23.</P>
<P>4. Placebo: N = 6.***</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: clinically significant response (30% reduction in positive symptoms, criterion unclear).</P>
<P>Unable to use:</P>
<UL>
<LI>Adverse effects: EPSE ratings and tardive dyskinesia (no data reported by dose).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-24 21:42:35 +0100" MODIFIED_BY="[Empty name]">
<P>* Bromocriptine Growth Hormone Test blockade used as neuroendocrine index of D<SUB>2</SUB> receptor occupancy for purpose of antipsychotic dose adjustment.</P>
<P>** Trialists reported results of group 1 and 2 together.</P>
<P>*** No data reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donlon-1980">
<CHAR_METHODS MODIFIED="2012-09-12 10:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double - no further details.<BR/>Duration: 10 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (no mention of standardised diagnostic criteria), CGI at least = 4.<BR/>N = 63.<BR/>Age: 18-45 years.<BR/>Sex: 45 males, 18 females.<BR/>History: newly admitted.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="Clive E Adams">
<P>1. Haloperidol: 5-day titration to dose 100 mg/day (mean: 90 mg). N = 20.<BR/>2. Haloperidol: 10-day titration to dose 100 mg/day (mean: 77 mg). N = 23.<BR/>Both above groups combined into &gt; 35 mg dose for analyses.<BR/>3. Haloperidol dose 10 mg/day fixed oral dose. n = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early (between 3 and 14 days).<BR/>Adverse effects: acute dystonia, postural hypotension (between 3 and 14 days).</P>
<P>Unable to use:</P>
<UL>
<LI>Global state: CGI (no data presented by dose).</LI>
<LI>Mental state: BPRS (no data presented by dose).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janicak-1997">
<CHAR_METHODS MODIFIED="2011-03-02 09:40:14 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Allocation concealment: stated random and baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder (RDC).<BR/>N = 95.<BR/>Age: mean about 32 years.<BR/>Sex: 47 males, 48 females.<BR/>History: mean number of previous hospitalisations about 5.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: plasma dose target 2 ng/mL. N = 38.<BR/>2. Haloperidol: plasma dose target 12 ng/mL. N = 25.<BR/>3. Haloperidol: plasma dose target 30 ng/mL. N = 32.</P>
<P>Also oral dosing 3.3 mg/day vs. 25.8 mg/day vs. 50.8 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early (2-10 weeks).</P>
<P>Global state: use of adjunctive medication for sedation.<BR/>Adverse effects: extrapyramidal side effects, use of antiparkinsonism drugs.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS (no SD).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kapur-2000">
<CHAR_METHODS MODIFIED="2012-09-12 10:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double - no further details.<BR/>Duration: 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizophreniform disorder (DSM-IV).<BR/>N = 26.<BR/>Age: mean 30 years (completers only).<BR/>Sex: 17 males, 5 females (completers only).<BR/>History: length of illness episode median 52 weeks (completers only).<BR/>Setting: hospital and outpatient clinic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: 1 mg/day fixed oral dose. N = 14.<BR/>2. Haloperidol: 2.5 mg/day fixed oral dose. N = 12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no clinically significant response, use of adjunctive sedatives.</P>
<P>Mental state and behaviour: clinically significant agitation.<BR/>Adverse effects: EPSE, use of antiparkinsonism drugs, withdrawal due to EPSE.</P>
<P>Unable to use:</P>
<UL>
<LI>Global state: CGI score (completer data only).</LI>
<LI>Mental state: PANSS score (completer data only).</LI>
<LI>Adverse effects: Barnes Akathisia Scale, ESRS (completer data only).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khanna-1997">
<CHAR_METHODS MODIFIED="2011-03-02 11:34:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: acute and transient psychotic disorder (ICD-10).<BR/>N = 47.<BR/>Age: 17-55 years.<BR/>Sex: male 22, female 18 (completers only).<BR/>History: drug naive in this episode.<BR/>Setting: psychiatric outpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 5 mg/day. N = 25.</P>
<P>2. Haloperidol: dose 20 mg/day. N = 22.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Mental state/behaviour - no psychotic symptoms (2-10 weeks).<BR/>Global state: use of adjunctive medication for sedation.</P>
<P>Adverse effects: blurred vision.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS.</LI>
<LI>Adverse effects: haloperidol side effects checklist - no data reported.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>Error in reporting, comparison of BPRS score in table 3 and 4 were identical but with columns reversed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klieser-1987">
<CHAR_METHODS MODIFIED="2012-09-12 10:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double - no further details.<BR/>Duration: 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (ICD-9).<BR/>N = 90.<BR/>Age: mean about 32 years (completers only).<BR/>Sex: 40 males, 47 females (completers only).<BR/>History: mean duration ill about 4 years (completers only).<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: 10 mg/day fixed oral dose. N = 30.<BR/>2. Haloperidol: 20 mg/day fixed oral dose. N = 30.<BR/>3. Haloperidol: flexible dose mean 16.3 mg, SD 14.1 mg (data not extracted for this group as dose did not conform to defined dose ranges). N = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS (completer data only).</LI>
<LI>Adverse effects: Simpson-Angus score (completer data only).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang-1987">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 10 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (ICD-9).<BR/>N = 88.<BR/>Age: mean 27 years.<BR/>Sex: 32 males, 35 females.<BR/>History: mean duration ill 3.5 years.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 0.15 mg/kg (mean 9.2 mg, SD 1.6 mg). N = 24.</P>
<P>2. Haloperidol: dose 0.40 mg/kg (mean 23.0 mg, SD 3.8 mg). N = 24.</P>
<P>3. Insulin coma therapy. N = 16 (completer).</P>
<P>4. Insulin coma therapy plus haloperidol dose 0.4 mg/kg (mean 20.4 mg, SD 3.8 mg). N = 11 (completer).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no clinically significant response in global state (unclear criterion).</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS, PSE (completer data only).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Louza-1988">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.</P>
<P>Blindness: double.</P>
<P>Duration: 6 weeks (4 weeks data extracted).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder (DSM-III and RDC).</P>
<P>N = 20.</P>
<P>Age: mean about 37 years.</P>
<P>Sex: 11 males, 9 females.</P>
<P>History: no details.</P>
<P>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 0.15 mg/kg (range 7.8-14.9 mg). N = 10.</P>
<P>2. Haloperidol: dose 0.40 mg/kg (range 20.0-39.6 mg). N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Adverse effects: clinically significant EPSE.</P>
<P>Unable to use:</P>
<UL>
<LI>Global state: change/score BPRS (no means or SD).</LI>
<LI>Mental state: change/score BPRS (no means or SD).</LI>
<LI>Adverse effects: Simpson-Angus scale (no means or SD).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McEvoy-1991">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder (RDC).<BR/>N = 106 (N = 48 in randomised portion of study).<BR/>Age: mean about 32 years.<BR/>Sex: 57 males, 49 females.<BR/>History: 30% neuroleptic naive.<BR/>Setting: hospital and outpatient clinic (3 participants).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol neuroleptic threshold dose (mean 3.4 mg, SD 2.3 mg). N = 23.<BR/>2. Haloperidol 2.5 x neuroleptic threshold dose (mean 11.6 mg, SD 4.7 mg). N = 25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early (2-10 weeks).<BR/>Global state: no clinically significant response (2-10 weeks).</P>
<P>Adverse effects: clinically significant EPSE (2-10 weeks).<BR/>Adverse effects: significant EPSE.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS (completer data only).</LI>
<LI>Adverse effects: EPSE (completer data only).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Modestin-1983">
<CHAR_METHODS MODIFIED="2012-09-12 10:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 3 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (ICD-9).<BR/>N = 57.<BR/>Age: mean 38 years.<BR/>Sex: 18 males, 23 women completed study. 16 who left early not reported.<BR/>History: previous hospitalisations 29/57, mean duration ill 3.5 years.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: flexible dose 5 mg tablets (mean 20 mg). N = 27.<BR/>2. Haloperidol: flexible dose 15 mg tablets (mean 58 mg). N = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early (2-10 weeks).<BR/>Global state: no significant response (2-10 weeks), use adjunctive sedatives.<BR/>Mental state/behaviour: significant agitation (2-10 weeks).<BR/>Adverse effects: significant EPSE, use of any antiparkinsonism drugs, akathisia.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS (no mean or SD).</LI>
<LI>Adverse effects: Simpson-Angus scale (no mean or SD).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neborsky-1981">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 6 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, acute paranoid reaction, manic-depressive illness-manic type (DSM-II).<BR/>N = 20.<BR/>Age: mean 22 years.<BR/>Sex: 20 males.<BR/>History: first episode 15/20.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: 2 mg tablets, 1-8 tablets per day 1st 48 h then dose fixed at final flexible dose at 48 h and continued up to day 6 (&gt; 50% received dose within &gt; 7.5-15 mg/day range). N = 10.<BR/>2. Haloperidol: 10 mg tablets, 1-8 tablets per day 1st 48 h then dose fixed at final flexible dose at 48 h and continued up to day 6 (&gt; 50% received dose within &gt; 35 mg/day range). N = 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Leaving the study early (3-14 days).<BR/>Global state: no clinically significant response (3-14 days).<BR/>Mental state/behaviour: no clinically significant response in psychotic symptoms (93-14 days).</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS change/score (data skewed).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oosthuizen-2004">
<CHAR_METHODS MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised 1:1. No further details but baseline demographics similar.</P>
<P>Blindness: double.</P>
<P>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophreniform disorder, schizophrenia or schizoaffective disorder DSM-IV.</P>
<P>N = 40</P>
<P>Age: 16-55 years.</P>
<P>Sex:</P>
<P>History: first episode psychosis, lifetime neuroleptic exposure &#8804; 4 weeks.</P>
<P>Setting: inpatient and outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 2 mg/day.</P>
<P>2. Haloperidol: dose 8 mg/day (with a build-up of dose over first week).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Reduction in PANNS.</P>
<P>Reduction in PANSS positive and general psychopathology subscale.</P>
<P>Reduction in PANSS negative subscale.</P>
<P>Calgary Depression Rating Scale.</P>
<P>ESRS total score.</P>
<P>ESRS parkinsonism subscale.</P>
<P>Dystonic reaction.</P>
<P>Akathisia.</P>
<P>Use of concomitant medication.</P>
<P>Prolactin level.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palao-1994">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 3 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N = 22.<BR/>Age: mean 29 years (completers).<BR/>Sex: 6 males, 14 females (completers).<BR/>History: mean duration ill 8.5 years (completers).<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: 10 mg/day fixed oral dose. N = 6.<BR/>2. Haloperidol: 20 mg/day fixed oral dose. N = 8.<BR/>3. Haloperidol: 30 mg/day fixed oral dose. N = 8.<BR/>Groups 2 and 3 combined for data extraction.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS, SANS, SAPS (completer data only).</LI>
<LI>Adverse effects: Simpson-Angus scale, use of antiparkinsonism drugs (completer data only).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rifkin-1991">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III).<BR/>N = 87.<BR/>Age: mean about 34 years.<BR/>Sex: 34 males, 33 females.<BR/>History: mean hospitalisations about 5.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: 10 mg/day fixed oral dose. N = 29.<BR/>2. Haloperidol: 30 mg/day fixed oral dose. N = 29.<BR/>3. Haloperidol: 80 mg/day fixed oral dose. N = 29.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving study early (2-10 weeks).<BR/>Global state: mean change CGI score, use of adjunctive sedatives, no clinically significant response.<BR/>Mental state/behaviour: mean change SADS score, clinically significant agitation (2-10 weeks).<BR/>Adverse effects: mean change EPSE score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-1967">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (no diagnostic criteria specified).<BR/>N = 16.<BR/>Age: mean about 37 years.<BR/>Sex: 16 males.<BR/>History: mean duration ill 12 years.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 6 mg/day. N = 8.<BR/>2. Haloperidol: dose 30 mg/day. N = 8.<BR/>3. Placebo. N = 8 (not extracted).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no significant change in global state, use of adjunctive sedation.<BR/>Adverse effects: significant EPSE, use of any antiparkinsonism drugs.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: IMPS scale, PRP scale (no SD).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stone-1995">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 2 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III).<BR/>N = 24.<BR/>Age: mean 27 years.<BR/>Sex: 11 males, 13 females.<BR/>History: mean duration ill about 5 years.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: 4 mg/day oral fixed dose. N = 8.<BR/>2. Haloperidol: 10 mg/day oral fixed dose. N = 8.<BR/>3. Haloperidol: 40 mg/day oral fixed dose. N = 8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Adverse effects: significant EPSE.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS (maximum response data only, data highly skewed).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volavka-1992">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder (RDC).<BR/>N = 132.<BR/>Age: mean 33 years.<BR/>Sex: 97 males, 35 females.<BR/>History: mean number of previous hospitalisations 7.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: plasma dose 2-13 ng/mL (data not extracted due to non-overlap with predefined ranges).<BR/>2. Haloperidol: plasma dose 13.1-24 ng/mL (15-35 mg oral dose). N = 45.<BR/>3. Haloperidol: plasma dose 24.1-35 ng/mL (&gt; 35 mg oral dose). N = 47.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early (2-10 weeks).<BR/>Global state: no clinically significant change global state, clinically significant EPSE (2-10 weeks).<BR/>Mental state/behaviour: no clinically important change in psychotic symptoms.</P>
<P>Adverse effects: clinically significant EPSE.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS (completers only).</LI>
<LI>Adverse effects: significant EPSE (completers only), use of antiparkinsonism drugs (completers only), Simpson-Angus score (completers only).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volavka-1995">
<CHAR_METHODS MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no details but baseline demographics similar.<BR/>Blindness: double.<BR/>Duration: 3 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder (DSM-III-R).<BR/>N = 65.<BR/>Age: mean 34 years (completers only).<BR/>Sex: 43 males, 11 females (completers only).<BR/>History: mean number of previous hospitalisations 15 (completers only).<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: plasma dose target 2 ng/mL. N = 33.<BR/>2. Haloperidol: plasma dose target 10 ng/mL. N = 32.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no significant response, significant response, use of adjunctive sedative.<BR/>Mental state: clinically significant agitation.<BR/>Adverse effects: significant EPSE, use of any antiparkinsonism drugs.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: BPRS score (completers only).</LI>
<LI>Adverse effects: Simpson-Angus score (completers only).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winter-1984">
<CHAR_METHODS MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - pills sent by manufacturer suggest concealed list but mean ages differ by 8 years.<BR/>Blindness: double.<BR/>Duration: 3 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (ICD-9).<BR/>N = 48.<BR/>Age: mean 35 years (completers only).<BR/>Sex: 16 males, 24 females (completers only).<BR/>History: mean length of illness 4 years (completers only).<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: 16 mg/day liquid formulation fixed dose. N = 24.<BR/>2. Haloperidol: 80 mg/day liquid formulation fixed dose. N = 24.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: no clinically significant improvement in global state.</P>
<P>Unable to use:</P>
<UL>
<LI>Mental state: AMDP Scale score (not validated scale, no SD).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AMDP: Association for Methodology and Documentation in Psychiatry; <BR/>BPRS - Brief Psychiatric Rating Scale; CGI: Clinical Global Impression; DSM - II/III/IV: Diagnostic Statistical Manual version 2/3/4; EPSE: extrapyramidal side effects; ESRS: Extrapyramidal Symptom Rating Scale; ICD: International Classification of Diseases; IMPS: Inpatient Multidimensional Psychiatric Scale; PANSS: Positive and Negative Symptom Scale; PRP: Psychotic Reaction Profile; PSE: Present State Examination; RDC: Research Diagnostic Criteria; SADS: Schedule for Affective Disorders and Schizophrenia; SANS: Schedule for Negative Symptoms; SAPS: Schedule for Positive Symptoms; SD: standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjorndal-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose mean 15, 103 mg/day (completers only).<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boyer-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: amisulpride vs. haloperidol, not different doses of haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coryell-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose mean 33.0, 40.0 mg/day (completers only).<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coryell-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose mean 24.8, 36.8 mg/day (completers only).<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davis-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 15, 60 mg/day (first 5 days of study only).<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubin-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 5, 10, 25 mg/day.<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dutoit-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 6, 10, 15 mg/day.<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garver-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 6, 12, 24 mg/day.<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garver-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol 6, 12 or 24 mg/day.<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerlach-1985a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: dogmatil vs. haloperidol, not comparing haloperidol doses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hirschowitz-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose mean 3.2, 6.5, 14.0 mg/day (completers only).<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose mean 1.6, 4.7, 10.0 mg/day (completers only).<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ortega_x002d_Soto-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with acute schizophrenia.</P>
<P>Interventions: individually determined threshold dose for parkinsonism plus haloperidol 20 mg/day or placebo. Unclear what dose range participants randomised to.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ortega_x002d_Soto-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose mean 3.4, 23.9 mg/day (completers only).<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reschke-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no details but baseline demographics similar.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol 1, 2 and 5 mg vs. chlorpromazine 25 mg intramuscular as needed every 30 minutes vs. placebo - unclear how many doses received in each group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santos-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 15, 20, 30 mg/day.<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sim-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 12, 30, 60 mg/day.<BR/>Outcomes: no usable data - reported as "no significant differences", so excluded.<BR/>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 10, 25 mg/day.<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 8, 40 mg/day.<BR/>Outcomes: no usable data - unclear how many originally randomised to groups.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Putten-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: quasi-randomised, by day of the week, and baseline demographics not similar.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volavka-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia.</P>
<P>Interventions: haloperidol plasma levels 8-12 ng/mL and &gt; 15 ng/mL.</P>
<P>Outcomes: unclear how many participants randomised to experimental and control groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="Clive E Adams" STUDY_ID="STD-Zimbroff-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="Clive E Adams">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol dose 4, 8, 16 mg/day, sertindole dose 12, 20, 24 mg/day.<BR/>Outcomes: leaving the study early: &gt; 50% dropout rate therefore study excluded.</P>
<P>Authors contacted 1 March 2002, no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-05-09 14:42:45 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curtis-1995">
<DESCRIPTION>
<P>"Randomly assigned" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 10:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donlon-1980">
<DESCRIPTION>
<P>"Randomised" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Janicak-1997">
<DESCRIPTION>
<P>"Random assignment" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kapur-2000">
<DESCRIPTION>
<P>"Randomly assigned" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khanna-1997">
<DESCRIPTION>
<P>"Randomly assigned" - no further details - no details but baseline demographics similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1987">
<DESCRIPTION>
<P>"Randomisation" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liang-1987">
<DESCRIPTION>
<P>Randomisation was undertaken with random number tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louza-1988">
<DESCRIPTION>
<P>"Randomised" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-1991">
<DESCRIPTION>
<P>"Randomisation" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Modestin-1983">
<DESCRIPTION>
<P>"Randomised" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neborsky-1981">
<DESCRIPTION>
<P>"Randomised" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oosthuizen-2004">
<DESCRIPTION>
<P>"Randomised" - no details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palao-1994">
<DESCRIPTION>
<P>"Randomised" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rifkin-1991">
<DESCRIPTION>
<P>Randomised - no details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>"Randomised" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stone-1995">
<DESCRIPTION>
<P>"Randomised" - no details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1992">
<DESCRIPTION>
<P>"Randomised" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1995">
<DESCRIPTION>
<P>"Randomised" - no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winter-1984">
<DESCRIPTION>
<P>"Assigned randomly" by authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 16:22:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curtis-1995">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 16:22:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donlon-1980">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-07 10:12:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Janicak-1997">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-07 10:11:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kapur-2000">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 10:16:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khanna-1997">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-07 10:10:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1987">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-07 10:09:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liang-1987">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-07 10:08:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louza-1988">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-07 10:15:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-1991">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-07 10:16:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Modestin-1983">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-07 10:16:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neborsky-1981">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oosthuizen-2004">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palao-1994">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rifkin-1991">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-02 09:46:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stone-1995">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1992">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1995">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winter-1984">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-02 11:29:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curtis-1995">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donlon-1980">
<DESCRIPTION>
<P>"Double": each treatment group given 10 capsules daily (haloperidol + placebo).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Janicak-1997">
<DESCRIPTION>
<P>"Double" - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kapur-2000">
<DESCRIPTION>
<P>"Double" raters blind to occupancy results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-09-07 10:11:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khanna-1997">
<DESCRIPTION>
<P>No details except doses in both groups administered in identical capsules in single daily dose.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1987">
<DESCRIPTION>
<P>"Double" - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liang-1987">
<DESCRIPTION>
<P>Double blind: participants, medical staff and assessors were all blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louza-1988">
<DESCRIPTION>
<P>"Double" - both haloperidol and adjunctive benzotropine administered in same way across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-1991">
<DESCRIPTION>
<P>"Double".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Modestin-1983">
<DESCRIPTION>
<P>"Double": tablets in both groups identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neborsky-1981">
<DESCRIPTION>
<P>"Double": note differences in route and frequency of administration between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oosthuizen-2004">
<DESCRIPTION>
<P>"Double". Doses given to both groups in a single identical capsule daily</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palao-1994">
<DESCRIPTION>
<P>Double-blind - assessing physicians, nursing staff and participants blinded to dose groups. Dose given to groups in identical oral solutions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rifkin-1991">
<DESCRIPTION>
<P>Double - participants, stall and raters blind to groups. Doses administered in 8 study tablets to all participants across study groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>"Double" - participants in all study groups received identical tablet regimens; 91% ward doctors and 89.5% ward nurses correctly guessed which participants were taking active medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stone-1995">
<DESCRIPTION>
<P>"Double" - no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1992">
<DESCRIPTION>
<P>"Double".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1995">
<DESCRIPTION>
<P>"Double" but with principal investigator, delegates and nominated psychiatrist in each centre not blind to allow dose adjustments according to monitoring of plasma haloperidol levels.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winter-1984">
<DESCRIPTION>
<P>"Double" - manufacturers controlled distribution of tablets to participants identified by numbers, tablets then administered by ward doctors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-02 11:29:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Curtis-1995">
<DESCRIPTION>
<P>Data reported on all participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-07 10:13:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donlon-1980">
<DESCRIPTION>
<P>Details of reasons for leaving early given but no details of how this was reflected in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Janicak-1997">
<DESCRIPTION>
<P>Reasons for leaving early reported; intention-to-treat analysis used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kapur-2000">
<DESCRIPTION>
<P>Reasons for leaving early reported; per-protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khanna-1997">
<DESCRIPTION>
<P>Reasons for leaving early reported; per-protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1987">
<DESCRIPTION>
<P>Seems to be per-protocol analysis - but unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-07 10:09:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liang-1987">
<DESCRIPTION>
<P>People leaving early were excluded from final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Louza-1988">
<DESCRIPTION>
<P>Reasons for leaving early reported</P>
<P>Per-protocol analysis (excluded from analysis from time of leaving study).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEvoy-1991">
<DESCRIPTION>
<P>Reasons for leaving early and exclusion reported; early termination data used in endpoint analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Modestin-1983">
<DESCRIPTION>
<P>Reasons for leaving early and withdrawal reported; per-protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neborsky-1981">
<DESCRIPTION>
<P>Data presented on all participants (no-one left early).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oosthuizen-2004">
<DESCRIPTION>
<P>Reasons for dropout reported</P>
<P>Intention-to-treat analysis - last observation carried forward</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Palao-1994">
<DESCRIPTION>
<P>Reason for dropouts reported.</P>
<P>Per-protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rifkin-1991">
<DESCRIPTION>
<P>Reasons for dropouts and exclusions reported.</P>
<P>Both per-protocol and survival analysis reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>Result available for only 7 of 8 in placebo group, no explanation given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stone-1995">
<DESCRIPTION>
<P>Reasons for withdrawal reported</P>
<P>Per-protocol analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volavka-1992">
<DESCRIPTION>
<P>Sample attrition fully reported.</P>
<P>Endpoint analysis included last observation carried forward data on all subjects observed beyond week 2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1995">
<DESCRIPTION>
<P>Sample attrition fully reported though it is not clear how this was accounted for in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winter-1984">
<DESCRIPTION>
<P>No reports of dropout given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Curtis-1995">
<DESCRIPTION>
<P>Results of different intervention groups combined, 1 intervention group not reported, outcomes (EPSE) not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 16:26:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Donlon-1980">
<DESCRIPTION>
<P>Continuous data not presented by dose.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Janicak-1997">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and non-significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kapur-2000">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and non-significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khanna-1997">
<DESCRIPTION>
<P>Only most common side effects at days 7 and 42 reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 11:05:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1987">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 09:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liang-1987">
<DESCRIPTION>
<P>All measured outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Louza-1988">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and non-significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-1991">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and non-significant outcomes; only highly significant (P value &lt; 0.01) correlations with outcome reported (<I>Psychopharmacology Bulletin</I>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Modestin-1983">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and non-significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neborsky-1981">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and non-significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oosthuizen-2004">
<DESCRIPTION>
<P>ESRS and parkinsonism reported only as t values, degree of freedom and P values.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palao-1994">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and not significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rifkin-1991">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and not significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-24 16:10:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and not significant outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-12 11:05:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stone-1995">
<DESCRIPTION>
<P>Not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volavka-1992">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and not significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volavka-1995">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and not significant outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-25 15:17:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winter-1984">
<DESCRIPTION>
<P>Presents a wide range of statistically significant and not significant outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Curtis-1995">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donlon-1980">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Janicak-1997">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kapur-2000">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khanna-1997">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1987">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 09:15:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liang-1987">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louza-1988">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-1991">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Modestin-1983">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neborsky-1981">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oosthuizen-2004">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palao-1994">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rifkin-1991">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stone-1995">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1992">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-1995">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 10:59:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Winter-1984">
<DESCRIPTION>
<P>None obvious.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-06-26 13:01:22 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-06-26 13:01:22 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-06-26 13:01:22 +0100" MODIFIED_BY="Grade Profiler">STANDARD LOWER DOSE (&gt; 3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>DOSES: 2. STANDARD LOWER DOSE (</B>&gt; <B>3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with the acute phase of schizophrenia</P>
<P>
<B>Settings: </B>in hospital</P>
<P>
<B>Intervention:</B> standard lower dose (&gt; 3-7.5 mg/day) versus other doses</P>
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>STANDARD LOWER DOSE (&gt; 3-7.5 mg/day) vs. OTHER DOSES</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Leaving the study early (2-10 weeks) vs. standard higher dose (</B>&gt; <B>7.5-15 mg/day)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>121 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
<BR/>(1 to 257)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.12 </B>
<BR/>(0.01 to 2.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>64<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853; &#8861; &#8861; &#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Leaving the study early (2-10 weeks) vs. high dose (</B>&gt; <B>15-35 mg/day)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.78 </B>
<BR/>(0.47 to 1.28)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>191<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853; &#8861; &#8861; &#8861;<BR/>
<B>very low</B>
<SUP>2,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>256 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
<BR/>(120 to 328)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>212 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>165 per 1000</B>
<BR/>(100 to 271)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Global state: 1. No clinically significant response in global state (2-10 weeks) vs. standard higher dose (</B>&gt; <B>7.5-15 mg/day)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.09 </B>
<BR/>(0.67 to 1.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853; &#8861; &#8861; &#8861;<BR/>
<B>very low</B>
<SUP>1,6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>560 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>610 per 1000</B>
<BR/>(375 to 980)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>560 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>610 per 1000</B>
<BR/>(375 to 980)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Global state: 1. No clinically significant response in global state (2-10 weeks) vs. high dose (</B>&gt; <B>15-35 mg/day)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.95 </B>
<BR/>(0.75 to 1.19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>81<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853; &#8861; &#8861; &#8861;<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>800 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>760 per 1000</B>
<BR/>(600 to 952)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>828 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>787 per 1000</B>
<BR/>(621 to 985)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Clinically significant extrapyramidal side effects (2-10 weeks) vs. standard higher dose (</B>&gt; <B>7.5-15 mg/day)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.12 </B>
<BR/>(0.01 to 2.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>64<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853; &#8861; &#8861; &#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>121 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
<BR/>(1 to 257)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>80 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
<BR/>(1 to 170)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Clinically significant extrapyramidal side effects (2-10 weeks) vs. high dose (</B>&gt; <B>15-35 mg/day)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.59 </B>
<BR/>(0.45 to 0.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>144<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853; &#8861; &#8861; &#8861;<BR/>
<B>very low</B>
<SUP>2,4,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>769 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>454 per 1000</B>
<BR/>(346 to 600)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>760 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>448 per 1000</B>
<BR/>(342 to 593)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mental state/behaviour: clinically significant agitation (2-10 weeks)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.93 </B>
<BR/>(0.69 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>65<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853; &#8861; &#8861; &#8861;<BR/>
<B>very low</B>
<SUP>1,6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>750 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>698 per 1000</B>
<BR/>(517 to 945)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>750 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>698 per 1000</B>
<BR/>(517 to 945)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations in design: rated as 'serious' - no trial described randomisation process or tested blinding.</P>
<P>
<SUP>2</SUP> Imprecision: rated as 'serious' - very small trials.</P>
<P>
<SUP>3</SUP> Publication bias: rated as 'serious' - two very small trials.</P>
<P>
<SUP>4</SUP> Limitations in design: rated as 'serious' - no trial described randomisation process and only one tested blinding informally and found it to be ineffective.</P>
<P>
<SUP>5</SUP> Publication bias: rated as 'serious' - four small trials.</P>
<P>
<SUP>6</SUP> Imprecision: rated as 'serious' - single small trial.</P>
<P>
<SUP>7</SUP> Publication bias: rated as 'serious' - single trial.</P>
<P>
<SUP>8</SUP> Publication bias: rated as 'serious' - three very small trials.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="Clive E Adams">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="Clive E Adams" NO="1">
<TITLE MODIFIED="2012-09-11 17:27:06 +0100" MODIFIED_BY="Clive E Adams">Suggested design for a trial</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>
<B>Methods</B>
</P>
</TH>
<TD>
<P>Allocation: randomised, clearly described, concealed.<BR/>Blindness: double, described and tested.<BR/>Duration: 8 weeks.</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Participants</B>
</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia.<BR/>N = 450.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: acutely unwell.</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Interventions</B>
</P>
</TH>
<TD>
<P>1. Haloperidol 1 mg/day. N = 150.<BR/>2. Haloperidol 2.5 mg/day. N = 150.</P>
<P>3. Haloperidol 5 mg/day. N = 150.</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Outcomes</B>
</P>
</TH>
<TD>
<P>Leaving the study early - reason.</P>
<P>Clinical response - no clinically significant response in global state.</P>
<P>Extrapyramidal side effects - no clinically significant extrapyramidal side effects, use of anticholinergic medication.</P>
<P>Behaviour - agitation, aggression, self harm.</P>
<P>Service utilisation - admission, duration of stay.</P>
<P>Quality of life - no clinically significant change in quality of life measure.</P>
<P>Satisfaction with treatment.</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Notes</B>
</P>
</TH>
<TD>
<P>* Powered to be able to identify a difference of about 20% between groups for primary outcome with adequate degree of certainty.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-06-26 13:00:52 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-06-26 13:00:52 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 11:01:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early (2-10 weeks)</NAME>
<GROUP_LABEL_1>Ultra low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ultra low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 11:01:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="2.398908192105095" CI_START="0.034029085952468244" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3800136275321904" LOG_CI_START="-1.4681497162327417" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2011-05-10 10:42:16 +0100" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="1.0856202966836188" STUDY_ID="STD-Kapur-2000" TOTAL_1="14" TOTAL_2="12" VAR="1.1785714285714286" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 13:00:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Global state: no clinically significant response in global state (2-10 weeks)</NAME>
<GROUP_LABEL_1>Ultra low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ultra low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 11:01:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt;1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="3.886452171822753" CI_START="0.9149523035759392" EFFECT_SIZE="1.8857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.5895533274792345" LOG_CI_START="-0.038601545096048316" LOG_EFFECT_SIZE="0.27547589119159305" MODIFIED="2011-05-10 10:43:29 +0100" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.3689812815674884" STUDY_ID="STD-Kapur-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.13614718614718613" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 11:02:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Global state: use of adjunctive medication for sedation (2-10 weeks)</NAME>
<GROUP_LABEL_1>Ultra low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ultra low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 11:02:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="2.8717261857642553" CI_START="0.11370534344937835" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4581430282998273" LOG_CI_START="-0.9442191256724162" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2011-05-10 10:45:48 +0100" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Kapur-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.6785714285714285" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 11:02:41 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: clinically significant agitation (2-10 weeks)</NAME>
<GROUP_LABEL_1>Ultra low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ultra low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 11:02:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="2.8717261857642553" CI_START="0.11370534344937835" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4581430282998273" LOG_CI_START="-0.9442191256724162" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2011-05-10 10:46:48 +0100" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Kapur-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.6785714285714285" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 13:00:30 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: clinically significant EPSE (2-10 weeks)</NAME>
<GROUP_LABEL_1>Ultra low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ultra low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 11:03:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="1.7176437570135297" CI_START="0.15398408129648267" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.23493309523085998" LOG_CI_START="-0.8125241737247992" LOG_EFFECT_SIZE="-0.2887955392469696" MODIFIED="2011-05-10 10:49:40 +0100" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.6152815847816581" STUDY_ID="STD-Kapur-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.3785714285714286" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 11:05:10 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: use of antiparkinsonism drugs (2-10 weeks)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ultra low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 11:05:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="1.7176437570135297" CI_START="0.15398408129648267" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.23493309523085998" LOG_CI_START="-0.8125241737247992" LOG_EFFECT_SIZE="-0.2887955392469696" MODIFIED="2011-05-10 10:51:01 +0100" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.6152815847816581" STUDY_ID="STD-Kapur-2000" TOTAL_1="14" TOTAL_2="12" VAR="0.3785714285714286" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-06-26 12:59:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES</NAME>
<DICH_OUTCOME CHI2="3.2831567782906426" CI_END="1.743279380394596" CI_START="0.2796965219870781" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6982758620689655" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="69.54150936037102" I2_Q="69.19372562149455" ID="CMP-002.01" LOG_CI_END="0.24136699332954464" LOG_CI_START="-0.5533129340260821" LOG_EFFECT_SIZE="-0.15597297034826874" METHOD="MH" MODIFIED="2013-06-26 12:08:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06999424265533238" P_Q="0.07159402446097962" P_Z="0.4416737640079531" Q="3.246091973710826" RANDOM="NO" SCALE="91.43" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="34" WEIGHT="100.0" Z="0.7693698907473129">
<NAME>Leaving the study early (2-10 weeks)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.386625353287414" CI_START="0.41685630291773607" DF="0" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="1.4681497162327417" LOG_CI_START="-0.38001362753219037" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2013-06-26 12:08:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.24851637253432124" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="10.344827586206897" Z="1.1539605259061028">
<NAME>versus ultra low doses (&gt; 0.25-1.5 mg/day)</NAME>
<DICH_DATA CI_END="29.386625353287414" CI_START="0.41685630291773607" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4681497162327417" LOG_CI_START="-0.38001362753219037" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="21768" O_E="0.0" SE="1.0856202966836188" STUDY_ID="STD-Kapur-2000" TOTAL_1="12" TOTAL_2="14" VAR="1.1785714285714286" WEIGHT="10.344827586206897"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2121841408909826" CI_START="0.11600960221822196" DF="0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.08356859779922722" LOG_CI_START="-0.9355060623437895" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2013-06-26 12:08:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10131479213540232" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="89.6551724137931" Z="1.6385126751688406">
<NAME>versus standard higher group (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="1.2121841408909826" CI_START="0.11600960221822196" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.08356859779922722" LOG_CI_START="-0.9355060623437895" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-05-09 13:31:00 +0100" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.5986094998689324" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.35833333333333334" WEIGHT="89.6551724137931"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:08:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 1. No clinically significant response in global state (2-10 weeks)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:08:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>versus ultra low doses (&gt; 0.25-1.5 mg/day)</NAME>
<DICH_DATA CI_END="1.0929531474937721" CI_START="0.2573040798623795" EFFECT_SIZE="0.5303030303030303" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.03860154509604832" LOG_CI_START="-0.5895533274792345" LOG_EFFECT_SIZE="-0.27547589119159305" ORDER="21769" O_E="0.0" SE="0.3689812815674884" STUDY_ID="STD-Kapur-2000" TOTAL_1="12" TOTAL_2="14" VAR="0.13614718614718616" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:09:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 2. Use of adjunctive medication for sedation (2-10 weeks)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:09:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>versus ultra low doses (&gt; 0.25-1.5 mg/day)</NAME>
<DICH_DATA CI_END="8.794661443903031" CI_START="0.3482226143137212" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9442191256724162" LOG_CI_START="-0.4581430282998273" LOG_EFFECT_SIZE="0.24303804868629444" ORDER="21770" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Kapur-2000" TOTAL_1="12" TOTAL_2="14" VAR="0.6785714285714285" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.04" MODIFIED="2013-06-26 12:09:29 +0100" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Global state: 3. CGI score at endpoint (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.04.01" MODIFIED="2013-06-26 12:09:29 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus standard higher dose (7.5-15 mg/day)</NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="455" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
</TD>
<TD>
<P>3.47</P>
</TD>
<TD>
<P>1.71</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Standard high dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>3.35</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = 0.23, d.f = 37, p = 0.82</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.05" MODIFIED="2013-06-26 12:09:45 +0100" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Global state: 4. Mean dose of lorazepam (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.05.01" MODIFIED="2013-06-26 12:09:45 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="456" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
<P> </P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>55.2</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>58.2</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = -0.01, d.f = 37, p = 99</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:10:03 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 1. Clinically significant agitation (2-10 weeks)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:10:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>versus ultra low doses (&gt; 0.25-1.5 mg/day)</NAME>
<DICH_DATA CI_END="8.794661443903031" CI_START="0.3482226143137212" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9442191256724162" LOG_CI_START="-0.4581430282998273" LOG_EFFECT_SIZE="0.24303804868629444" ORDER="21771" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Kapur-2000" TOTAL_1="12" TOTAL_2="14" VAR="0.6785714285714285" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.07" MODIFIED="2013-06-26 12:10:31 +0100" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental State/behaviour: 2. PANNS general endpoint score (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.07.01" MODIFIED="2013-06-26 12:10:31 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<OTHER_DATA MODIFIED="2012-09-12 10:13:11 +0100" MODIFIED_BY="[Empty name]" ORDER="458" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
</TD>
<TD>
<P>34.6</P>
</TD>
<TD>
<P>12.9</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>38.1</P>
</TD>
<TD>
<P>20.9</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2013-06-26 12:11:02 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 3. PANSS positive endpoint score</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.08.01" MODIFIED="2013-06-26 12:11:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<CONT_DATA CI_END="5.728052623950787" CI_START="-4.128052623950793" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="16.6" MODIFIED="2011-05-11 10:08:36 +0100" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="8.8" SD_2="7.0" SE="2.514358765172544" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.09" MODIFIED="2013-06-26 12:11:19 +0100" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state/behaviour: 4. PANNS negative endpoint score (skewed data)</NAME>
<TR>
<TH>
<P>Study Group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.09.01" MODIFIED="2013-06-26 12:11:19 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<OTHER_DATA MODIFIED="2012-09-12 10:13:11 +0100" MODIFIED_BY="[Empty name]" ORDER="460" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
</TD>
<TD>
<P>20.3</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>21.5</P>
</TD>
<TD>
<P>8.4</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.10" MODIFIED="2013-06-26 12:59:51 +0100" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state/behaviour: 5. Calgary Depression Rating Scale endpoint score (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.10.01" MODIFIED="2013-06-26 12:11:44 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="461" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
</TD>
<TD>
<P>0.6</P>
</TD>
<TD>
<P>1.35</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Standrad high dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>1.2</P>
</TD>
<TD>
<P>2.97</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = 0.8, d.f = 38, p = 0.42</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:12:13 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 1. Clinically significant extrapyramidal side effects (2-10 weeks)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:12:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>versus ultra low doses (&gt; 0.25-1.5 mg/day)</NAME>
<DICH_DATA CI_END="6.494177785004857" CI_START="0.5821928999635535" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8125241737247991" LOG_CI_START="-0.23493309523085995" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="21772" O_E="0.0" SE="0.615281584781658" STUDY_ID="STD-Kapur-2000" TOTAL_1="12" TOTAL_2="14" VAR="0.37857142857142856" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:12:33 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 2a. Use of any antiparkinsonism drugs (2-10 weeks)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:12:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>versus ultra low doses (&gt; 0.25-1.5 mg/day)</NAME>
<DICH_DATA CI_END="6.494177785004857" CI_START="0.5821928999635535" EFFECT_SIZE="1.9444444444444444" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8125241737247991" LOG_CI_START="-0.23493309523085995" LOG_EFFECT_SIZE="0.28879553924696955" ORDER="21773" O_E="0.0" SE="0.615281584781658" STUDY_ID="STD-Kapur-2000" TOTAL_1="12" TOTAL_2="14" VAR="0.37857142857142856" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.13" MODIFIED="2013-06-26 12:12:58 +0100" MODIFIED_BY="[Empty name]" NO="13" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 2b. Mean dose of orphenadrine (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.13.01" MODIFIED="2013-06-26 12:12:58 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus standard higher dose (&gt;7.5-15mg/day)</NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="464" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
<P> </P>
</TD>
<TD>
<P>555.3</P>
</TD>
<TD>
<P>943.5</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>1967.5</P>
</TD>
<TD>
<P>2261.9</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = 2.5, d.f = 37, p = 0.016</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:13:17 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3. Dystonic reaction (duration unclear)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:13:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg)</NAME>
<DICH_DATA CI_END="1.4576054684368849" CI_START="0.07622852240686574" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.16363998895624796" LOG_CI_START="-1.1178824983955729" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-05-09 13:44:24 +0100" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:13:56 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 4. Dyskinesia (duration unclear)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:13:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-05-09 13:54:26 +0100" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:59:23 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 5. Akathisia (duration unclear)</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-002.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:14:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="1.2121841408909826" CI_START="0.11600960221822196" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.08356859779922722" LOG_CI_START="-0.9355060623437895" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2011-05-09 14:01:49 +0100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.5986094998689324" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.35833333333333334" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.17" MODIFIED="2013-06-26 12:14:30 +0100" MODIFIED_BY="[Empty name]" NO="17" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 6. Prolactin at endpoint (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean (ng/ml) </P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.17.01" MODIFIED="2013-06-26 12:14:30 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="468" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
<P> </P>
</TD>
<TD>
<P>15.5</P>
</TD>
<TD>
<P>8.4</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = -0.38, d.f = 9, p = 0.7</P>
</TD>
</TR>
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>51.4</P>
</TD>
<TD>
<P>34.8</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = -3.49, d.f = 10, p = 0.006</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-06-26 12:19:28 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES</NAME>
<DICH_OUTCOME CHI2="6.880439717763769" CI_END="1.047411672546643" CI_START="0.4518633787903119" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6879585578661972" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="37" I2="27.33022589979084" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.020117409449322297" LOG_CI_START="-0.34499285458328227" LOG_EFFECT_SIZE="-0.16243772256698003" METHOD="MH" MODIFIED="2013-06-26 12:15:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2296851683805161" P_Q="0.45206735432251266" P_Z="0.08116297202358481" Q="1.5878489422829742" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="178" TOTAL_2="163" WEIGHT="300.0" Z="1.743977736728646">
<NAME>Leaving the study early (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.119967375409463" CI_START="0.0068345514328028885" DF="0" EFFECT_SIZE="0.12037037037037036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.3263291775378711" LOG_CI_START="-2.1652899838980972" LOG_EFFECT_SIZE="-0.9194804031801129" MODIFIED="2013-06-26 12:15:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14801790877879445" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="1.4465681614719779">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="2.119967375409464" CI_START="0.0068345514328028885" EFFECT_SIZE="0.12037037037037036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3263291775378713" LOG_CI_START="-2.1652899838980972" LOG_EFFECT_SIZE="-0.9194804031801129" ORDER="21774" O_E="0.0" SE="1.4635894291412526" STUDY_ID="STD-McEvoy-1991" TOTAL_1="23" TOTAL_2="25" VAR="2.1420940170940175" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21775" O_E="0.0" SE="0.0" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7559495782596937" CI_END="1.2828021419972768" CI_START="0.47249955467001364" DF="2" EFFECT_SIZE="0.7785392994727067" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="46.75114885523322" ID="CMP-003.01.02" LOG_CI_END="0.1081596764332199" LOG_CI_START="-0.32559859647629885" LOG_EFFECT_SIZE="-0.10871946002153948" MODIFIED="2013-06-26 12:15:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15289954835577957" P_Z="0.32584797758739326" STUDIES="4" TAU2="0.0" TOTAL_1="101" TOTAL_2="90" WEIGHT="100.0" Z="0.982511409553261">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="1.1490108338477512" CI_START="0.24108415872953576" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.060324123603963414" LOG_CI_START="-0.6178313255096214" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="21776" O_E="0.0" SE="0.3983518677329326" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="25" VAR="0.1586842105263158" WEIGHT="48.052028148248105"/>
<DICH_DATA CI_END="13.205028206198888" CI_START="0.611188733320632" EFFECT_SIZE="2.840909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1207393332054532" LOG_CI_START="-0.2138246601617154" LOG_EFFECT_SIZE="0.453457336521869" MODIFIED="2011-03-02 13:06:31 +0000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.7839294959021854" STUDY_ID="STD-Khanna-1997" TOTAL_1="22" TOTAL_2="25" VAR="0.6145454545454545" WEIGHT="7.4580191504447795"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-29 13:47:02 +0000" MODIFIED_BY="[Empty name]" ORDER="21777" O_E="0.0" SE="0.0" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5231928153879855" CI_START="0.32652151132512597" EFFECT_SIZE="0.7052341597796143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18275488256041533" LOG_CI_START="-0.48608820200894126" LOG_EFFECT_SIZE="-0.15166665972426294" ORDER="21778" O_E="0.0" SE="0.39288173870270504" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.1543560606060606" WEIGHT="44.48995270130712"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6976466646610928" CI_END="1.6035169730411818" CI_START="0.3090715668469466" DF="1" EFFECT_SIZE="0.703989703989704" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="41.09492741826618" ID="CMP-003.01.03" LOG_CI_END="0.2050735612455095" LOG_CI_START="-0.5099409461804765" LOG_EFFECT_SIZE="-0.1524336924674835" MODIFIED="2013-06-26 12:15:32 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.192596116355931" P_Z="0.4033304159857646" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="40" WEIGHT="100.0" Z="0.8356880711197278">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="2.3642771009253085" CI_START="0.3917583676710501" EFFECT_SIZE="0.9624060150375939" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.37369837591065524" LOG_CI_START="-0.40698171854909015" LOG_EFFECT_SIZE="-0.01664167131921745" ORDER="21779" O_E="0.0" SE="0.4585753519144467" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="32" VAR="0.21029135338345864" WEIGHT="68.46846846846847"/>
<DICH_DATA CI_END="2.3858386537426313" CI_START="0.008553874015450344" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3776410704497642" LOG_CI_START="-2.0678371504782778" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="21780" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="31.531531531531535"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.33204649394764973" CI_END="1.2266712899023593" CI_START="0.7944459583115717" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.987179846046186" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.088728200781545" LOG_CI_START="-0.09993564006179396" LOG_EFFECT_SIZE="-0.005603719640124502" METHOD="MH" MODIFIED="2013-06-26 12:16:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.847026568389755" P_Q="0.6075256856221358" P_Z="0.9073115657924593" Q="0.2637938308512961" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="65" WEIGHT="200.0" Z="0.11643024572179488">
<NAME>Global state: 1. No clinically significant response in global state (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7523913977822287" CI_START="0.6742069617817488" DF="0" EFFECT_SIZE="1.0869565217391304" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.2436311126270693" LOG_CI_START="-0.17120676731817994" LOG_EFFECT_SIZE="0.03621217265444471" MODIFIED="2013-06-26 12:15:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7322156489509672" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="0.3421797171175648">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="1.7523913977822287" CI_START="0.6742069617817489" EFFECT_SIZE="1.0869565217391304" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.2436311126270693" LOG_CI_START="-0.17120676731817988" LOG_EFFECT_SIZE="0.03621217265444471" ORDER="21781" O_E="0.0" SE="0.2436778241604632" STUDY_ID="STD-McEvoy-1991" TOTAL_1="23" TOTAL_2="25" VAR="0.05937888198757763" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09939563477349815" CI_END="1.1919898557522068" CI_START="0.7505260318982713" DF="1" EFFECT_SIZE="0.9458432304038004" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="32" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.0762725594230212" LOG_CI_START="-0.12463423971157644" LOG_EFFECT_SIZE="-0.024180840144277613" MODIFIED="2013-06-26 12:16:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7525561297482692" P_Z="0.6370719552336177" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="99.99999999999999" Z="0.47179663408955214">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="1.4483114741184893" CI_START="0.6904592125866069" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.16086197135292193" LOG_CI_START="-0.16086197135292193" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-29 13:47:28 +0000" MODIFIED_BY="[Empty name]" ORDER="21782" O_E="0.0" SE="0.18898223650461357" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.0357142857142857" WEIGHT="21.615201900237526"/>
<DICH_DATA CI_END="1.2292121573392452" CI_START="0.704997693329861" EFFECT_SIZE="0.9309090909090909" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.08962684693028825" LOG_CI_START="-0.15181230396711448" LOG_EFFECT_SIZE="-0.03109272851841309" ORDER="21783" O_E="0.0" SE="0.1418225523802063" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.02011363636363636" WEIGHT="78.38479809976246"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.404310381745093" CI_END="1.2424054593600087" CI_START="0.7895283424555497" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9904111888434184" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="56" I2="61.554395695285976" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.09426335109519403" LOG_CI_START="-0.10263227509062971" LOG_EFFECT_SIZE="-0.004184461997717865" METHOD="MH" MODIFIED="2013-06-26 12:16:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.03414096505850461" P_Q="0.8146908407804238" P_Z="0.9336074114755711" Q="0.0549334680594144" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="115" WEIGHT="100.0" Z="0.08330702889726285">
<NAME>Global state: 2. Use of adjunctive medication for sedation</NAME>
<GROUP_LABEL_1>Standard low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.765938059305004" CI_END="1.3326387165750662" CI_START="0.702794131919243" DF="2" EFFECT_SIZE="0.9677658136023135" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="31" I2="77.18441555861772" ID="CMP-003.03.01" LOG_CI_END="0.12471242648476384" LOG_CI_START="-0.15317187336588825" LOG_EFFECT_SIZE="-0.01422972344056218" MODIFIED="2013-06-26 12:16:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.012488269881154035" P_Z="0.8409103326663259" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="58" WEIGHT="57.486996857353816" Z="0.20072919174243745">
<NAME>versus high dose (&gt; 15-35 mg/day) - less than 2 weeks</NAME>
<DICH_DATA CI_END="0.9307913467617497" CI_START="0.41734796024271037" EFFECT_SIZE="0.6232686980609419" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="-0.03114766284887804" LOG_CI_START="-0.37950170473971273" LOG_EFFECT_SIZE="-0.20532468379429542" MODIFIED="2011-05-10 13:16:32 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.20462488858699412" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="25" VAR="0.04187134502923976" WEIGHT="38.50660280410664"/>
<DICH_DATA CI_END="2.357087061493795" CI_START="0.7651742844111904" EFFECT_SIZE="1.3429752066115703" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.37237562394479495" LOG_CI_START="-0.11623963394790872" LOG_EFFECT_SIZE="0.12806799499844312" MODIFIED="2011-03-02 13:11:36 +0000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.28701502117070876" STUDY_ID="STD-Khanna-1997" TOTAL_1="22" TOTAL_2="25" VAR="0.08237762237762239" WEIGHT="17.300396839494603"/>
<DICH_DATA CI_END="33.7768109506405" CI_START="0.7401527644671237" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5286186431059408" LOG_CI_START="-0.1306786344339033" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-05-10 14:44:38 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.95" WEIGHT="1.6799972137525752"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.540512472331557" CI_END="1.3972442129621245" CI_START="0.7461171577644699" DF="1" EFFECT_SIZE="1.0210327521084492" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" I2="35.08653659346844" ID="CMP-003.03.02" LOG_CI_END="0.14527231955198236" LOG_CI_START="-0.12719297282804998" LOG_EFFECT_SIZE="0.009039673361966177" MODIFIED="2013-06-26 12:16:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21454199966137533" P_Z="0.8965246696897483" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="57" WEIGHT="42.51300314264618" Z="0.13005277895540313">
<NAME>versus high dose (&gt; 15-35 mg/day) - (2-10 weeks)</NAME>
<DICH_DATA CI_END="30.444091378318625" CI_START="0.3817456951506541" EFFECT_SIZE="3.409090909090909" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4835030168115966" LOG_CI_START="-0.41822585167260906" LOG_EFFECT_SIZE="0.5326385825694938" MODIFIED="2011-03-02 13:14:30 +0000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Khanna-1997" TOTAL_1="22" TOTAL_2="25" VAR="1.2478787878787878" WEIGHT="1.572763349044964"/>
<DICH_DATA CI_END="1.2557241452105465" CI_START="0.6877189960292087" EFFECT_SIZE="0.9292929292929293" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.09889424499763476" LOG_CI_START="-0.16258897950162401" LOG_EFFECT_SIZE="-0.03184736725199465" MODIFIED="2011-03-02 12:41:33 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.15359654043370108" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.02359189723320157" WEIGHT="40.940239793601215"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:17:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="33" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: clinically significant agitation (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="24" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:17:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="1.2557241452105465" CI_START="0.6877189960292087" EFFECT_SIZE="0.9292929292929293" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.09889424499763476" LOG_CI_START="-0.16258897950162401" LOG_EFFECT_SIZE="-0.03184736725199465" MODIFIED="2011-03-02 13:24:43 +0000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.15359654043370108" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.02359189723320157" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:17:39 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: no psychotic symptoms (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:17:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-02 13:32:28 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.0" STUDY_ID="STD-Khanna-1997" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.232589808908994" CI_END="0.7579369594413917" CI_START="0.47191400905942293" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5980644356123314" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="76" I2="4.445022778452596" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.12036691482346401" LOG_CI_START="-0.3261371301652121" LOG_EFFECT_SIZE="-0.22325202249433804" METHOD="MH" MODIFIED="2013-06-26 12:18:38 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3881592121541657" P_Q="0.4313162571472553" P_Z="2.1096623839900368E-5" Q="1.681828629674855" RANDOM="NO" SCALE="931.4032691680169" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="138" WEIGHT="300.0" Z="4.252956851290735">
<NAME>Adverse effects: 1. Clinically significant extrapyramidal side effects (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.119967375409463" CI_START="0.0068345514328028885" DF="0" EFFECT_SIZE="0.12037037037037036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.3263291775378711" LOG_CI_START="-2.1652899838980972" LOG_EFFECT_SIZE="-0.9194804031801129" MODIFIED="2013-06-26 12:18:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14801790877879445" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="33" WEIGHT="100.0" Z="1.4465681614719779">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="2.119967375409464" CI_START="0.0068345514328028885" EFFECT_SIZE="0.12037037037037036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3263291775378713" LOG_CI_START="-2.1652899838980972" LOG_EFFECT_SIZE="-0.9194804031801129" ORDER="21786" O_E="0.0" SE="1.4635894291412526" STUDY_ID="STD-McEvoy-1991" TOTAL_1="23" TOTAL_2="25" VAR="2.1420940170940175" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21787" O_E="0.0" SE="0.0" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4521966043209626" CI_END="0.7761593962551762" CI_START="0.44779096701462767" DF="2" EFFECT_SIZE="0.5895397922164329" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="50" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="-0.11004908053901176" LOG_CI_START="-0.3489246713985022" LOG_EFFECT_SIZE="-0.22948687596875697" MODIFIED="2013-06-26 12:18:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4837930068446137" P_Z="1.6597680605795392E-4" STUDIES="3" TAU2="0.0" TOTAL_1="79" TOTAL_2="65" WEIGHT="100.00000000000001" Z="3.7658599625437974">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="0.9307913467617497" CI_START="0.41734796024271037" EFFECT_SIZE="0.6232686980609419" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="-0.03114766284887804" LOG_CI_START="-0.37950170473971273" LOG_EFFECT_SIZE="-0.20532468379429542" ORDER="21788" O_E="0.0" SE="0.20462488858699412" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="25" VAR="0.04187134502923976" WEIGHT="42.19507918882591"/>
<DICH_DATA CI_END="1.3510724380256207" CI_START="0.029606110578684966" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.13067863443390323" LOG_CI_START="-1.5286186431059408" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="21789" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.95" WEIGHT="9.204605224709253"/>
<DICH_DATA CI_END="0.9183612629224321" CI_START="0.43773338145722074" EFFECT_SIZE="0.634032634032634" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="-0.03698644338451269" LOG_CI_START="-0.35879033291653845" LOG_EFFECT_SIZE="-0.19788838815052556" ORDER="21790" O_E="0.0" SE="0.18902919766605597" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.035732037570272865" WEIGHT="48.60031558646485"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5476645389846326" CI_END="1.0932646022835288" CI_START="0.45176944244034223" DF="1" EFFECT_SIZE="0.7027827116637064" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" I2="35.38651466059536" ID="CMP-003.06.03" LOG_CI_END="0.038725286747567284" LOG_CI_START="-0.34508314798040207" LOG_EFFECT_SIZE="-0.15317893061641738" MODIFIED="2013-06-26 12:18:38 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.2134810253614179" P_Z="0.1177111506539419" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="40" WEIGHT="100.00000000000001" Z="1.564453305521165">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.239934429646643" CI_START="0.5133006950704966" EFFECT_SIZE="0.7977839335180056" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.09339871935934481" LOG_CI_START="-0.28962814765219885" LOG_EFFECT_SIZE="-0.09811471414642704" ORDER="21791" O_E="0.0" SE="0.22499187769615098" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="32" VAR="0.05062134502923976" WEIGHT="85.49437537004145"/>
<DICH_DATA CI_END="2.3858386537426313" CI_START="0.008553874015450344" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3776410704497642" LOG_CI_START="-2.0678371504782778" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="21792" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="14.505624629958556"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3633176601841126" CI_END="0.816733085486026" CI_START="0.5123121105414353" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.646855664560777" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" I2="0.0" I2_Q="23.16133963207761" ID="CMP-003.07" LOG_CI_END="-0.0879198509831022" LOG_CI_START="-0.2904653777189105" LOG_EFFECT_SIZE="-0.18919261435100634" METHOD="MH" MODIFIED="2013-06-26 12:19:04 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5004997185718614" P_Q="0.2539526315531291" P_Z="2.507381520632577E-4" Q="1.3014282071183363" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="117" TOTAL_2="97" WEIGHT="200.0" Z="3.6615048107442822">
<NAME>Adverse effects: 2. Use of any antiparkinsonism drugs (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4521966043209626" CI_END="0.7761593962551762" CI_START="0.44779096701462767" DF="2" EFFECT_SIZE="0.5895397922164329" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="50" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="-0.11004908053901176" LOG_CI_START="-0.3489246713985022" LOG_EFFECT_SIZE="-0.22948687596875697" MODIFIED="2013-06-26 12:18:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4837930068446137" P_Z="1.6597680605795392E-4" STUDIES="3" TAU2="0.0" TOTAL_1="79" TOTAL_2="65" WEIGHT="100.00000000000001" Z="3.7658599625437974">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="0.9307913467617497" CI_START="0.41734796024271037" EFFECT_SIZE="0.6232686980609419" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="-0.03114766284887804" LOG_CI_START="-0.37950170473971273" LOG_EFFECT_SIZE="-0.20532468379429542" ORDER="21793" O_E="0.0" SE="0.20462488858699412" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="25" VAR="0.04187134502923976" WEIGHT="42.19507918882591"/>
<DICH_DATA CI_END="1.3510724380256207" CI_START="0.029606110578684966" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.13067863443390323" LOG_CI_START="-1.5286186431059408" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="21794" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.95" WEIGHT="9.204605224709253"/>
<DICH_DATA CI_END="0.9183612629224321" CI_START="0.43773338145722074" EFFECT_SIZE="0.634032634032634" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="-0.03698644338451269" LOG_CI_START="-0.35879033291653845" LOG_EFFECT_SIZE="-0.19788838815052556" ORDER="21795" O_E="0.0" SE="0.18902919766605597" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.035732037570272865" WEIGHT="48.60031558646485"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.239934429646643" CI_START="0.5133006950704966" DF="0" EFFECT_SIZE="0.7977839335180056" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.09339871935934481" LOG_CI_START="-0.28962814765219885" LOG_EFFECT_SIZE="-0.09811471414642704" MODIFIED="2013-06-26 12:19:04 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.3153237160858603" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="1.0041139285127172">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.239934429646643" CI_START="0.5133006950704966" EFFECT_SIZE="0.7977839335180056" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.09339871935934481" LOG_CI_START="-0.28962814765219885" LOG_EFFECT_SIZE="-0.09811471414642704" ORDER="21796" O_E="0.0" SE="0.22499187769615098" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="32" VAR="0.05062134502923976" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:19:28 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3. Specific adverse effects-blurred vision (&lt; 2 weeks)</NAME>
<GROUP_LABEL_1>Standard low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours standard low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:19:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="2.807914723706236" CI_START="0.1149716463206136" EFFECT_SIZE="0.5681818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4483839141464466" LOG_CI_START="-0.939409249774746" LOG_EFFECT_SIZE="-0.2455126678141498" MODIFIED="2011-03-02 13:16:17 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.815196574174263" STUDY_ID="STD-Khanna-1997" TOTAL_1="22" TOTAL_2="25" VAR="0.6645454545454546" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-06-26 12:58:27 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:58:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Mortality (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:21:32 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21797" O_E="0.0" SE="0.0" STUDY_ID="STD-Neborsky-1981" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:21:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early (day 1-2)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:21:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>versus high to very high dose range</NAME>
<DICH_DATA CI_END="91.60140785423062" CI_START="0.12002500934582783" EFFECT_SIZE="3.3157894736842106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9619021485436698" LOG_CI_START="-0.9207282515421643" LOG_EFFECT_SIZE="0.5205869485007527" MODIFIED="2011-05-10 15:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-Louza-1988" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9472030067550203" CI_START="0.2637686514088919" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.289411231498205" LOG_CI_START="-0.5787768211063192" LOG_EFFECT_SIZE="-0.1446827948040571" METHOD="MH" MODIFIED="2013-06-26 12:22:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5135934256811414" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="53" WEIGHT="100.0" Z="0.6532526361030762">
<NAME>Leaving the study early: 1. By between 3 and 14 days</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9472030067550203" CI_START="0.2637686514088919" DF="0" EFFECT_SIZE="0.7166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.289411231498205" LOG_CI_START="-0.5787768211063192" LOG_EFFECT_SIZE="-0.1446827948040571" MODIFIED="2013-06-26 12:22:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5135934256811414" STUDIES="2" TAU2="0.0" TOTAL_1="30" TOTAL_2="53" WEIGHT="100.0" Z="0.6532526361030762">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.9472030067550203" CI_START="0.2637686514088919" EFFECT_SIZE="0.7166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.289411231498205" LOG_CI_START="-0.5787768211063192" LOG_EFFECT_SIZE="-0.1446827948040571" MODIFIED="2013-01-29 13:48:01 +0000" MODIFIED_BY="[Empty name]" ORDER="21798" O_E="0.0" SE="0.5099779597000688" STUDY_ID="STD-Donlon-1980" TOTAL_1="20" TOTAL_2="43" VAR="0.26007751937984497" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21799" O_E="0.0" SE="0.0" STUDY_ID="STD-Neborsky-1981" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.81884692172827" CI_END="1.5633346460918192" CI_START="0.6669701375790207" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.021125616163805" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="33" I2="18.52403786541693" I2_Q="42.079214262934244" ID="CMP-004.04" LOG_CI_END="0.19405195267997974" LOG_CI_START="-0.17589361042374682" LOG_EFFECT_SIZE="0.009079171128116462" METHOD="MH" MODIFIED="2013-06-26 12:23:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.27797152962095883" P_Q="0.1409409119641417" P_Z="0.9233597264144994" Q="6.905983662166111" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="189" TOTAL_2="197" WEIGHT="500.0" Z="0.09620252380534583">
<NAME>Leaving the study early: 2. By between 2 and 10 weeks</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.619976113002542" CI_START="0.8249571713295782" DF="0" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.9355060623437894" LOG_CI_START="-0.08356859779922725" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2013-06-26 12:22:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10131479213540232" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.6385126751688406">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="8.619976113002542" CI_START="0.8249571713295782" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9355060623437894" LOG_CI_START="-0.08356859779922725" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2011-05-09 13:35:00 +0100" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.5986094998689324" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.35833333333333334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="146.31538146021302" CI_START="0.47170537226161513" DF="0" EFFECT_SIZE="8.307692307692308" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="2.1652899838980972" LOG_CI_START="-0.3263291775378711" LOG_EFFECT_SIZE="0.9194804031801129" MODIFIED="2013-06-26 12:22:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.14801790877879445" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="100.0" Z="1.4465681614719779">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="146.31538146021302" CI_START="0.47170537226161496" EFFECT_SIZE="8.307692307692308" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1652899838980972" LOG_CI_START="-0.3263291775378713" LOG_EFFECT_SIZE="0.9194804031801129" ORDER="21800" O_E="0.0" SE="1.4635894291412526" STUDY_ID="STD-McEvoy-1991" TOTAL_1="25" TOTAL_2="23" VAR="2.1420940170940175" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21801" O_E="0.0" SE="0.0" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9335643244860619" CI_END="1.6531219508389166" CI_START="0.4531336531009703" DF="3" EFFECT_SIZE="0.8654970760233919" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.21830489266571956" LOG_CI_START="-0.34377368266011243" LOG_EFFECT_SIZE="-0.06273439499719642" MODIFIED="2013-06-26 12:22:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5863097869684128" P_Z="0.6617424141044703" STUDIES="4" TAU2="0.0" TOTAL_1="89" TOTAL_2="99" WEIGHT="100.0" Z="0.4375087761177788">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="21802" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Klieser-1987" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="6.432748538011696"/>
<DICH_DATA CI_END="3.543628888699885" CI_START="0.2821965932123575" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.549448233522865" LOG_CI_START="-0.549448233522865" LOG_EFFECT_SIZE="0.0" ORDER="21803" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Liang-1987" TOTAL_1="24" TOTAL_2="24" VAR="0.41666666666666663" WEIGHT="25.730994152046783"/>
<DICH_DATA CI_END="36.198059001465566" CI_START="0.19645006686196073" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.5586852835841862" LOG_CI_START="-0.706747819039624" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="21805" O_E="0.0" SE="1.3307266185559425" STUDY_ID="STD-Palao-1994" TOTAL_1="6" TOTAL_2="16" VAR="1.7708333333333333" WEIGHT="3.508771929824561"/>
<DICH_DATA CI_END="1.4342540261118382" CI_START="0.2510015614011799" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.15662607766948694" LOG_CI_START="-0.6003235769021996" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="21806" O_E="0.0" SE="0.4446359740566291" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.19770114942528733" WEIGHT="64.32748538011695"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.482217907416576" CI_END="1.4903631674948106" CI_START="0.2571319279801381" DF="1" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="32.53353673597529" ID="CMP-004.04.04" LOG_CI_END="0.17329210896318653" LOG_CI_START="-0.5898439938173514" LOG_EFFECT_SIZE="-0.20827594242708247" MODIFIED="2013-06-26 12:23:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.22342817153012762" P_Z="0.28469538303621" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="1.069831041974994">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="2.241505645779265" CI_START="0.3277680245572624" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.35053983707988023" LOG_CI_START="-0.48443341634110665" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="21807" O_E="0.0" SE="0.4904674222437513" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.2405582922824302" WEIGHT="66.66666666666667"/>
<DICH_DATA CI_END="2.3858386537426313" CI_START="0.008553874015450344" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3776410704497642" LOG_CI_START="-2.0678371504782778" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="21808" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="33.333333333333336"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.13913386929134" CI_START="0.1168697310574681" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-004.04.05" LOG_CI_END="0.3302379640363697" LOG_CI_START="-0.932297955364332" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-06-26 12:23:21 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.349974143204844" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.9346394676005982">
<NAME>versus high and very high dose (&gt; 15 mg/day)</NAME>
<DICH_DATA CI_END="2.13913386929134" CI_START="0.1168697310574681" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3302379640363697" LOG_CI_START="-0.932297955364332" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-05-10 15:57:01 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.7416198487095663" STUDY_ID="STD-Louza-1988" TOTAL_1="10" TOTAL_2="10" VAR="0.55" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:23:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 1. No clinically significant response (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:23:35 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="24.17099317690655" CI_START="0.37234713253730845" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3832944957691864" LOG_CI_START="-0.4290519863298616" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="21809" O_E="0.0" SE="1.064581294844754" STUDY_ID="STD-Neborsky-1981" TOTAL_1="10" TOTAL_2="10" VAR="1.133333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5382081969253185" CI_END="1.555083161598223" CI_START="0.9100516804985799" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.189624329159213" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.19175361886606412" LOG_CI_START="-0.04093394403270144" LOG_EFFECT_SIZE="0.07540983741668135" METHOD="MH" MODIFIED="2013-06-26 12:24:07 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6734804216977288" P_Q="0.4815293120045655" P_Z="0.20395008709601048" Q="1.4615766995915054" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="107" TOTAL_2="105" WEIGHT="300.0" Z="1.270377871300491">
<NAME>Global state: 2. No clinically significant response in global state (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4832240790828788" CI_START="0.5706487724520722" DF="0" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="0.17120676731817994" LOG_CI_START="-0.24363111262706935" LOG_EFFECT_SIZE="-0.036212172654444715" MODIFIED="2013-06-26 12:23:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7322156489509672" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="0.34217971711756484">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="1.4832240790828786" CI_START="0.5706487724520724" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.17120676731817988" LOG_CI_START="-0.24363111262706927" LOG_EFFECT_SIZE="-0.036212172654444715" ORDER="21810" O_E="0.0" SE="0.2436778241604632" STUDY_ID="STD-McEvoy-1991" TOTAL_1="25" TOTAL_2="23" VAR="0.059378881987577625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01704581891196963" CI_END="2.0748049388392227" CI_START="0.8568409224880577" DF="1" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="0.3169772731118253" LOG_CI_START="-0.06709979989522541" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-06-26 12:23:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8961236789267778" P_Z="0.20226081639452897" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.2751368995238543">
<NAME>versus high dose (&gt;15-35mg/day)</NAME>
<DICH_DATA CI_END="4.095794361137198" CI_START="0.3814888791355656" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6123381437526143" LOG_CI_START="-0.41851811773650155" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="21811" O_E="0.0" SE="0.6055300708194983" STUDY_ID="STD-Liang-1987" TOTAL_1="24" TOTAL_2="24" VAR="0.36666666666666664" WEIGHT="22.22222222222222"/>
<DICH_DATA CI_END="2.149916957815606" CI_START="0.8567013381601729" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.33242168528353416" LOG_CI_START="-0.06717055473435225" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="21813" O_E="0.0" SE="0.23472245979999556" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.05509463313456053" WEIGHT="77.77777777777777"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.061454871711699" CI_START="0.8018905711562828" DF="0" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" I2="0.0" ID="CMP-004.06.03" LOG_CI_END="0.31417383189453935" LOG_CI_START="-0.0958848930444032" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-06-26 12:24:07 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Z="0.2967820731805605" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.043358993113579">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="2.061454871711699" CI_START="0.8018905711562828" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.31417383189453935" LOG_CI_START="-0.0958848930444032" LOG_EFFECT_SIZE="0.10914446942506807" ORDER="21814" O_E="0.0" SE="0.2408705248525599" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.05801860974274767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.08386593018884309" CI_END="-0.01697803504837142" CI_START="-0.6913940983273765" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.354186066687874" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2013-06-26 12:57:58 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7721252242693736" P_Q="0.7721252242693736" P_Z="0.0395281715225885" Q="0.08386593018884309" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="200.0" Z="2.0586459081623283">
<NAME>Global state: 3. Mean change CGI</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19819472001017868" CI_START="-0.7981947200101783" DF="0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.01" MODIFIED="2013-06-26 12:57:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.23790490754375893" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.180239717012663">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<CONT_DATA CI_END="0.19819472001017868" CI_START="-0.7981947200101783" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.1" ORDER="21815" SD_1="0.89" SD_2="1.04" SE="0.2541856503180032" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.058093465231399743" CI_START="-0.8580934652313996" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.02" MODIFIED="2013-06-26 12:57:47 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.0870055102468112" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.7114096867109903">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<CONT_DATA CI_END="0.058093465231399743" CI_START="-0.8580934652313996" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.0" ORDER="21816" SD_1="0.89" SD_2="0.89" SE="0.23372545049030616" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:24:58 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 4. Use of adjunctive medication for sedation</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:24:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="2.0329362925830625" CI_START="0.4918993298749137" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3081237690890228" LOG_CI_START="-0.30812376908902284" LOG_EFFECT_SIZE="0.0" ORDER="21817" O_E="0.0" SE="0.36198685440029543" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.13103448275862067" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-004.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:24:58 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="3.2348614411700365" CI_START="0.6308821455401988" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5098556832662342" LOG_CI_START="-0.20005176329474786" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="21818" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-004.09" MODIFIED="2013-06-26 12:25:10 +0100" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Global state: 5. CGI score at endpoint (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.09.01" MODIFIED="2013-06-26 12:25:10 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="522" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Standard high dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>3.35</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg) </P>
</TD>
<TD>
<P>3.47</P>
</TD>
<TD>
<P>1.71</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = 0.23, d.f = 37, p = 0.82</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-004.10" MODIFIED="2013-06-26 12:25:20 +0100" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Global state: 6. Mean dose of lorazepam (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.10.01" MODIFIED="2013-06-26 12:25:20 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="523" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>58.2</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
<P> </P>
</TD>
<TD>
<P>48.7</P>
</TD>
<TD>
<P>55.2</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = -0.01, d.f = 37, p = 99</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:25:31 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 1. No clinically significant response in psychotic symptoms (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:25:31 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>versus very high doses (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="24.17099317690655" CI_START="0.37234713253730845" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3832944957691864" LOG_CI_START="-0.4290519863298616" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="21819" O_E="0.0" SE="1.064581294844754" STUDY_ID="STD-Neborsky-1981" TOTAL_1="10" TOTAL_2="10" VAR="1.133333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:25:54 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 2. Clinically significant agitation (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-004.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:25:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="2.0329362925830625" CI_START="0.4918993298749137" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3081237690890228" LOG_CI_START="-0.30812376908902284" LOG_EFFECT_SIZE="0.0" ORDER="21820" O_E="0.0" SE="0.36198685440029543" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.13103448275862067" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-004.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:25:54 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="3.2348614411700365" CI_START="0.6308821455401988" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5098556832662342" LOG_CI_START="-0.20005176329474786" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="21821" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.13" MODIFIED="2013-06-26 12:26:04 +0100" MODIFIED_BY="[Empty name]" NO="13" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental State/behaviour: 3. PANNS general endpoint score (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.13.01" MODIFIED="2013-06-26 12:26:04 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<OTHER_DATA MODIFIED="2012-09-12 10:13:11 +0100" MODIFIED_BY="[Empty name]" ORDER="527" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>38.1</P>
</TD>
<TD>
<P>20.9</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
</TD>
<TD>
<P>34.6</P>
</TD>
<TD>
<P>12.9</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.14" MODIFIED="2013-06-26 12:26:14 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 3. PANSS positive endpoint score</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.14.01" MODIFIED="2013-06-26 12:26:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt; 1.5-3 mg)</NAME>
<CONT_DATA CI_END="3.958516472450375" CI_START="-5.5585164724503695" EFFECT_SIZE="-0.7999999999999972" ESTIMABLE="YES" MEAN_1="16.6" MEAN_2="17.4" MODIFIED="2011-05-11 10:31:12 +0100" MODIFIED_BY="[Empty name]" ORDER="219" SD_1="7.0" SD_2="8.3" SE="2.427859139241814" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.15" MODIFIED="2013-06-26 12:26:28 +0100" MODIFIED_BY="[Empty name]" NO="15" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state/behaviour: 4. PANNS negative endpoint score (skewed data)</NAME>
<TR>
<TH>
<P>Study Group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.15.01" MODIFIED="2013-06-26 12:26:28 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<OTHER_DATA MODIFIED="2012-09-12 10:13:11 +0100" MODIFIED_BY="[Empty name]" ORDER="529" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>21.5</P>
</TD>
<TD>
<P>8.4</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
</TD>
<TD>
<P>20.3</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.16" MODIFIED="2013-06-26 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="16" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state/behaviour: 5. Calgary Depression Rating Scale endpoint score (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.16.01" MODIFIED="2013-06-26 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<OTHER_DATA MODIFIED="2012-09-12 10:13:11 +0100" MODIFIED_BY="[Empty name]" ORDER="530" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Standrad high dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>1.2</P>
</TD>
<TD>
<P>2.97</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>low dose (&gt;1.5-3mg/day) </P>
</TD>
<TD>
<P>0.6</P>
</TD>
<TD>
<P>1.35</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:27:29 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 1. Acute dystonia (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="28" I2="0.0" ID="CMP-004.17.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:27:29 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.1759812709086743" CI_START="0.40611167133531967" EFFECT_SIZE="0.6910714285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="28" LOG_CI_END="0.07040040506853341" LOG_CI_START="-0.39135452904311147" LOG_EFFECT_SIZE="-0.16047706198728903" ORDER="21822" O_E="0.0" SE="0.2712371340209678" STUDY_ID="STD-Donlon-1980" TOTAL_1="20" TOTAL_2="43" VAR="0.07356958287190843" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:28:00 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: dystonic reaction (duration unclear)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-004.18.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:28:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="13.118449215931964" CI_START="0.6860567016617917" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1178824983955729" LOG_CI_START="-0.16363998895624793" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-05-09 13:47:27 +0100" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.7527726527090809" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5666666666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.19" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:28:26 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: dyskinesia (duration unclear)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.19.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:28:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-05-09 13:56:38 +0100" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:29:02 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: akathisia (duration unclear)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-004.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:29:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<DICH_DATA CI_END="8.619976113002542" CI_START="0.8249571713295782" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9355060623437894" LOG_CI_START="-0.08356859779922725" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2011-05-09 14:05:14 +0100" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.5986094998689324" STUDY_ID="STD-Oosthuizen-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.35833333333333334" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4720351588303573" CI_END="9.066175019879761" CI_START="0.4915843907363592" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="59.54750091527218" I2_Q="56.41787689929045" ID="CMP-004.21" LOG_CI_END="0.9574240987326317" LOG_CI_START="-0.3084019157056234" LOG_EFFECT_SIZE="0.3245110915135041" METHOD="MH" MODIFIED="2013-06-26 12:29:29 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.11588803760219779" P_Q="0.12983156918220473" P_Z="0.3149330183675355" Q="2.294518781678443" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="41" WEIGHT="100.0" Z="1.0049249181097064">
<NAME>Adverse effects: 2a. Clinically significant extrapyramidal side effects (2-10 weeks)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="146.31538146021302" CI_START="0.47170537226161513" DF="0" EFFECT_SIZE="8.307692307692308" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.21.01" LOG_CI_END="2.1652899838980972" LOG_CI_START="-0.3263291775378711" LOG_EFFECT_SIZE="0.9194804031801129" MODIFIED="2013-06-26 12:29:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14801790877879445" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="20.634920634920636" Z="1.4465681614719779">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="146.31538146021302" CI_START="0.47170537226161496" EFFECT_SIZE="8.307692307692308" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1652899838980972" LOG_CI_START="-0.3263291775378713" LOG_EFFECT_SIZE="0.9194804031801129" ORDER="21823" O_E="0.0" SE="1.4635894291412526" STUDY_ID="STD-McEvoy-1991" TOTAL_1="25" TOTAL_2="23" VAR="2.1420940170940175" WEIGHT="20.634920634920636"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21824" O_E="0.0" SE="0.0" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.671852101612961" CI_START="0.05351196796527168" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.21.02" LOG_CI_END="0.6694890857160595" LOG_CI_START="-1.2715490770440219" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-06-26 12:29:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5432337102222069" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="79.36507936507937" Z="0.6079302932701574">
<NAME>versus high and very high dose (&gt; 15 mg/day)</NAME>
<DICH_DATA CI_END="4.671852101612958" CI_START="0.05351196796527171" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6694890857160593" LOG_CI_START="-1.2715490770440216" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-05-10 16:00:00 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Louza-1988" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="79.36507936507937"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-004.22" MODIFIED="2013-06-26 12:57:00 +0100" MODIFIED_BY="[Empty name]" NO="22" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 2b. Mean dose of orphenadrine (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.22.01" MODIFIED="2013-06-26 12:57:00 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus low dose (&gt; 1.5-3 mg/day)</NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="538" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>1967.5</P>
</TD>
<TD>
<P>2261.9</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
<P> </P>
</TD>
<TD>
<P>555.3</P>
</TD>
<TD>
<P>943.5</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = 2.5, d.f = 37, p = 0.016</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.23" MODIFIED="2013-06-26 12:30:18 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3. Mean score/change in EPS</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.23.01" MODIFIED="2013-06-26 12:30:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<CONT_DATA CI_END="1.4147838108648723" CI_START="-1.2147838108648725" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="1.6" ORDER="21825" SD_1="2.7" SD_2="2.4" SE="0.6708203932499369" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.23.02" MODIFIED="2013-06-26 12:30:18 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<CONT_DATA CI_END="1.296209625615281" CI_START="-1.696209625615281" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="1.9" ORDER="21826" SD_1="2.7" SD_2="3.1" SE="0.7633862853691147" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:30:31 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 4. Postural hypotension (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Standard high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours st. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.24.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:30:31 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="16.430916902757556" CI_START="0.02968673630272234" EFFECT_SIZE="0.6984126984126984" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2156617992656886" LOG_CI_START="-1.5274375452004774" LOG_EFFECT_SIZE="-0.1558878729673943" ORDER="21827" O_E="0.0" SE="1.6113101335001732" STUDY_ID="STD-Donlon-1980" TOTAL_1="20" TOTAL_2="43" VAR="2.596320346320346" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-004.25" MODIFIED="2013-06-26 12:56:49 +0100" MODIFIED_BY="[Empty name]" NO="25" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 6. Prolactin at endpoint (skewed data)</NAME>
<TR>
<TH>
<P>Study group</P>
</TH>
<TH>
<P>Mean (ng/ml) </P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.25.01" MODIFIED="2013-06-26 12:30:51 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>versus low dose (&gt; 1.5-3 mg/day) </NAME>
<OTHER_DATA MODIFIED="2013-06-05 10:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="542" STUDY_ID="STD-Oosthuizen-2004">
<TR>
<TD>
<P>Standard higher dose (&gt;7.5-15mg/day) </P>
</TD>
<TD>
<P>51.4</P>
</TD>
<TD>
<P>34.8</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = -3.49, d.f = 10, p = 0.006</P>
</TD>
</TR>
<TR>
<TD>
<P>Low dose (&gt;1.5-3mg/day) </P>
<P> </P>
</TD>
<TD>
<P>15.5</P>
</TD>
<TD>
<P>8.4</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>t = -0.38, d.f = 9, p = 0.7</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-06-26 12:55:48 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES</NAME>
<DICH_OUTCOME CHI2="11.043818345780123" CI_END="1.5240367771939034" CI_START="0.8517875016629308" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1393662619581202" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="66" I2="9.451607343568531" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.1829954472789461" LOG_CI_START="-0.06966873664856289" LOG_EFFECT_SIZE="0.05666335531519161" METHOD="MH" MODIFIED="2013-06-26 12:32:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.35411445497759253" P_Q="0.8190464310050148" P_Z="0.3793488111669179" Q="0.3992291897156668" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="339" TOTAL_2="352" WEIGHT="300.0" Z="0.8790967832056095">
<NAME>Leaving the study early (2-10 weeks)</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7559495782596954" CI_END="2.116404111107331" CI_START="0.7795434442002379" DF="2" EFFECT_SIZE="1.2844566750545352" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="46.75114885523325" ID="CMP-005.01.01" LOG_CI_END="0.32559859647629885" LOG_CI_START="-0.10815967643321997" LOG_EFFECT_SIZE="0.10871946002153945" MODIFIED="2013-06-26 12:31:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15289954835577946" P_Z="0.3258479775873935" STUDIES="4" TAU2="0.0" TOTAL_1="90" TOTAL_2="101" WEIGHT="100.0" Z="0.9825114095532606">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="4.147929110190382" CI_START="0.870313813013624" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.6178313255096214" LOG_CI_START="-0.06032412360396347" LOG_EFFECT_SIZE="0.2787536009528289" ORDER="21828" O_E="0.0" SE="0.3983518677329326" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="38" VAR="0.1586842105263158" WEIGHT="32.484604371013525"/>
<DICH_DATA CI_END="1.636155814860867" CI_START="0.0757287288133596" EFFECT_SIZE="0.352" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.21382466016171528" LOG_CI_START="-1.1207393332054532" LOG_EFFECT_SIZE="-0.453457336521869" MODIFIED="2011-03-02 13:34:54 +0000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.7839294959021854" STUDY_ID="STD-Khanna-1997" TOTAL_1="25" TOTAL_2="22" VAR="0.6145454545454545" WEIGHT="27.214495683162927"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21829" O_E="0.0" SE="0.0" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.062585359052421" CI_START="0.6565157016876301" EFFECT_SIZE="1.41796875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.48608820200894126" LOG_CI_START="-0.18275488256041533" LOG_EFFECT_SIZE="0.15166665972426296" ORDER="21830" O_E="0.0" SE="0.39288173870270504" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.1543560606060606" WEIGHT="40.30089994582355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9335643244860619" CI_END="2.2068544085318096" CI_START="0.6049160495948444" DF="3" EFFECT_SIZE="1.1554054054054053" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.34377368266011243" LOG_CI_START="-0.21830489266571962" LOG_EFFECT_SIZE="0.0627343949971964" MODIFIED="2013-06-26 12:31:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5863097869684128" P_Z="0.6617424141044704" STUDIES="4" TAU2="0.0" TOTAL_1="99" TOTAL_2="89" WEIGHT="100.0" Z="0.4375087761177786">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="21831" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Klieser-1987" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="14.864864864864865"/>
<DICH_DATA CI_END="3.543628888699885" CI_START="0.2821965932123575" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.549448233522865" LOG_CI_START="-0.549448233522865" LOG_EFFECT_SIZE="0.0" ORDER="21832" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Liang-1987" TOTAL_1="24" TOTAL_2="24" VAR="0.41666666666666663" WEIGHT="29.72972972972973"/>
<DICH_DATA CI_END="5.090352047081096" CI_START="0.02762579065246323" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.706747819039624" LOG_CI_START="-1.5586852835841862" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="21834" O_E="0.0" SE="1.3307266185559425" STUDY_ID="STD-Palao-1994" TOTAL_1="16" TOTAL_2="6" VAR="1.7708333333333333" WEIGHT="10.81081081081081"/>
<DICH_DATA CI_END="3.9840389614217724" CI_START="0.6972265594477218" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6003235769021996" LOG_CI_START="-0.156626077669487" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="21835" O_E="0.0" SE="0.4446359740566291" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.19770114942528733" WEIGHT="44.5945945945946"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.875490245266399" CI_END="1.5974443554883893" CI_START="0.6759308657933378" DF="3" EFFECT_SIZE="1.039115944571128" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" I2="38.46772633967031" ID="CMP-005.01.03" LOG_CI_END="0.2034257391151136" LOG_CI_START="-0.17009772142503568" LOG_EFFECT_SIZE="0.016664008845038967" MODIFIED="2013-06-26 12:32:01 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.18114484418076227" P_Z="0.8611740698081379" STUDIES="5" TAU2="0.0" TOTAL_1="150" TOTAL_2="162" WEIGHT="100.0" Z="0.17487981679706377">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="4.118379477235624" CI_START="0.811890571976171" EFFECT_SIZE="1.8285714285714285" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6147263610475422" LOG_CI_START="-0.0905025017803191" LOG_EFFECT_SIZE="0.2621119296336115" ORDER="21836" O_E="0.0" SE="0.4142549249642578" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="32" VAR="0.17160714285714285" WEIGHT="20.17189966672514"/>
<DICH_DATA CI_END="1.5886801182575485" CI_START="0.27975703814554403" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.2010364605423236" LOG_CI_START="-0.5532189786536861" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="21837" O_E="0.0" SE="0.44305337860837524" STUDY_ID="STD-Modestin-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.1962962962962963" WEIGHT="31.122359485804495"/>
<DICH_DATA CI_END="3.2348614411700365" CI_START="0.6308821455401988" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5098556832662342" LOG_CI_START="-0.20005176329474786" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="21838" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="22.995965620066656"/>
<DICH_DATA CI_END="1.6141516523016624" CI_START="0.16895317673146942" EFFECT_SIZE="0.5222222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.20794433501044488" LOG_CI_START="-0.7722336380176595" LOG_EFFECT_SIZE="-0.2821446515036074" ORDER="21839" O_E="0.0" SE="0.5757613933159265" STUDY_ID="STD-Volavka-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.331501182033097" WEIGHT="25.709775227403714"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21840" O_E="0.0" SE="0.0" STUDY_ID="STD-Winter-1984" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.470366218394342" CI_END="1.0694596954733018" CI_START="0.7926437027091667" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9207065183423955" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="134" I2="0.0" I2_Q="0.9943171075415878" ID="CMP-005.02" LOG_CI_END="0.02916442204137361" LOG_CI_START="-0.10092198635182253" LOG_EFFECT_SIZE="-0.03587878215522446" METHOD="MH" MODIFIED="2013-06-26 12:33:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8383543384979526" P_Q="0.3642034293557157" P_Z="0.2796327323274803" Q="2.0200860612945144" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="218" TOTAL_2="224" WEIGHT="300.0" Z="1.0811447821796627">
<NAME>Global state: 1. No clinically significant response in global state (2-10 weeks)</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.09939563477349792" CI_END="1.3323988209586086" CI_START="0.8389333140498486" DF="1" EFFECT_SIZE="1.0572576594676042" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.12463423971157632" LOG_CI_START="-0.07627255942302126" LOG_EFFECT_SIZE="0.02418084014427755" MODIFIED="2013-06-26 12:33:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7525561297482695" P_Z="0.6370719552336185" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="41" WEIGHT="99.99999999999999" Z="0.4717966340895509">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="1.4483114741184893" CI_START="0.6904592125866069" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.16086197135292193" LOG_CI_START="-0.16086197135292193" LOG_EFFECT_SIZE="0.0" ORDER="21841" O_E="0.0" SE="0.18898223650461357" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.0357142857142857" WEIGHT="22.85283776996484"/>
<DICH_DATA CI_END="1.4184443572811953" CI_START="0.8135292138377493" EFFECT_SIZE="1.07421875" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.15181230396711443" LOG_CI_START="-0.08962684693028826" LOG_EFFECT_SIZE="0.03109272851841309" ORDER="21842" O_E="0.0" SE="0.1418225523802063" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.02011363636363636" WEIGHT="77.14716223003515"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.017045818911969636" CI_END="1.167077778097063" CI_START="0.4819730188995325" DF="1" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.06709979989522542" LOG_CI_START="-0.3169772731118253" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-06-26 12:33:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8961236789267778" P_Z="0.20226081639452886" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="53" WEIGHT="100.0" Z="1.2751368995238548">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="2.621308391127807" CI_START="0.24415288264676202" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4185181177365015" LOG_CI_START="-0.6123381437526143" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="21843" O_E="0.0" SE="0.6055300708194983" STUDY_ID="STD-Liang-1987" TOTAL_1="24" TOTAL_2="24" VAR="0.36666666666666664" WEIGHT="20.833333333333336"/>
<DICH_DATA CI_END="1.167267932775232" CI_START="0.46513424454125724" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.06717055473435225" LOG_CI_START="-0.3324216852835342" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="21845" O_E="0.0" SE="0.23472245979999556" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.05509463313456053" WEIGHT="79.16666666666667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1367149482608736" CI_END="1.124261725567847" CI_START="0.7521950893649278" DF="3" EFFECT_SIZE="0.9195999940914934" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="79" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="0.050867425768872175" LOG_CI_START="-0.12366950615514574" LOG_EFFECT_SIZE="-0.036401040193136794" MODIFIED="2013-06-26 12:33:39 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.7682191899105854" P_Z="0.4136247114079815" STUDIES="4" TAU2="0.0" TOTAL_1="125" TOTAL_2="130" WEIGHT="100.0" Z="0.8175315904991605">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.581825063159143" CI_START="0.48182111428650976" EFFECT_SIZE="0.873015873015873" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.1991584524198332" LOG_CI_START="-0.3171141723385089" LOG_EFFECT_SIZE="-0.05897785995933786" ORDER="21846" O_E="0.0" SE="0.3032610953737587" STUDY_ID="STD-Modestin-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.09196729196729198" WEIGHT="17.122852627069825"/>
<DICH_DATA CI_END="1.3966727946304096" CI_START="0.6426035708995508" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.14509467373708668" LOG_CI_START="-0.1920568654361325" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="21847" O_E="0.0" SE="0.19804448303738395" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.03922161726154466" WEIGHT="24.529165866556376"/>
<DICH_DATA CI_END="1.0922828107245137" CI_START="0.65656034771687" EFFECT_SIZE="0.8468468468468469" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="0.0383350992068138" LOG_CI_START="-0.1827253495807314" LOG_EFFECT_SIZE="-0.07219512518695877" ORDER="21848" O_E="0.0" SE="0.12985200188467366" STUDY_ID="STD-Volavka-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.01686154239345729" WEIGHT="46.728902938005"/>
<DICH_DATA CI_END="2.4010283283259546" CI_START="0.6221614059569859" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.3803972840732982" LOG_CI_START="-0.2060969326354978" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="21849" O_E="0.0" SE="0.3445096060879416" STUDY_ID="STD-Winter-1984" TOTAL_1="24" TOTAL_2="24" VAR="0.1186868686868687" WEIGHT="11.61907856836881"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2013-06-26 12:34:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 2. Mean change CGI</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.01" MODIFIED="2013-06-26 12:33:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<CONT_DATA CI_END="0.7981947200101783" CI_START="-0.19819472001017868" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.4" ORDER="21850" SD_1="1.04" SD_2="0.89" SE="0.2541856503180032" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.02" MODIFIED="2013-06-26 12:34:05 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<CONT_DATA CI_END="0.3981947200101784" CI_START="-0.5981947200101786" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.0" ORDER="21851" SD_1="1.04" SD_2="0.89" SE="0.2541856503180032" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.631171431704823" CI_END="1.5458331493575188" CI_START="0.9847055272797601" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2337708241098213" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="72" I2="42.070435750661446" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.18916261621631156" LOG_CI_START="-0.006693624322464465" LOG_EFFECT_SIZE="0.09123449594692354" METHOD="MH" MODIFIED="2013-06-26 12:34:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.12471120270794234" P_Q="0.48048936449200064" P_Z="0.06785091004297643" Q="1.4659007330113596" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="150" TOTAL_2="167" WEIGHT="300.0" Z="1.8259956967593611">
<NAME>Global state: 3a. Use of adjunctive medication for sedation</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.847790814793832" CI_END="1.8287486026454676" CI_START="1.0669648438892907" DF="2" EFFECT_SIZE="1.3968573539679634" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="40" I2="58.74409444614089" ID="CMP-005.04.01" LOG_CI_END="0.2621540072872458" LOG_CI_START="0.028150109812077415" LOG_EFFECT_SIZE="0.14515205854966168" MODIFIED="2013-06-26 12:34:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08857595199037704" P_Z="0.015035537087484518" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="79" WEIGHT="100.0" Z="2.4315219541963007">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="2.3960821550881573" CI_START="1.0743546375662272" EFFECT_SIZE="1.6044444444444443" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.3795017047397128" LOG_CI_START="0.031147662848878068" LOG_EFFECT_SIZE="0.20532468379429542" ORDER="21852" O_E="0.0" SE="0.20462488858699412" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="38" VAR="0.041871345029239754" WEIGHT="39.65590873040083"/>
<DICH_DATA CI_END="1.3510724380256207" CI_START="0.029606110578684966" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.13067863443390323" LOG_CI_START="-1.5286186431059408" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="21853" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.95" WEIGHT="13.87956805564029"/>
<DICH_DATA CI_END="2.28449563675264" CI_START="1.0888961026271675" EFFECT_SIZE="1.5772058823529411" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.35879033291653833" LOG_CI_START="0.036986443384512624" LOG_EFFECT_SIZE="0.19788838815052553" ORDER="21854" O_E="0.0" SE="0.18902919766605597" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.035732037570272865" WEIGHT="46.464523213958884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0329362925830625" CI_START="0.4918993298749137" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.3081237690890228" LOG_CI_START="-0.30812376908902284" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-26 12:34:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="2.0329362925830625" CI_START="0.4918993298749137" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3081237690890228" LOG_CI_START="-0.30812376908902284" LOG_EFFECT_SIZE="0.0" ORDER="21855" O_E="0.0" SE="0.36198685440029543" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.13103448275862067" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9086135409361911" CI_END="1.6905640703267921" CI_START="0.673434225122698" DF="1" EFFECT_SIZE="1.066997518610422" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-005.04.03" LOG_CI_END="0.22803163464754267" LOG_CI_START="-0.1717048157705885" LOG_EFFECT_SIZE="0.02816340943847711" MODIFIED="2013-06-26 12:34:46 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.34048268353106814" P_Z="0.7824111178832159" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="59" WEIGHT="100.00000000000001" Z="0.27617830760007595">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.5454169756938763" CI_START="0.5112687832585546" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.18904567846011988" LOG_CI_START="-0.2913507233548825" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="21856" O_E="0.0" SE="0.2821872244266732" STUDY_ID="STD-Modestin-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.07962962962962963" WEIGHT="66.99751861042185"/>
<DICH_DATA CI_END="3.2348614411700365" CI_START="0.6308821455401988" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5098556832662342" LOG_CI_START="-0.20005176329474786" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="21857" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="33.002481389578165"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:35:05 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 3b. Use of adjunctive medication for sedation (&lt; 2 weeks).</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:35:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="1.306891802786486" CI_START="0.4242524666722552" EFFECT_SIZE="0.7446153846153846" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.1162396339479087" LOG_CI_START="-0.3723756239447949" LOG_EFFECT_SIZE="-0.12806799499844312" MODIFIED="2011-03-02 13:52:47 +0000" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.2870150211707087" STUDY_ID="STD-Khanna-1997" TOTAL_1="25" TOTAL_2="22" VAR="0.08237762237762238" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:35:23 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Global state: 3c. Use of adjunctive medication for sedation (2-10 weeks).</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:35:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="2.6195449292633275" CI_START="0.032847096258296286" EFFECT_SIZE="0.29333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41822585167260906" LOG_CI_START="-1.4835030168115966" LOG_EFFECT_SIZE="-0.5326385825694938" MODIFIED="2011-03-02 13:47:47 +0000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Khanna-1997" TOTAL_1="25" TOTAL_2="22" VAR="1.2478787878787878" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:35:41 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour 1: No psychotic symptoms (2-10 weeks)</NAME>
<GROUP_LABEL_1>experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:35:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-05-09 11:30:14 +0100" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.0" STUDY_ID="STD-Khanna-1997" TOTAL_1="25" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:35:54 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 2. No clinically important change in psychotic symptoms</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-005.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:35:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="3.116794328810166" CI_START="0.7874900251700044" EFFECT_SIZE="1.5666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.49370814497499366" LOG_CI_START="-0.10375493854288359" LOG_EFFECT_SIZE="0.19497660321605503" ORDER="21859" O_E="0.0" SE="0.3509527727483623" STUDY_ID="STD-Volavka-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.1231678486997636" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9360756848051051" CI_END="1.3678875767302747" CI_START="0.8189030461621245" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0583795648970877" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.1360504052700486" LOG_CI_START="-0.08676751339133487" LOG_EFFECT_SIZE="0.02464144593935686" METHOD="MH" MODIFIED="2013-06-26 12:36:32 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8167144880907093" P_Q="0.9827138182133834" P_Z="0.6646478988129731" Q="0.03487467220272191" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="117" TOTAL_2="121" WEIGHT="300.0" Z="0.4335050507452787">
<NAME>Mental state/behaviour: 3. Clinically significant agitation (2-10 weeks)</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4540822716456245" CI_START="0.7963532467015918" DF="0" EFFECT_SIZE="1.076086956521739" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="0.16258897950162404" LOG_CI_START="-0.09889424499763483" LOG_EFFECT_SIZE="0.0318473672519946" MODIFIED="2013-06-26 12:36:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6330574556117093" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="0.4774278956966641">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="1.4540822716456243" CI_START="0.7963532467015919" EFFECT_SIZE="1.076086956521739" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.16258897950162396" LOG_CI_START="-0.09889424499763476" LOG_EFFECT_SIZE="0.0318473672519946" ORDER="21860" O_E="0.0" SE="0.15359654043370108" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.02359189723320157" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0329362925830625" CI_START="0.4918993298749137" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-005.09.02" LOG_CI_END="0.3081237690890228" LOG_CI_START="-0.30812376908902284" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-26 12:36:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="2.0329362925830625" CI_START="0.4918993298749137" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3081237690890228" LOG_CI_START="-0.30812376908902284" LOG_EFFECT_SIZE="0.0" ORDER="21861" O_E="0.0" SE="0.36198685440029543" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.13103448275862067" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9086135409361911" CI_END="1.6905640703267921" CI_START="0.673434225122698" DF="1" EFFECT_SIZE="1.066997518610422" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-005.09.03" LOG_CI_END="0.22803163464754267" LOG_CI_START="-0.1717048157705885" LOG_EFFECT_SIZE="0.02816340943847711" MODIFIED="2013-06-26 12:36:32 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.34048268353106814" P_Z="0.7824111178832159" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="59" WEIGHT="100.00000000000001" Z="0.27617830760007595">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.5454169756938763" CI_START="0.5112687832585546" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.18904567846011988" LOG_CI_START="-0.2913507233548825" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="21862" O_E="0.0" SE="0.2821872244266732" STUDY_ID="STD-Modestin-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.07962962962962963" WEIGHT="66.99751861042185"/>
<DICH_DATA CI_END="3.2348614411700365" CI_START="0.6308821455401988" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5098556832662342" LOG_CI_START="-0.20005176329474786" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="21863" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="33.002481389578165"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2013-06-26 12:37:04 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 4. Mean score - SADS mean score</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.10.01" MODIFIED="2013-06-26 12:36:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<CONT_DATA CI_END="0.21502714434025172" CI_START="-0.4150271443402517" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.6" ORDER="21864" SD_1="0.66" SD_2="0.56" SE="0.16073108833894173" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.10.02" MODIFIED="2013-06-26 12:37:04 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<CONT_DATA CI_END="0.3882385848647009" CI_START="-0.18823858486470096" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.7" ORDER="21865" SD_1="0.56" SD_2="0.56" SE="0.14706320480288929" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.825938082812108" CI_END="1.6948136564350933" CI_START="1.1139883557922303" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3740460976642477" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="69" I2="41.399995847133376" I2_Q="80.72728561890918" ID="CMP-005.11" LOG_CI_END="0.2291219547923155" LOG_CI_START="0.04688065130305103" LOG_EFFECT_SIZE="0.13800130304768324" METHOD="MH" MODIFIED="2013-06-26 12:37:28 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.145377652914092" P_Q="0.022734486738023363" P_Z="0.0029940750129998886" Q="5.1886827160222815" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="117" TOTAL_2="141" WEIGHT="200.0" Z="2.96834557934327">
<NAME>Adverse effects: 1. Clinically significant extrapyramidal side effects (2-10 weeks)</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4521966043209629" CI_END="2.233184842175107" CI_START="1.2883951477297224" DF="2" EFFECT_SIZE="1.6962383425220566" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="36" I2="0.0" ID="CMP-005.11.01" LOG_CI_END="0.34892467139850214" LOG_CI_START="0.11004908053901169" LOG_EFFECT_SIZE="0.22948687596875691" MODIFIED="2013-06-26 12:37:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4837930068446137" P_Z="1.6597680605795438E-4" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="79" WEIGHT="99.99999999999999" Z="3.7658599625437965">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="2.3960821550881573" CI_START="1.0743546375662272" EFFECT_SIZE="1.6044444444444443" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.3795017047397128" LOG_CI_START="0.031147662848878068" LOG_EFFECT_SIZE="0.20532468379429542" ORDER="21866" O_E="0.0" SE="0.20462488858699412" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="38" VAR="0.041871345029239754" WEIGHT="44.60915517123052"/>
<DICH_DATA CI_END="33.7768109506405" CI_START="0.7401527644671237" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5286186431059408" LOG_CI_START="-0.1306786344339033" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="21867" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.95" WEIGHT="3.1226408619861363"/>
<DICH_DATA CI_END="2.28449563675264" CI_START="1.0888961026271675" EFFECT_SIZE="1.5772058823529411" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.35879033291653833" LOG_CI_START="0.036986443384512624" LOG_EFFECT_SIZE="0.19788838815052553" ORDER="21868" O_E="0.0" SE="0.18902919766605597" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.035732037570272865" WEIGHT="52.26820396678333"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5869311252368483" CI_END="1.4321773989188142" CI_START="0.73976563640631" DF="1" EFFECT_SIZE="1.0293083235638922" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" I2="61.3441583254968" ID="CMP-005.11.02" LOG_CI_END="0.1559968158767181" LOG_CI_START="-0.13090584639955893" LOG_EFFECT_SIZE="0.012545484738579573" MODIFIED="2013-06-26 12:37:28 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.10774931079139127" P_Z="0.863903006022321" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="62" WEIGHT="100.0" Z="0.1714079476372013">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.8373595305333967" CI_START="0.8917144264761085" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.26419414642500094" LOG_CI_START="-0.04977420712926421" LOG_EFFECT_SIZE="0.10720996964786837" ORDER="21869" O_E="0.0" SE="0.18442656504619076" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="32" VAR="0.03401315789473683" WEIGHT="55.68581477139507"/>
<DICH_DATA CI_END="1.377062728665527" CI_START="0.3705016997497838" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.138953723911825" LOG_CI_START="-0.431209795268301" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="21870" O_E="0.0" SE="0.33491687352134436" STUDY_ID="STD-Modestin-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.11216931216931217" WEIGHT="44.31418522860492"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.04081632653061222" CI_END="0.7750581104505607" CI_START="-1.1587315798383155" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1918367346938774" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2013-06-26 12:37:50 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8398929760205399" P_Q="0.8398929760205399" P_Z="0.6973748469754923" Q="0.04081632653061222" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="200.0" Z="0.3888665792355094">
<NAME>Adverse effects: 2. Mean score/change in EPS on Simpson Angus scale</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2147838108648725" CI_START="-1.4147838108648723" DF="0" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" I2="0.0" ID="CMP-005.12.01" MODIFIED="2013-06-26 12:37:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8814974522341973" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.1490711984999858">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<CONT_DATA CI_END="1.2147838108648725" CI_START="-1.4147838108648723" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.7" ORDER="21871" SD_1="2.4" SD_2="2.7" SE="0.6708203932499369" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.12687531864837" CI_START="-1.7268753186483696" DF="0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.12.02" MODIFIED="2013-06-26 12:37:50 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.6802795483941668" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.4120816918460668">
<NAME>versus very high (&gt; 35 mg/day)</NAME>
<CONT_DATA CI_END="1.12687531864837" CI_START="-1.7268753186483696" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.9" ORDER="21872" SD_1="2.4" SD_2="3.1" SE="0.7280109889280518" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="15.512041689598757" CI_END="1.6121111383228892" CI_START="1.1692931516026022" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3729641341503533" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="82" I2="74.21358142247576" I2_Q="83.22810512319946" ID="CMP-005.13" LOG_CI_END="0.20739497859597913" LOG_CI_START="0.06792340608286486" LOG_EFFECT_SIZE="0.13765919233942198" METHOD="MH" MODIFIED="2013-06-26 12:38:18 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.003748966238866447" P_Q="0.014614551145678112" P_Z="1.092871272776322E-4" Q="5.962355520026742" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="117" TOTAL_2="141" WEIGHT="200.0" Z="3.868989992218948">
<NAME>Adverse effects: 3. Use of any antiparkinsonism drugs (2-10 weeks)</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4521966043209629" CI_END="2.233184842175107" CI_START="1.2883951477297224" DF="2" EFFECT_SIZE="1.6962383425220566" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="36" I2="0.0" ID="CMP-005.13.01" LOG_CI_END="0.34892467139850214" LOG_CI_START="0.11004908053901169" LOG_EFFECT_SIZE="0.22948687596875691" MODIFIED="2013-06-26 12:38:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4837930068446137" P_Z="1.6597680605795438E-4" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="79" WEIGHT="99.99999999999999" Z="3.7658599625437965">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="2.3960821550881573" CI_START="1.0743546375662272" EFFECT_SIZE="1.6044444444444443" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.3795017047397128" LOG_CI_START="0.031147662848878068" LOG_EFFECT_SIZE="0.20532468379429542" ORDER="21873" O_E="0.0" SE="0.20462488858699412" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="38" VAR="0.041871345029239754" WEIGHT="44.60915517123052"/>
<DICH_DATA CI_END="33.7768109506405" CI_START="0.7401527644671237" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5286186431059408" LOG_CI_START="-0.1306786344339033" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="21874" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="0.95" WEIGHT="3.1226408619861363"/>
<DICH_DATA CI_END="2.28449563675264" CI_START="1.0888961026271675" EFFECT_SIZE="1.5772058823529411" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.35879033291653833" LOG_CI_START="0.036986443384512624" LOG_EFFECT_SIZE="0.19788838815052553" ORDER="21875" O_E="0.0" SE="0.18902919766605597" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.035732037570272865" WEIGHT="52.26820396678333"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7390578562746626" CI_END="1.3474952929269912" CI_START="0.9441028513167041" DF="1" EFFECT_SIZE="1.127906976744186" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="46" I2="42.49760027293408" ID="CMP-005.13.02" LOG_CI_END="0.12952725678315172" LOG_CI_START="-0.024980690737797462" LOG_EFFECT_SIZE="0.052273283022677135" MODIFIED="2013-06-26 12:38:18 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.18725835363724974" P_Z="0.18477546505834266" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="62" WEIGHT="100.0" Z="1.3261939430555818">
<NAME>versus high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.8373595305333967" CI_START="0.8917144264761085" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.26419414642500094" LOG_CI_START="-0.04977420712926421" LOG_EFFECT_SIZE="0.10720996964786837" ORDER="21876" O_E="0.0" SE="0.18442656504619076" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="32" VAR="0.03401315789473683" WEIGHT="39.45182724252492"/>
<DICH_DATA CI_END="1.207352400827311" CI_START="0.8766644993637471" EFFECT_SIZE="1.02880658436214" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.08183405004525886" LOG_CI_START="-0.057166579897808045" LOG_EFFECT_SIZE="0.012333735073725415" ORDER="21877" O_E="0.0" SE="0.08164965809277265" STUDY_ID="STD-Modestin-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.006666666666666675" WEIGHT="60.54817275747508"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:38:33 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="27" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 4. Akathisia</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="14" I2="0.0" ID="CMP-005.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:38:33 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>versus very high dose (&gt; 35 mg/day)</NAME>
<DICH_DATA CI_END="1.377062728665527" CI_START="0.3705016997497838" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.138953723911825" LOG_CI_START="-0.431209795268301" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="21878" O_E="0.0" SE="0.33491687352134436" STUDY_ID="STD-Modestin-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.11216931216931217" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:38:50 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3. Specific adverse effects-blurred vision (&lt; 2 weeks)</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>

Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-005.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:38:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="8.697796648152433" CI_START="0.35613617164273265" EFFECT_SIZE="1.76" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.939409249774746" LOG_CI_START="-0.4483839141464465" LOG_EFFECT_SIZE="0.24551266781414982" MODIFIED="2011-03-02 13:58:29 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.815196574174263" STUDY_ID="STD-Khanna-1997" TOTAL_1="25" TOTAL_2="22" VAR="0.6645454545454546" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-06-26 12:55:21 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:39:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Death (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower doses</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:39:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21879" O_E="0.0" SE="0.0" STUDY_ID="STD-Neborsky-1981" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.791201094817779" CI_START="0.5135571363288323" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3953488372093024" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.5787768211063192" LOG_CI_START="-0.289411231498205" LOG_EFFECT_SIZE="0.14468279480405713" METHOD="MH" MODIFIED="2013-06-26 12:40:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5135934256811414" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="30" WEIGHT="100.0" Z="0.6532526361030763">
<NAME>Leaving the study early: 1. By between 3 and 14 days</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.791201094817779" CI_START="0.5135571363288323" DF="0" EFFECT_SIZE="1.3953488372093024" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.5787768211063192" LOG_CI_START="-0.289411231498205" LOG_EFFECT_SIZE="0.14468279480405713" MODIFIED="2013-06-26 12:40:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5135934256811414" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="30" WEIGHT="100.0" Z="0.6532526361030763">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="3.791201094817779" CI_START="0.5135571363288323" EFFECT_SIZE="1.3953488372093024" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.5787768211063192" LOG_CI_START="-0.289411231498205" LOG_EFFECT_SIZE="0.14468279480405713" ORDER="21880" O_E="0.0" SE="0.5099779597000688" STUDY_ID="STD-Donlon-1980" TOTAL_1="43" TOTAL_2="20" VAR="0.26007751937984497" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21881" O_E="0.0" SE="0.0" STUDY_ID="STD-Neborsky-1981" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.90899485471775" CI_END="1.6040716434809663" CI_START="0.7997871339628182" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1326587581485739" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="44" I2="21.427724292677574" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.20522376150026383" LOG_CI_START="-0.09702558656645759" LOG_EFFECT_SIZE="0.054099087466903124" METHOD="MH" MODIFIED="2013-06-26 12:40:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2592562008985829" P_Q="0.4805296569200964" P_Z="0.4829154819695626" Q="1.4657330255353396" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="239" TOTAL_2="233" WEIGHT="300.0" Z="0.7016211198457624">
<NAME>Leaving the study early: 2. By between 2 and 10 weeks</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6976466646610926" CI_END="3.23549658806112" CI_START="0.6236291955821522" DF="1" EFFECT_SIZE="1.4204753199268738" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="41.09492741826618" ID="CMP-006.03.01" LOG_CI_END="0.5099409461804765" LOG_CI_START="-0.20507356124550954" LOG_EFFECT_SIZE="0.15243369246748348" MODIFIED="2013-06-26 12:40:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1925961163559311" P_Z="0.4033304159857647" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.0" Z="0.8356880711197276">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="2.55259384999193" CI_START="0.42296226597492714" EFFECT_SIZE="1.0390625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.40698171854909004" LOG_CI_START="-0.3736983759106552" LOG_EFFECT_SIZE="0.016641671319217427" ORDER="21882" O_E="0.0" SE="0.4585753519144467" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="38" VAR="0.21029135338345864" WEIGHT="93.60146252285192"/>
<DICH_DATA CI_END="116.90609403338892" CI_START="0.4191398267570667" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0678371504782778" LOG_CI_START="-0.3776410704497643" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="21883" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="6.39853747714808"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.482217907416576" CI_END="3.889054182634387" CI_START="0.6709773978653307" DF="1" EFFECT_SIZE="1.6153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="32.53353673597529" ID="CMP-006.03.02" LOG_CI_END="0.5898439938173515" LOG_CI_START="-0.17329210896318653" LOG_EFFECT_SIZE="0.2082759424270825" MODIFIED="2013-06-26 12:40:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.22342817153012762" P_Z="0.2846953830362099" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="1.0698310419749941">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="3.050938240088444" CI_START="0.44612870009182937" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.48443341634110665" LOG_CI_START="-0.35053983707988023" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="21884" O_E="0.0" SE="0.4904674222437513" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.2405582922824302" WEIGHT="92.3076923076923"/>
<DICH_DATA CI_END="116.90609403338892" CI_START="0.4191398267570667" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0678371504782778" LOG_CI_START="-0.3776410704497643" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="21885" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="7.6923076923076925"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.8754902452664" CI_END="1.4794412425985362" CI_START="0.6259998957486494" DF="3" EFFECT_SIZE="0.962356515867657" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" I2="38.46772633967032" ID="CMP-006.03.03" LOG_CI_END="0.17009772142503574" LOG_CI_START="-0.20342573911511352" LOG_EFFECT_SIZE="-0.0166640088450389" MODIFIED="2013-06-26 12:40:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1811448441807625" P_Z="0.8611740698081385" STUDIES="5" TAU2="0.0" TOTAL_1="162" TOTAL_2="150" WEIGHT="100.0" Z="0.17487981679706302">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="1.2316930809603612" CI_START="0.2428139528004906" EFFECT_SIZE="0.546875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.09050250178031909" LOG_CI_START="-0.6147263610475422" LOG_EFFECT_SIZE="-0.2621119296336115" ORDER="21886" O_E="0.0" SE="0.4142549249642578" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="25" VAR="0.17160714285714285" WEIGHT="35.497250892254264"/>
<DICH_DATA CI_END="3.5745302660794844" CI_START="0.6294533358274741" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5532189786536861" LOG_CI_START="-0.20103646054232363" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="21887" O_E="0.0" SE="0.44305337860837524" STUDY_ID="STD-Modestin-1983" TOTAL_1="30" TOTAL_2="27" VAR="0.1962962962962963" WEIGHT="19.967203626893028"/>
<DICH_DATA CI_END="1.5850821061733178" CI_START="0.3091322513146974" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.20005176329474786" LOG_CI_START="-0.5098556832662342" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="21888" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="31.61473907591396"/>
<DICH_DATA CI_END="5.918799630440681" CI_START="0.6195204760185161" EFFECT_SIZE="1.9148936170212767" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7722336380176597" LOG_CI_START="-0.2079443350104448" LOG_EFFECT_SIZE="0.28214465150360746" ORDER="21889" O_E="0.0" SE="0.5757613933159265" STUDY_ID="STD-Volavka-1992" TOTAL_1="47" TOTAL_2="45" VAR="0.331501182033097" WEIGHT="12.92080640493875"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21890" O_E="0.0" SE="0.0" STUDY_ID="STD-Winter-1984" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6856659085451735" CI_START="0.04137190361525646" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.42905198632986186" LOG_CI_START="-1.3832944957691868" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2013-06-26 12:40:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.30208780121476186" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="1.031966552472931">
<NAME>Global state: 1. No clinically significant response (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6856659085451735" CI_START="0.04137190361525646" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.42905198632986186" LOG_CI_START="-1.3832944957691868" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-06-26 12:40:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.30208780121476186" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="1.031966552472931">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="2.685665908545172" CI_START="0.04137190361525649" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42905198632986163" LOG_CI_START="-1.3832944957691864" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="21891" O_E="0.0" SE="1.064581294844754" STUDY_ID="STD-Neborsky-1981" TOTAL_1="10" TOTAL_2="10" VAR="1.133333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0855996069358964" CI_END="1.2331105303272416" CI_START="0.8519544703445987" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0249653792891213" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="88" I2="0.0" I2_Q="38.9830977567662" ID="CMP-006.05" LOG_CI_END="0.09100200649011052" LOG_CI_START="-0.06958361392631672" LOG_EFFECT_SIZE="0.010709196281896908" METHOD="MH" MODIFIED="2013-06-26 12:41:29 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5436041972731083" P_Q="0.20047787571936115" P_Z="0.7937735086693517" Q="1.6388901488536163" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="159" TOTAL_2="154" WEIGHT="199.99999999999997" Z="0.26141368027172424">
<NAME>Global state: 2. No clinically significant response (2-10 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.247052947084855" CI_START="0.48509429613157845" DF="0" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.09588489304440326" LOG_CI_START="-0.31417383189453935" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2013-06-26 12:41:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2967820731805607" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.0433589931135785">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="1.247052947084855" CI_START="0.48509429613157845" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.09588489304440326" LOG_CI_START="-0.31417383189453935" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="21892" O_E="0.0" SE="0.2408705248525599" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.05801860974274767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1367149482608738" CI_END="1.3294423403432374" CI_START="0.8894725998920897" DF="3" EFFECT_SIZE="1.087429324081213" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="70" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="0.12366950615514587" LOG_CI_START="-0.05086742576887216" LOG_EFFECT_SIZE="0.036401040193136835" MODIFIED="2013-06-26 12:41:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7682191899105854" P_Z="0.41362471140798085" STUDIES="4" TAU2="0.0" TOTAL_1="130" TOTAL_2="125" WEIGHT="99.99999999999997" Z="0.8175315904991615">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="2.075459066340046" CI_START="0.6321811578853413" EFFECT_SIZE="1.1454545454545455" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3171141723385089" LOG_CI_START="-0.1991584524198331" LOG_EFFECT_SIZE="0.05897785995933788" ORDER="21893" O_E="0.0" SE="0.3032610953737587" STUDY_ID="STD-Modestin-1983" TOTAL_1="30" TOTAL_2="27" VAR="0.09196729196729198" WEIGHT="16.25546132099717"/>
<DICH_DATA CI_END="1.556169379202401" CI_START="0.7159873120207958" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.19205686543613248" LOG_CI_START="-0.1450946737370867" LOG_EFFECT_SIZE="0.0234810958495229" ORDER="21894" O_E="0.0" SE="0.19804448303738395" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.03922161726154466" WEIGHT="25.2698535080956"/>
<DICH_DATA CI_END="1.5230892384491552" CI_START="0.9155138121570344" EFFECT_SIZE="1.1808510638297873" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.18272534958073142" LOG_CI_START="-0.038335099206813786" LOG_EFFECT_SIZE="0.07219512518695881" ORDER="21895" O_E="0.0" SE="0.12985200188467366" STUDY_ID="STD-Volavka-1992" TOTAL_1="47" TOTAL_2="45" VAR="0.01686154239345729" WEIGHT="43.0319969159599"/>
<DICH_DATA CI_END="1.607299955325639" CI_START="0.4164882139050897" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2060969326354979" LOG_CI_START="-0.38039728407329815" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="21896" O_E="0.0" SE="0.3445096060879416" STUDY_ID="STD-Winter-1984" TOTAL_1="24" TOTAL_2="24" VAR="0.1186868686868687" WEIGHT="15.442688254947313"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.7547933716995856" CI_END="0.5997662317031249" CI_START="-0.07464983157588018" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2625582000636224" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2013-06-26 12:41:58 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3849628856626365" P_Q="0.3849628856626365" P_Z="0.12699128400231885" Q="0.7547933716995856" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="200.0" Z="1.5260746117711337">
<NAME>Global state: 3. Mean change CGI</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8580934652313996" CI_START="-0.058093465231399743" DF="0" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" MODIFIED="2013-06-26 12:41:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0870055102468112" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.7114096867109903">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<CONT_DATA CI_END="0.8580934652313996" CI_START="-0.058093465231399743" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.4" ORDER="21897" SD_1="0.89" SD_2="0.89" SE="0.23372545049030616" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5981947200101786" CI_START="-0.3981947200101784" DF="0" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.02" MODIFIED="2013-06-26 12:41:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.694014293985225" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.3934132390042216">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<CONT_DATA CI_END="0.5981947200101786" CI_START="-0.3981947200101784" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.1" ORDER="21898" SD_1="0.89" SD_2="1.04" SE="0.2541856503180032" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.3835585072251506" CI_END="1.2916995911901632" CI_START="0.5786083253833667" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8645161290322579" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="0.11116152212780521" LOG_CI_START="-0.237615321738773" LOG_EFFECT_SIZE="-0.06322689980548392" METHOD="MH" MODIFIED="2013-06-26 12:42:25 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.500684485249421" P_Q="0.5419996280467254" P_Z="0.47732491905616303" Q="0.37184675813651497" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="85" WEIGHT="200.0" Z="0.7106116627414438">
<NAME>Global state: 4. Use of adjunctive medication for sedation</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5850821061733178" CI_START="0.3091322513146974" DF="0" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="0.20005176329474786" LOG_CI_START="-0.5098556832662342" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2013-06-26 12:42:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.39236896880637184" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.8553291395307019">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="1.5850821061733178" CI_START="0.3091322513146974" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.20005176329474786" LOG_CI_START="-0.5098556832662342" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="21899" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9086135409361911" CI_END="1.48492601459007" CI_START="0.5915185455270539" DF="1" EFFECT_SIZE="0.9372093023255813" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-006.07.02" LOG_CI_END="0.17170481577058846" LOG_CI_START="-0.22803163464754264" LOG_EFFECT_SIZE="-0.02816340943847712" MODIFIED="2013-06-26 12:42:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34048268353106814" P_Z="0.7824111178832158" STUDIES="2" TAU2="0.0" TOTAL_1="59" TOTAL_2="56" WEIGHT="100.0" Z="0.27617830760007606">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="1.9559183598625622" CI_START="0.6470745538116083" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.2913507233548825" LOG_CI_START="-0.18904567846011985" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="21900" O_E="0.0" SE="0.2821872244266732" STUDY_ID="STD-Modestin-1983" TOTAL_1="30" TOTAL_2="27" VAR="0.07962962962962963" WEIGHT="55.81395348837209"/>
<DICH_DATA CI_END="1.5850821061733178" CI_START="0.3091322513146974" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.20005176329474786" LOG_CI_START="-0.5098556832662342" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="21901" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="44.18604651162791"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:42:44 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 1. No clinically significant response in psychotic symptoms (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:42:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher doses (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="2.685665908545172" CI_START="0.04137190361525649" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42905198632986163" LOG_CI_START="-1.3832944957691864" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="21902" O_E="0.0" SE="1.064581294844754" STUDY_ID="STD-Neborsky-1981" TOTAL_1="10" TOTAL_2="10" VAR="1.133333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:42:57 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="47" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 2. No clinically important change in psychotic symptoms</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="30" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:42:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="1.5230892384491552" CI_START="0.9155138121570344" EFFECT_SIZE="1.1808510638297873" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.18272534958073142" LOG_CI_START="-0.038335099206813786" LOG_EFFECT_SIZE="0.07219512518695881" ORDER="21903" O_E="0.0" SE="0.12985200188467366" STUDY_ID="STD-Volavka-1992" TOTAL_1="47" TOTAL_2="45" VAR="0.01686154239345729" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.10" MODIFIED="2013-06-26 12:43:13 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mental state/behaviour: 3. Mean score SADS mean score</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.10.01" MODIFIED="2013-06-26 12:43:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<CONT_DATA CI_END="0.18823858486470096" CI_START="-0.3882385848647009" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.6" ORDER="21904" SD_1="0.56" SD_2="0.56" SE="0.14706320480288929" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.3835585072251506" CI_END="1.2916995911901632" CI_START="0.5786083253833667" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8645161290322579" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-006.11" LOG_CI_END="0.11116152212780521" LOG_CI_START="-0.237615321738773" LOG_EFFECT_SIZE="-0.06322689980548392" METHOD="MH" MODIFIED="2013-06-26 12:43:30 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.500684485249421" P_Q="0.5419996280467254" P_Z="0.47732491905616303" Q="0.37184675813651497" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="85" WEIGHT="200.0" Z="0.7106116627414438">
<NAME>Mental state/behaviour: 4. Clinically significant agitation (2-10 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5850821061733178" CI_START="0.3091322513146974" DF="0" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-006.11.01" LOG_CI_END="0.20005176329474786" LOG_CI_START="-0.5098556832662342" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2013-06-26 12:43:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.39236896880637184" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.8553291395307019">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="1.5850821061733178" CI_START="0.3091322513146974" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.20005176329474786" LOG_CI_START="-0.5098556832662342" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="21905" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9086135409361911" CI_END="1.48492601459007" CI_START="0.5915185455270539" DF="1" EFFECT_SIZE="0.9372093023255813" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" ID="CMP-006.11.02" LOG_CI_END="0.17170481577058846" LOG_CI_START="-0.22803163464754264" LOG_EFFECT_SIZE="-0.02816340943847712" MODIFIED="2013-06-26 12:43:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34048268353106814" P_Z="0.7824111178832158" STUDIES="2" TAU2="0.0" TOTAL_1="59" TOTAL_2="56" WEIGHT="100.0" Z="0.27617830760007606">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="1.9559183598625622" CI_START="0.6470745538116083" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.2913507233548825" LOG_CI_START="-0.18904567846011985" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="21906" O_E="0.0" SE="0.2821872244266732" STUDY_ID="STD-Modestin-1983" TOTAL_1="30" TOTAL_2="27" VAR="0.07962962962962963" WEIGHT="55.81395348837209"/>
<DICH_DATA CI_END="1.5850821061733178" CI_START="0.3091322513146974" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.20005176329474786" LOG_CI_START="-0.5098556832662342" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="21907" O_E="0.0" SE="0.417003148208456" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" VAR="0.17389162561576355" WEIGHT="44.18604651162791"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-006.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:43:43 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 1. Acute dystonia (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="9" I2="0.0" ID="CMP-006.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:43:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="2.4623769041454526" CI_START="0.8503536788705023" EFFECT_SIZE="1.4470284237726099" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="9" LOG_CI_END="0.39135452904311147" LOG_CI_START="-0.07040040506853341" LOG_EFFECT_SIZE="0.16047706198728903" ORDER="21908" O_E="0.0" SE="0.2712371340209678" STUDY_ID="STD-Donlon-1980" TOTAL_1="43" TOTAL_2="20" VAR="0.07356958287190843" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.257345169592702" CI_END="1.4742906651101495" CI_START="0.8688381828068253" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1317773731628356" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" I2="52.05634468466962" I2_Q="45.58928542924678" ID="CMP-006.13" LOG_CI_END="0.16858311568632142" LOG_CI_START="-0.06106110140862911" LOG_EFFECT_SIZE="0.05376100713884618" METHOD="MH" MODIFIED="2013-06-26 12:44:16 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.09973955085551678" P_Q="0.17520058585031772" P_Z="0.3587878677171985" Q="1.837873308389739" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="102" TOTAL_2="98" WEIGHT="200.0" Z="0.91767725830581">
<NAME>Adverse effects: 2. Clinically significant extrapyramidal side effects (2-10 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5476645389846326" CI_END="2.2135184588808343" CI_START="0.9146916473022866" DF="1" EFFECT_SIZE="1.422914911541702" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="35.38651466059536" ID="CMP-006.13.01" LOG_CI_END="0.3450831479804021" LOG_CI_START="-0.03872528674756721" LOG_EFFECT_SIZE="0.1531789306164175" MODIFIED="2013-06-26 12:44:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2134810253614179" P_Z="0.11771115065394164" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="99.99999999999999" Z="1.564453305521166">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="1.9481758150798147" CI_START="0.8064942597690271" EFFECT_SIZE="1.2534722222222223" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2896281476521989" LOG_CI_START="-0.09339871935934473" LOG_EFFECT_SIZE="0.09811471414642711" ORDER="21909" O_E="0.0" SE="0.22499187769615098" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="38" VAR="0.05062134502923976" WEIGHT="97.05139005897219"/>
<DICH_DATA CI_END="116.90609403338892" CI_START="0.4191398267570667" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0678371504782778" LOG_CI_START="-0.3776410704497643" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="21910" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Stone-1995" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="2.9486099410278013"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5869311252368483" CI_END="1.3517794701276966" CI_START="0.698237523336791" DF="1" EFFECT_SIZE="0.9715261958997722" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" I2="61.3441583254968" ID="CMP-006.13.02" LOG_CI_END="0.1309058463995589" LOG_CI_START="-0.155996815876718" LOG_EFFECT_SIZE="-0.012545484738579547" MODIFIED="2013-06-26 12:44:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10774931079139127" P_Z="0.8639030060223212" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="100.0" Z="0.17140794763720094">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="2.6990429481844327" CI_START="0.7261833315095761" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.431209795268301" LOG_CI_START="-0.13895372391182503" LOG_EFFECT_SIZE="0.146128035678238" ORDER="27" O_E="0.0" SE="0.33491687352134436" STUDY_ID="STD-Modestin-1983" TOTAL_1="30" TOTAL_2="27" VAR="0.11216931216931217" WEIGHT="30.751708428246012"/>
<DICH_DATA CI_END="1.1214352603353253" CI_START="0.5442592935034842" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.04977420712926423" LOG_CI_START="-0.26419414642500094" LOG_EFFECT_SIZE="-0.10720996964786837" ORDER="21911" O_E="0.0" SE="0.18442656504619076" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="25" VAR="0.034013157894736835" WEIGHT="69.24829157175398"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.14" MODIFIED="2013-06-26 12:44:48 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3. Mean score/change in EPS Simpson Angus Scale</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.14.01" MODIFIED="2013-06-26 12:44:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<CONT_DATA CI_END="1.696209625615281" CI_START="-1.296209625615281" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.7" ORDER="21913" SD_1="3.1" SD_2="2.7" SE="0.7633862853691147" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.14.02" MODIFIED="2013-06-26 12:44:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<CONT_DATA CI_END="1.7268753186483696" CI_START="-1.12687531864837" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.6" ORDER="21914" SD_1="3.1" SD_2="2.4" SE="0.7280109889280518" STUDY_ID="STD-Rifkin-1991" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.722067008810277" CI_END="1.1734944299488528" CI_START="0.8197147561102576" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.980780658680762" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="62" I2="26.526422989339558" I2_Q="50.91470476662418" ID="CMP-006.15" LOG_CI_END="0.06948103253860098" LOG_CI_START="-0.08633724688290849" LOG_EFFECT_SIZE="-0.00842810717215379" METHOD="MH" MODIFIED="2013-06-26 12:45:07 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.256395868752781" P_Q="0.15348530991052056" P_Z="0.8320865175971104" Q="2.037270011814138" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="94" TOTAL_2="90" WEIGHT="200.0" Z="0.21202629853946217">
<NAME>Adverse effects: 4. Use of any antiparkinsonism drugs (2-10 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9481758150798147" CI_START="0.8064942597690271" DF="0" EFFECT_SIZE="1.2534722222222223" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" I2="0.0" ID="CMP-006.15.01" LOG_CI_END="0.2896281476521989" LOG_CI_START="-0.09339871935934473" LOG_EFFECT_SIZE="0.09811471414642711" MODIFIED="2013-06-26 12:44:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3153237160858601" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="38" WEIGHT="100.0" Z="1.0041139285127176">
<NAME>versus standard lower dose (&gt; 3-7.5 mg/day)</NAME>
<DICH_DATA CI_END="1.9481758150798147" CI_START="0.8064942597690271" EFFECT_SIZE="1.2534722222222223" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2896281476521989" LOG_CI_START="-0.09339871935934473" LOG_EFFECT_SIZE="0.09811471414642711" ORDER="21915" O_E="0.0" SE="0.22499187769615098" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="38" VAR="0.05062134502923976" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7390578562746644" CI_END="1.0592066305120655" CI_START="0.7421176201868789" DF="1" EFFECT_SIZE="0.8865979381443297" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="44" I2="42.497600272934136" ID="CMP-006.15.02" LOG_CI_END="0.024980690737797365" LOG_CI_START="-0.12952725678315175" LOG_EFFECT_SIZE="-0.052273283022677204" MODIFIED="2013-06-26 12:45:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.18725835363724952" P_Z="0.18477546505834205" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="52" WEIGHT="100.0" Z="1.3261939430555836">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="1.1214352603353253" CI_START="0.5442592935034842" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.04977420712926423" LOG_CI_START="-0.26419414642500094" LOG_EFFECT_SIZE="-0.10720996964786837" ORDER="21916" O_E="0.0" SE="0.18442656504619076" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="25" VAR="0.034013157894736835" WEIGHT="44.77172312223858"/>
<DICH_DATA CI_END="1.1406872306632303" CI_START="0.8282585923668786" EFFECT_SIZE="0.972" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.05716657989780802" LOG_CI_START="-0.08183405004525883" LOG_EFFECT_SIZE="-0.012333735073725434" ORDER="21917" O_E="0.0" SE="0.08164965809277265" STUDY_ID="STD-Modestin-1983" TOTAL_1="30" TOTAL_2="27" VAR="0.006666666666666675" WEIGHT="55.22827687776141"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-006.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:45:19 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 5. Akathisia</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-006.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:45:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>versus high dose (&gt; 15-35 mg/day)</NAME>
<DICH_DATA CI_END="2.6990429481844327" CI_START="0.7261833315095761" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.431209795268301" LOG_CI_START="-0.13895372391182503" LOG_EFFECT_SIZE="0.146128035678238" ORDER="21918" O_E="0.0" SE="0.33491687352134436" STUDY_ID="STD-Modestin-1983" TOTAL_1="30" TOTAL_2="27" VAR="0.11216931216931217" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:45:31 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 6. Postural hypotension (3 days-2 weeks)</NAME>
<GROUP_LABEL_1>Very high dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours v. high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.17.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:45:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<DICH_DATA CI_END="33.68507705942393" CI_START="0.06086087623218232" EFFECT_SIZE="1.4318181818181819" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5274375452004771" LOG_CI_START="-1.2156617992656886" LOG_EFFECT_SIZE="0.1558878729673943" ORDER="21919" O_E="0.0" SE="1.6113101335001732" STUDY_ID="STD-Donlon-1980" TOTAL_1="43" TOTAL_2="20" VAR="2.596320346320346" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-06-26 12:46:15 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>DOSES: 6. HIGH AND VERY HIGH DOSES (&gt; 15 mg/day) versus OTHER DOSES</NAME>
<DICH_OUTCOME CHI2="1.2911293321392525" CI_END="6.022076930222651" CI_START="0.416002181556932" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5827814569536425" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.7797462991936426" LOG_CI_START="-0.38090439188370606" LOG_EFFECT_SIZE="0.19942095365496829" METHOD="MH" MODIFIED="2013-06-26 12:46:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5243663966687058" P_Q="0.5265499108737193" P_Z="0.5006196458107083" Q="1.2828184170066208" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.6735151065365994">
<NAME>versus standard higher dose (&gt; 7.5-15 mg/day)</NAME>
<GROUP_LABEL_1>High and V. h
igh dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High and V. High</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.33159693509127" CI_START="0.010916862780006007" DF="0" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.9207282515421643" LOG_CI_START="-1.9619021485436698" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2013-06-24 15:37:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.47899674792242397" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="41.72185430463576" Z="0.7079170953395216">
<NAME>Leaving the study early (day 1-2)</NAME>
<DICH_DATA CI_END="8.33159693509127" CI_START="0.010916862780006007" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9207282515421643" LOG_CI_START="-1.9619021485436698" LOG_EFFECT_SIZE="-0.5205869485007528" MODIFIED="2011-05-10 15:55:07 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="1.693271366261031" STUDY_ID="STD-Louza-1988" TOTAL_1="10" TOTAL_2="10" VAR="2.8671679197994986" WEIGHT="41.72185430463576"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.71163593866233" CI_START="0.36075702357932676" DF="0" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="1.2947226694164484" LOG_CI_START="-0.44278520487188616" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2012-09-11 10:02:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.33654590595165146" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="34.966887417218544" Z="0.9610124778695641">
<NAME>Leaving the study early (2-10 weeks)</NAME>
<DICH_DATA CI_END="19.71163593866233" CI_START="0.36075702357932676" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.2947226694164484" LOG_CI_START="-0.44278520487188616" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2011-05-10 15:58:25 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="1.0206207261596574" STUDY_ID="STD-Louza-1988" TOTAL_1="10" TOTAL_2="10" VAR="1.0416666666666665" WEIGHT="34.966887417218544"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.767271480010873" CI_START="0.17006933280396686" DF="0" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-007.01.03" LOG_CI_END="1.4737390282818574" LOG_CI_START="-0.7693739920591324" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2011-05-10 16:02:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5382557599921562" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="23.311258278145697" Z="0.6154527616071386">
<NAME>Adverse effects: clinically significant EPSE</NAME>
<DICH_DATA CI_END="29.767271480010887" CI_START="0.17006933280396677" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4737390282818577" LOG_CI_START="-0.7693739920591326" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2011-05-10 16:02:11 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.3176156917368247" STUDY_ID="STD-Louza-1988" TOTAL_1="10" TOTAL_2="10" VAR="1.7361111111111112" WEIGHT="23.311258278145697"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-06-26 12:54:47 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS</NAME>
<DICH_OUTCOME CHI2="0.9939632547213311" CI_END="1.1124993815793638" CI_START="0.4387171401031013" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6986218913353398" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.046299778235670816" LOG_CI_START="-0.35781539794795325" LOG_EFFECT_SIZE="-0.15575780985614118" METHOD="MH" MODIFIED="2013-06-26 12:46:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6083642203779722" P_Q="0.39960326927594636" P_Z="0.13082542288081928" Q="0.7095212163257092" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="109" TOTAL_2="89" WEIGHT="200.0" Z="1.5108549028614553">
<NAME>Leaving the study early (2-10 weeks)</NAME>
<GROUP_LABEL_1>Very Low levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours very low levels</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.27366541584500126" CI_END="1.058044543076181" CI_START="0.3543801084759193" DF="1" EFFECT_SIZE="0.612331560470054" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.024503951635824632" LOG_CI_START="-0.45053066325674124" LOG_EFFECT_SIZE="-0.21301335581045833" MODIFIED="2013-06-26 12:46:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6008835661877946" P_Z="0.07878829431537301" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="57" WEIGHT="100.0" Z="1.7577603506175477">
<NAME>versus medium plasma levels (&gt; 7.0-16.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.1490108338477512" CI_START="0.24108415872953576" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.060324123603963414" LOG_CI_START="-0.6178313255096214" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="21920" O_E="0.0" SE="0.3983518677329326" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="25" VAR="0.1586842105263158" WEIGHT="51.92457272593496"/>
<DICH_DATA CI_END="1.5231928153879855" CI_START="0.32652151132512597" EFFECT_SIZE="0.7052341597796143" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18275488256041533" LOG_CI_START="-0.48608820200894126" LOG_EFFECT_SIZE="-0.15166665972426294" ORDER="21921" O_E="0.0" SE="0.39288173870270504" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.1543560606060606" WEIGHT="48.07542727406504"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3642771009253085" CI_START="0.3917583676710501" DF="0" EFFECT_SIZE="0.9624060150375939" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="0.37369837591065524" LOG_CI_START="-0.40698171854909015" LOG_EFFECT_SIZE="-0.01664167131921745" MODIFIED="2013-06-26 12:46:53 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.9334057371954498" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="0.08356067141891557">
<NAME>versus high plasma levels (&gt; 16.5 ng/mL)</NAME>
<DICH_DATA CI_END="2.3642771009253085" CI_START="0.3917583676710501" EFFECT_SIZE="0.9624060150375939" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.37369837591065524" LOG_CI_START="-0.40698171854909015" LOG_EFFECT_SIZE="-0.01664167131921745" ORDER="21922" O_E="0.0" SE="0.4585753519144467" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="32" VAR="0.21029135338345864" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:47:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="32" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>Global state: clinically significant response in global state (2-10 weeks)</NAME>
<GROUP_LABEL_1>Very Low levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours very low levels</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:47:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>versus medium plasma levels (&gt; 7.0-16.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.8949615773475517" CI_START="0.3394990596651648" EFFECT_SIZE="0.8020833333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.27760040854413903" LOG_CI_START="-0.469161424278312" LOG_EFFECT_SIZE="-0.09578050786708653" MODIFIED="2011-03-02 11:00:31 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.4386515971305971" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.19241522366522365" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:47:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Mental state: clinically significant response in mental state, positive symptoms (unclear duration)</NAME>
<GROUP_LABEL_1>Very l
ow levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours very low levels</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:47:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>versus medium plasma levels (&gt; 7.0-16.5 ng/mL)</NAME>
<DICH_DATA CI_END="6.773280630483585" CI_START="0.5423680652736855" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8307990696630055" LOG_CI_START="-0.26570588972306947" LOG_EFFECT_SIZE="0.28254658996996806" MODIFIED="2013-01-29 13:51:15 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.6440924409304677" STUDY_ID="STD-Curtis-1995" TOTAL_1="24" TOTAL_2="23" VAR="0.41485507246376807" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8195487403602824" CI_END="0.8563638330094135" CI_START="0.5380487712522827" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6787971037766808" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="-0.06734168263882673" LOG_CI_START="-0.26917835607015983" LOG_EFFECT_SIZE="-0.16826001935449328" METHOD="MH" MODIFIED="2013-06-26 12:47:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6638002755433893" P_Q="0.3687053026221566" P_Z="0.0010837692166862556" Q="0.8080235087399544" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="109" TOTAL_2="89" WEIGHT="200.0" Z="3.2678261325488513">
<NAME>Adverse effects: clinically significant extrapyramidal side effects (2-10 weeks)</NAME>
<GROUP_LABEL_1>Very l
ow levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours very low levels</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.003778088537461902" CI_END="0.8257741136244202" CI_START="0.4791615090908183" DF="1" EFFECT_SIZE="0.6290303414402282" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="45" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="-0.08313873551590732" LOG_CI_START="-0.31951807597111254" LOG_EFFECT_SIZE="-0.20132840574350994" MODIFIED="2013-06-26 12:47:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9509880123063932" P_Z="8.41802009251292E-4" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="57" WEIGHT="100.0" Z="3.338670998592823">
<NAME>versus medium plasma levels (&gt; 7.0-16.5 ng/mL)</NAME>
<DICH_DATA CI_END="0.9307913467617497" CI_START="0.41734796024271037" EFFECT_SIZE="0.6232686980609419" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="-0.03114766284887804" LOG_CI_START="-0.37950170473971273" LOG_EFFECT_SIZE="-0.20532468379429542" ORDER="21924" O_E="0.0" SE="0.20462488858699412" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="25" VAR="0.04187134502923976" WEIGHT="46.47270854788878"/>
<DICH_DATA CI_END="0.9183612629224321" CI_START="0.43773338145722074" EFFECT_SIZE="0.634032634032634" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="-0.03698644338451269" LOG_CI_START="-0.35879033291653845" LOG_EFFECT_SIZE="-0.19788838815052556" ORDER="21925" O_E="0.0" SE="0.18902919766605597" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.035732037570272865" WEIGHT="53.52729145211123"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.239934429646643" CI_START="0.5133006950704966" DF="0" EFFECT_SIZE="0.7977839335180056" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="0.09339871935934481" LOG_CI_START="-0.28962814765219885" LOG_EFFECT_SIZE="-0.09811471414642704" MODIFIED="2013-06-26 12:47:51 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.3153237160858603" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="1.0041139285127172">
<NAME>versus high plasma levels (&gt; 16.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.239934429646643" CI_START="0.5133006950704966" EFFECT_SIZE="0.7977839335180056" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.09339871935934481" LOG_CI_START="-0.28962814765219885" LOG_EFFECT_SIZE="-0.09811471414642704" ORDER="21926" O_E="0.0" SE="0.22499187769615098" STUDY_ID="STD-Janicak-1997" TOTAL_1="38" TOTAL_2="32" VAR="0.05062134502923976" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2013-06-26 12:54:05 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS</NAME>
<DICH_OUTCOME CHI2="3.977767403915962" CI_END="2.065705893073398" CI_START="0.9050244619674878" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3673018556492273" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="31" I2="24.580808896804445" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.3150684884770897" LOG_CI_START="-0.04333968206118252" LOG_EFFECT_SIZE="0.13586440320795357" METHOD="MH" MODIFIED="2013-06-26 12:48:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2638749516350757" P_Q="0.35147574401354265" P_Z="0.1372908314925517" Q="0.8681223337306396" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="127" TOTAL_2="150" WEIGHT="200.0" Z="1.4859557284572666">
<NAME>Leaving the study early (2-10 weeks)</NAME>
<GROUP_LABEL_1>Medium levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours medium level</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2736654158450009" CI_END="2.8218288105974536" CI_START="0.945139792595668" DF="1" EFFECT_SIZE="1.6331021697335897" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="0.4505306632567412" LOG_CI_START="-0.02450395163582464" LOG_EFFECT_SIZE="0.21301335581045833" MODIFIED="2013-06-26 12:48:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6008835661877948" P_Z="0.07878829431537307" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="71" WEIGHT="100.00000000000001" Z="1.7577603506175474">
<NAME>versus very low plasma levels (&gt; 1.4-3.5 ng/mL)</NAME>
<DICH_DATA CI_END="4.147929110190382" CI_START="0.870313813013624" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.6178313255096214" LOG_CI_START="-0.06032412360396347" LOG_EFFECT_SIZE="0.2787536009528289" ORDER="21927" O_E="0.0" SE="0.3983518677329326" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="38" VAR="0.1586842105263158" WEIGHT="44.63059599011261"/>
<DICH_DATA CI_END="3.062585359052421" CI_START="0.6565157016876301" EFFECT_SIZE="1.41796875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.48608820200894126" LOG_CI_START="-0.18275488256041533" LOG_EFFECT_SIZE="0.15166665972426296" ORDER="21928" O_E="0.0" SE="0.39288173870270504" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.1543560606060606" WEIGHT="55.369404009887404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1838535313439897" CI_END="2.0687158427134484" CI_START="0.5812505419080823" DF="1" EFFECT_SIZE="1.0965592572364828" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="68.59151998811097" ID="CMP-009.01.02" LOG_CI_END="0.3157008403918023" LOG_CI_START="-0.23563662920292705" LOG_EFFECT_SIZE="0.04003210559443759" MODIFIED="2013-06-26 12:48:20 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.07436919390257857" P_Z="0.7759334809507779" STUDIES="2" TAU2="0.0" TOTAL_1="70" TOTAL_2="79" WEIGHT="100.0" Z="0.28462235751209386">
<NAME>versus high plasma levels (&gt; 16.5 ng/mL)</NAME>
<DICH_DATA CI_END="4.118379477235624" CI_START="0.811890571976171" EFFECT_SIZE="1.8285714285714285" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6147263610475422" LOG_CI_START="-0.0905025017803191" LOG_EFFECT_SIZE="0.2621119296336115" ORDER="21929" O_E="0.0" SE="0.4142549249642578" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="32" VAR="0.17160714285714285" WEIGHT="43.96504642271983"/>
<DICH_DATA CI_END="1.6141516523016624" CI_START="0.16895317673146942" EFFECT_SIZE="0.5222222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.20794433501044488" LOG_CI_START="-0.7722336380176595" LOG_EFFECT_SIZE="-0.2821446515036074" ORDER="21930" O_E="0.0" SE="0.5757613933159265" STUDY_ID="STD-Volavka-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.331501182033097" WEIGHT="56.03495357728018"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:48:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="77" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Global state: no clinically significant response in global state (2-10 weeks)</NAME>
<GROUP_LABEL_1>Medium levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours medium level</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:48:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>versus very low plasma levels (&gt; 1.4-3.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.8949615773475517" CI_START="0.3394990596651648" EFFECT_SIZE="0.8020833333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.27760040854413903" LOG_CI_START="-0.469161424278312" LOG_EFFECT_SIZE="-0.09578050786708653" ORDER="21931" O_E="0.0" SE="0.4386515971305971" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.19241522366522365" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-009.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:48:42 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>versus high plasma levels (16.5 ng/mL)</NAME>
<DICH_DATA CI_END="3.116794328810166" CI_START="0.7874900251700044" EFFECT_SIZE="1.5666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.49370814497499366" LOG_CI_START="-0.10375493854288359" LOG_EFFECT_SIZE="0.19497660321605503" ORDER="21932" O_E="0.0" SE="0.3509527727483623" STUDY_ID="STD-Volavka-1992" TOTAL_1="45" TOTAL_2="47" VAR="0.1231678486997636" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6503621059783988" CI_END="1.9636391317514728" CI_START="0.5066420303297544" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9974277500378271" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.29306167821210255" LOG_CI_START="-0.2952987845748439" LOG_EFFECT_SIZE="-0.0011185531813707097" METHOD="MH" MODIFIED="2013-06-26 12:48:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.419983518997858" P_Q="1.0" P_Z="0.9940539674159876" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="56" TOTAL_2="56" WEIGHT="100.0" Z="0.007452315677007553">
<NAME>Mental state: clinically significant response in mental state, positive symptoms (duration unclear)</NAME>
<GROUP_LABEL_1>Medium levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours medium level</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6503621059783988" CI_END="1.9636391317514728" CI_START="0.5066420303297544" DF="1" EFFECT_SIZE="0.9974277500378271" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="0.0" ID="CMP-009.03.01" LOG_CI_END="0.29306167821210255" LOG_CI_START="-0.2952987845748439" LOG_EFFECT_SIZE="-0.0011185531813707097" MODIFIED="2013-06-26 12:48:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.419983518997858" P_Z="0.9940539674159876" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="100.0" Z="0.007452315677007553">
<NAME>versus very low plasma levels (&gt; 1.4-3.5 ng/mL)</NAME>
<DICH_DATA CI_END="2.150286501610317" CI_START="0.22505463653682142" EFFECT_SIZE="0.6956521739130435" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3324963286499581" LOG_CI_START="-0.6477120353732944" LOG_EFFECT_SIZE="-0.1576078533616681" MODIFIED="2011-03-02 11:58:29 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.5757792451369143" STUDY_ID="STD-Curtis-1995" TOTAL_1="23" TOTAL_2="24" VAR="0.33152173913043476" WEIGHT="45.24133756998033"/>
<DICH_DATA CI_END="2.945516258531798" CI_START="0.5277151853388696" EFFECT_SIZE="1.2467532467532467" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.469161424278312" LOG_CI_START="-0.27760040854413903" LOG_EFFECT_SIZE="0.09578050786708653" MODIFIED="2011-05-10 15:21:26 +0100" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.4386515971305971" STUDY_ID="STD-Volavka-1995" TOTAL_1="33" TOTAL_2="32" VAR="0.19241522366522365" WEIGHT="54.75866243001967"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8898340697135758" CI_END="1.8419296046455718" CI_START="1.1915989183151279" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.481499687650414" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.26527302819623577" LOG_CI_START="0.07613010030837665" LOG_EFFECT_SIZE="0.1707015642523062" METHOD="MH" MODIFIED="2013-06-26 12:49:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6408774699835476" P_Q="0.34785141850413825" P_Z="4.0357261439082586E-4" Q="0.8812800816336097" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="83" TOTAL_2="104" WEIGHT="200.0" Z="3.537736480821873">
<NAME>Adverse effects: clinically significant extrapyramidal side effects (2-10 weeks)</NAME>
<GROUP_LABEL_1>Medium levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours medium level</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0037780885374619514" CI_END="2.086978985222421" CI_START="1.2109849213011554" DF="1" EFFECT_SIZE="1.589748433613551" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="0.3195180759711125" LOG_CI_START="0.08313873551590728" LOG_EFFECT_SIZE="0.20132840574350988" MODIFIED="2013-06-26 12:49:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9509880123063928" P_Z="8.418020092512945E-4" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="71" WEIGHT="100.0" Z="3.3386709985928222">
<NAME>versus very low levels (&gt; 1.4-3.5 ng/mL)</NAME>
<DICH_DATA CI_END="2.3960821550881573" CI_START="1.0743546375662272" EFFECT_SIZE="1.6044444444444443" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.3795017047397128" LOG_CI_START="0.031147662848878068" LOG_EFFECT_SIZE="0.20532468379429542" ORDER="21933" O_E="0.0" SE="0.20462488858699412" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="38" VAR="0.041871345029239754" WEIGHT="46.047038821195805"/>
<DICH_DATA CI_END="2.28449563675264" CI_START="1.0888961026271675" EFFECT_SIZE="1.5772058823529411" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.35879033291653833" LOG_CI_START="0.036986443384512624" LOG_EFFECT_SIZE="0.19788838815052553" ORDER="21934" O_E="0.0" SE="0.18902919766605597" STUDY_ID="STD-Volavka-1995" TOTAL_1="32" TOTAL_2="33" VAR="0.035732037570272865" WEIGHT="53.95296117880419"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.837359530533397" CI_START="0.8917144264761085" DF="0" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="0.0" ID="CMP-009.04.02" LOG_CI_END="0.264194146425001" LOG_CI_START="-0.04977420712926421" LOG_EFFECT_SIZE="0.10720996964786837" MODIFIED="2013-06-26 12:49:24 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.18072445566031992" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="33" WEIGHT="100.0" Z="1.3385277650738556">
<NAME>versus high plasma levels (&gt; 16.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.8373595305333967" CI_START="0.8917144264761085" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.26419414642500094" LOG_CI_START="-0.04977420712926421" LOG_EFFECT_SIZE="0.10720996964786837" ORDER="21935" O_E="0.0" SE="0.18442656504619076" STUDY_ID="STD-Janicak-1997" TOTAL_1="25" TOTAL_2="32" VAR="0.03401315789473683" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21936" O_E="0.0" SE="0.0" STUDY_ID="STD-Volavka-1992" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2013-06-26 12:53:19 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS</NAME>
<DICH_OUTCOME CHI2="3.3019484726302415" CI_END="1.6002500988022268" CI_START="0.5675789191625847" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9530310705679995" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="39.42970289882037" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.20418786268192618" LOG_CI_START="-0.24597374334384958" LOG_EFFECT_SIZE="-0.02089294033096171" METHOD="MH" MODIFIED="2013-06-26 12:52:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1918630856215615" P_Q="0.8161918418098858" P_Z="0.8556360566672927" Q="0.05403101369980709" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="111" TOTAL_2="108" WEIGHT="200.0" Z="0.1819320441001119">
<NAME>Leaving the study early (2-10 weeks)</NAME>
<GROUP_LABEL_1>High levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high levels</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.55259384999193" CI_START="0.42296226597492714" DF="0" EFFECT_SIZE="1.0390625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="0.40698171854909004" LOG_CI_START="-0.3736983759106552" LOG_EFFECT_SIZE="0.016641671319217427" MODIFIED="2013-06-26 12:52:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.93340573719545" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="38" WEIGHT="100.0" Z="0.08356067141891545">
<NAME>versus very low plasma levels (&gt; 1.40-3.5 ng/mL)</NAME>
<DICH_DATA CI_END="2.55259384999193" CI_START="0.42296226597492714" EFFECT_SIZE="1.0390625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.40698171854909004" LOG_CI_START="-0.3736983759106552" LOG_EFFECT_SIZE="0.016641671319217427" ORDER="21937" O_E="0.0" SE="0.4585753519144467" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="38" VAR="0.21029135338345864" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.183853531343991" CI_END="1.7204285035456155" CI_START="0.4833916671167084" DF="1" EFFECT_SIZE="0.9119434206594282" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="68.59151998811099" ID="CMP-010.01.02" LOG_CI_END="0.2356366292029271" LOG_CI_START="-0.31570084039180224" LOG_EFFECT_SIZE="-0.04003210559443757" MODIFIED="2013-06-26 12:52:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07436919390257868" P_Z="0.7759334809507781" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="70" WEIGHT="100.0" Z="0.28462235751209364">
<NAME>versus medium plasma levels (&gt; 7.0-16.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.2316930809603612" CI_START="0.2428139528004906" EFFECT_SIZE="0.546875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.09050250178031909" LOG_CI_START="-0.6147263610475422" LOG_EFFECT_SIZE="-0.2621119296336115" ORDER="21938" O_E="0.0" SE="0.4142549249642578" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="25" VAR="0.17160714285714285" WEIGHT="73.31407510708237"/>
<DICH_DATA CI_END="5.918799630440681" CI_START="0.6195204760185161" EFFECT_SIZE="1.9148936170212767" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7722336380176597" LOG_CI_START="-0.2079443350104448" LOG_EFFECT_SIZE="0.28214465150360746" ORDER="21939" O_E="0.0" SE="0.5757613933159265" STUDY_ID="STD-Volavka-1992" TOTAL_1="47" TOTAL_2="45" VAR="0.331501182033097" WEIGHT="26.685924892917622"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-26 12:52:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="47" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Global state: no clinically significant response in global state (2-10 weeks)</NAME>
<GROUP_LABEL_1>High levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high levels</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="30" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-26 12:52:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>versus medium plasma levels (&gt; 7.0-16.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.5230892384491552" CI_START="0.9155138121570344" EFFECT_SIZE="1.1808510638297873" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.18272534958073142" LOG_CI_START="-0.038335099206813786" LOG_EFFECT_SIZE="0.07219512518695881" ORDER="21940" O_E="0.0" SE="0.12985200188467366" STUDY_ID="STD-Volavka-1992" TOTAL_1="47" TOTAL_2="45" VAR="0.01686154239345729" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7347175949346685" CI_END="1.3090495564994526" CI_START="0.7440222981189017" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9868951612903226" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="37" I2="63.4331529569184" I2_Q="62.13536758559307" ID="CMP-010.03" LOG_CI_END="0.1169560878852629" LOG_CI_START="-0.12841404858734454" LOG_EFFECT_SIZE="-0.005728980351040813" METHOD="MH" MODIFIED="2013-06-26 12:53:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.09818893356894687" P_Q="0.10413888505764035" P_Z="0.92707645093525" Q="2.6409869480721935" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="64" WEIGHT="200.0" Z="0.09152373078156695">
<NAME>Adverse effects: clinically significant extrapyramidal side effects (2-10 weeks)</NAME>
<GROUP_LABEL_1>High levels</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high levels</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours comparator</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9481758150798147" CI_START="0.8064942597690271" DF="0" EFFECT_SIZE="1.2534722222222223" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="0.2896281476521989" LOG_CI_START="-0.09339871935934473" LOG_EFFECT_SIZE="0.09811471414642711" MODIFIED="2013-06-26 12:53:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3153237160858601" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="38" WEIGHT="100.0" Z="1.0041139285127176">
<NAME>versus very low plasma level (&gt; 1.40-3.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.9481758150798147" CI_START="0.8064942597690271" EFFECT_SIZE="1.2534722222222223" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.2896281476521989" LOG_CI_START="-0.09339871935934473" LOG_EFFECT_SIZE="0.09811471414642711" ORDER="21941" O_E="0.0" SE="0.22499187769615098" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="38" VAR="0.05062134502923976" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.153724298403835E-31" CI_END="1.121435260335325" CI_START="0.5442592935034841" DF="0" EFFECT_SIZE="0.7812499999999999" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="100.0" ID="CMP-010.03.02" LOG_CI_END="0.04977420712926414" LOG_CI_START="-0.264194146425001" LOG_EFFECT_SIZE="-0.10720996964786843" MODIFIED="2013-06-26 12:53:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.18072445566031964" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.0" Z="1.3385277650738563">
<NAME>versus medium plasma level (&gt; 7.0-16.5 ng/mL)</NAME>
<DICH_DATA CI_END="1.1214352603353253" CI_START="0.5442592935034842" EFFECT_SIZE="0.78125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.04977420712926423" LOG_CI_START="-0.26419414642500094" LOG_EFFECT_SIZE="-0.10720996964786837" ORDER="21942" O_E="0.0" SE="0.18442656504619076" STUDY_ID="STD-Janicak-1997" TOTAL_1="32" TOTAL_2="25" VAR="0.034013157894736835" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21943" O_E="0.0" SE="0.0" STUDY_ID="STD-Volavka-1992" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-06-24 21:20:50 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram (from results of 2010 search only).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAMICAYAAADi4GP2AABIVElEQVR42u3df+RX9//4/xczycyM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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-06-24 21:20:50 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram (2002 review).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAK8CAYAAADFzDkhAAA/4UlEQVR42u3df+RW9//48TeTJJNI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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASoAAANUCAIAAACL7/fgAAArR0lEQVR42u3dv24cydXG4QEMGA4Y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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-06-26 10:59:24 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAXKUlEQVR42u1da2wc13U+FHdeXL5mloxNOxAkkfAfxUAqQ5aomI6x
klMTdqs0aFADbRFLP2gIkV0U+WMX6CP9UQkG/MOJE1RCUbXNAzVqqJBSW6olr2Et1cJUK6CInRYG
KapyzaVDcoaUSO7OzJLb+5j3PrhcLsmleD4+ZubOvfecnf3mzpnZ++0BQCAqowlUPAiISjB24DFA
rADkCAI5gkCOIJAjCOQIAjmCQI4g7nfE8BCUgIGHIPBsFTlSxfC6HQfbPF5rEBiPIJAjCOQIAjmC
QI7UDfqGN0RU4kiSQFRGStVLbpaDD5exrcVX8PCh0g2TpWu3ZpEL1Y0jqVRqUvx6QznYT7wqNUr8
7mcrNDxUuqH7SiPbd1Qcd6q+1mjjSwBdiiir5GTrlMU0gB0X6UM3u0VqIQcyeUY8rKUliZ94miTK
ZE1vkeI6q3IuyU9S8me3inGbrHUMiqSKPSie88pYd0MqqTQSF1tGuCnN6yfZKREfBOJDkv3AiGO7
07W7p12jthXfNnh9dVN7TkPie8AHim6F2SMv8kVJIq8rKwqDadBO7kEyVB2P9JGiBd1qWSTrhYn3
DwMkxEn6HqiSKe8ky6HJfzGfy8x2sNoLLVYLeW93zpmXyfFOyJmX/J4ShiUl6MrP3m8nzb/XcYKV
iQm+VzhNe93/mTVzhCyXJ1oXvH7g7QzxwSY+pPgZn3RsL7t280eZbcW3Tfv6wJrZT971f1/odBsm
BOtCzPOBwvy8ZT9bmf8Dc5aY7HjXPv80wFEbyVAVR2g8Yl4jR1kB/Wtke1wbeIIc1THtBn1bxmCU
PqG9oSkHxjXlCdYiZmuj5ATNCzCgkJqjWuCjDlMA3eS9DABY+6ZyrMww+d5xVlfWQLHI8rZGLTr9
wD7N84FTgti2WS3HrrU3apv29TgoZM2+JZieD7dgn+z5QDGjTctsJTcAtLPY4WyWOLYXOVIOoXnx
yRSk3/pLOuTvXsofStFt+ieZbEG3RMstZH+k5pfzL/zzFLu6DFt0t1uTLkiheNnbSrmx4jDlhFeX
rKbtYJNhbsP3odg2wDOXqe2l7/i2w31BoCHx329I/w+dpQu7+/uv9KdoL4WOKe6PCwM/r8mrZQ4G
wMBjO9nNhHgtdBtJrwrXyWKgKHxZnPynu2QfiXbJMW7SYcS/8xwmhZe9msMsZhjmFcGr20QK/FP4
urc77EOR7dQItZ0J2Pb7Gg6En2RdL4Q87gb9H9hKe6H9LnsFmTNkOYLjRdXxyDEg48jy/4we8Yuk
PWywERTo+yhaXclqTXSfDefIKC/1Am03nNZ30aHfhqstXk3xpi2zMpWXSbvhyDDA1RHQFK+S0w8F
8WG/R63XorbFR4ltzbWd5VcPpy9xjy0R6jDmmX1w0wx5nIVHePS6NH2URkakl+cJix4VkQxVx6zK
AR1ajvcEdszYLPRMJcRs0d3ke5qwMEv2dYgn7tKaIm03l+xppu06hdf9pxjK660GKzvIy2byEq1r
PCVl7/rDA++HIn68hzJTfJDdASfEXMi28ACxnRUWSF+pTlG9x0dF3peRa71K4oxWNmSawtF8+PUN
ZnnMdKath1LsvQNiB6n6AM6SqCoeqQuSqaqrXntmseanqD0Zra6Pc0P9YTwSjEfqz5Fg7FcJhSNp
YVao2cy5l+br6XX8zWOAHNkojtwPwLmKgbmKBl6FKx4fBODcAARyBIEcQSBHEJsPjFnxvmaluB05
gqeOi6XgRgGvNQiMRxDIEQRyBIEcQWx7jqyjEEHffBe2GZpBqenm+dBsDiA5Tn9L4Y18uT1VoVLb
H/ApQ2rMqtzmB6VdcMqiuwpaLrCV25bDa3hOp7LWg2F/9IcV91cWQK0J/XyUOGisXG8VGqz8QRx3
6nut0a3P/to7pnZcbLXJQpY0gC5ZHPKUU3arwAVQspDmVVkdvUVUdE925ZTFRSqyyiiifJWf6Koo
aV1McuXs4/WTXIbZe12ArCjKXZ7MinnC7NmK5LkQtsV9YD55ttIC7UW43otkqCtH+kxN8I5pQrRi
CYBOpW0RYP6K1e8ppxIxW6RPLAsTqcOsKq+jSpbCBFVMduWUzVr/qgIc1y3lWYeHk7M5i0mu6L5d
bn2na0sE6Gi1WueJlVlLepV7Mstm3qpS20G3XtgWK5m4zEVg1NZzhC1t1pV7AKKJZKgrRywNLniC
B3MMbplUJjWdY8KmY55y6vlbMPYiUOXUAFdO8TqyJ6hisitWpnAh1SUFDKe5oSkHueSK7vNlWs61
4VMA4c/Tn3JZl/5Dbo+sPU81WNOX3HphWxR3tIHn2Qq1dYjOrUzvJe5/uoRkKIOa5irqD5J3bnhS
K9JHkfenOz9gpioJoCAiqPK1WWkb9F0vnPWEV0FhVkCmxeoL9JrSaQ/813REg3XdLNJghcRbvk+O
LdJLU9t0RIOFn9cUymuwqrvUCKlUSuxztoY9iRZBR+HS33r1ruuRO1BehxY3Rcu4fOrhHT+9V2Tu
ekim5Yx/pJWwMPnqfFDWRSuabo++C03hcNv1ybFFelFIL5FaiDVea2aoXkk47my93Ad7ZIBYXzf5
n5/e+7r3xuf6oDd4S+nUoWIuIVKW4+KrZWG0+BTO+cIsOqIwRV3sE3IdyWrSclDqJWWYwCvW2zXo
1gvbomiHTyS24tiS01qGnEGf4CfgdeXIi2Pk39ibzvl4yhTsGYDZxXvk/Zlr6/kbUvZaDwsaTNEK
DSS8zp2EmLsTKTM6JCq+is+/UiybMXxhFiUCC23EjwHaVPHw+0zW9Vtc1jXeJ+aIa7PfvnferXcn
IQVsUdw9+cwMW3Fstb4lUk3nx6jTq2s80gDQf/+iUM/+7N/+mYbxSOl4ZMvqa9T6BhCFRHDAQ44E
ObJlD4ZR3xizKRxc5/EKE4gi8RCUGqTwEKz5GRoCOYJAIEcQyBEExqzrfNOEhwA1WHUbXrf2OFzh
s27UYCEwHkEgRxDIEQRyBIEc2QToK2wj6sERmnVC7mZzS8NpopJlclGday1RmBULtThSJj9Vxcqh
tYcjdR5eVR6s+DnkQlXjSCo1qfDppEXqpZK5qE6UKu1oXcun9rUrt/qLt1ehwfrsBI47VV5rNGPZ
GzlUnpmKCpp4AZdS2XGpk5+FveLjkMwyAZSbzUqVk098lWamcrJWUSmV7GTN6lZEqrZy+uXSK6cd
RXcLa+PVc7JcEaRZRizfvqem4mu8D6q4cjJikQ7O+XmwIjKwMnY0EfNgVRuPBHJAcNnSW0rGfRpX
mLhLs2IJmVN82/qC/Ds7SfNa7Z/l2axggmqfdkqm/BOycTED8FeTRs7MzHYC/F7cii94/f5Yub0Y
aAfw6/9r2clWnHrzLZbOnwd/g2XEcu3HxEk+HxUSlybpXCDeB7X71pw5TbOf/aLjhCcDu2DzvFus
bQU7X2COo6o4QgKSr77mbY0z2dLbo5rzljhJqMxb2mPOefxLOqRrY1RWJYBChW5j7BQ/MAajF8ny
K2TrMU05uE9TSE9vTrvJteji4lhPoB1BXps+wFaceoLN8lOBn5WL25d5Vi4C8yvabQj28cdk7Yib
cYsjtw+of+Al7ipn55fIkXIIzmel8qTuu2ZAvUT+/NRW4axYAN4alTRBVCYVyZjF8k7Zy/2pktIr
CAqznHojTy3BPJvXrO+eVQ6Vt+/bDmTRqpgHq6QdKSDmNPDzmgoarKnoTcmOqI4KvIKC7m2FZVLF
wicWzBamA/dBIekVRZfbxqn3+GKm5bv8DqUpca2UfeCZtPw+nIxYwxENVvgllbGjF3DAqPI8UJuj
t7K9sCtUQLNiDbM1gSr1dkGvxGRSgUjmtSLhExvkp7OBUzXWmxkMtcvCI7lgPZph6+94YPTfoaxc
N12HyBotd/ogbHiNr4k3qarLkYF9DL1y+AWVtqOgvqbKeETMfRipcMOSzocKZmzxLF9jSr1m0Zph
EqqsP0gUZa1imGv7dsDaB9ldH4XatQwu3gjWi39LWJjjzy6OPxjMynVUesNZ+6ZEGU36WLxLSPcg
9HeKix/SjFt3DbZNiTDI/AugjJ0/xVkS1cQjVUO12Pc06A9NaMnU/XEc7LYJDeOR0vHI6jnSahdi
8Sl+o2wuVJv1qtHROhX8zi/kyH2h01tX4FxFzINV9fFBAM4NQCBHEMgRBHIEsfnAmBXva1aK25Ej
mzK81tb/Rn49KGqwEBiPIJAjCOQIAjmCQI5Eode0a7VN9OAu1ELUC7V87lv1nBG/oqOCKAU25X11
vcmhLxhX7Xm/3DFE6pJ+SznqlEV3tYqh72fFe9+15hRYPfrL7zq4+t4OhQYPPyPWIc9QivW7Cg2W
kcVxp87XmmTnkEjOWPukdA08yZU6JGlpVp7MSgo/5vobYlznAqk4qwV+fdoP+8koVKM1Ex9icqmr
0lA2LQ+xEjHOJxra8SHK6y5FcrJsdZ9kAirgGbG8ctZf55DTL8+DxeVgzC/WlUz7TNLOhqi8LCuK
J9MgLGIerHrHI8un52iGqp+2nQLYKZsSlTXpp2dzz7JykDM/5mOV2m9Nq0wQpc6aP9rFytz6zgmd
glNSeyeAJpxlWbO+lenXnpvoJ92cmrUkrveKiafpQDv/ntnPU2Hd+0crzi8x1juBcqa8ajrt9Ett
/chitri/rKuJy7vZyn79bJxc5zri1mNPA3RbSIY6c4TroXjGKXsUxqh4wc9cBXntKJ/7Jz8OCl9T
BDjG3we3voczt6ZMgBdvwRjNGjKjHesf146Rbn7oZbh6cYzJrWiWLS6lyk2D7uTW2hsspxgLzEy1
j3Jbtz0N1g1tgE/Pv8SlXeJfpI+S+OZT/PrvOsesYSFVkeSKLoSILKqU3CoglIKoXMpvDJ7cyu7O
57kay+62nzT9jFheeci3cnmweMHI00t5Jw/W7R7eD8as9Y9ZS+W1cm48dd7z9VCSKhvC9Z04cdjr
5juhXvq8xo7wqr0w5eTl7ShMX3QOtx4sL+FhxLdu0F9gK19vetfJg/UOufjo+KRofZ6P8IxTwgXo
jUiudkEfTzaVG2GyqGE7kM3KqT+s6bs4QcTebolnzToT6qXdBnWQrUl7mPBqaTrLsmzZkL+STTg+
KMHy4RG3MSdesW8LoLTzs1KQaRdONq0L+An4+nBkNkszTt35rmiGc03Becm8zQeqp0QqkBJa3UxX
4NVvXeih74v4ABi537nKsmbZ4aDgVKeQ+w+2NpOXaN33eZYt0tvckz2ONIwqwvxy0QtLSL/cViQP
1pzc9SdsJT4/QCVcTjatF1CnV894pI5P2eqA+mTEqlWDtR3ikfXhiLSRCZW1mTqkOypowblnyJH1
z4O1oTm365I0rSk8PXF5nX1ehi0EjNRKATVY9YtZEcgRBAI5gkCOIDBmXR+gBgs1WPfF8FoHHzEP
FgLjEQRyBIEcQSBHEMiRWqBvQIu1tUNEUfe5AXbHUkGe8WZ0RGeSKNnVTi6Rc6VbqCt83lumXTkN
Vo3fz3r/3vuuowarXcpMQqLs7v5Vp7o6VCYJVy5fUzsH0V13VBx3NuxaszymaXdzwQxXTnYqe9DL
TjVoky23nJ7UnbKXSeuc2EInunuZtBwtFanCs3LJThKuC4JQUzuwFVYfoEuWuAZLGEyDdhLzYG0Y
R4Tdqg0WwP4PrJn9rGTnnHmZvBex73nZqa5/Cb70b245RWbCq//S5EUyCqmSKVPp1NsZR0vlZM9S
pQlnes5JsbZ2kPi8hfs1f8WcJbs637XPPw1wFPU1G8aRO0tWXOkKiq/yAgyQNcnPTvWOBbbgllNk
Na++oe0zSZsxGKVCi33eJNPbLHuWcsvNymV/Wls7mNGmebKS3ABQXVbzYZYHay/q9DYsZqUXl91W
tmJ2Kr3HpBEluAorppDy6sMzl0vLtPysXMAlU7W08+Vhdvf3X+lPgf7lJ1MdU7XmwcKYtQZIOmhz
xHZThexUmtAZC8qzGFmd+iOgf8ClUwOlKK2DI6fbodfWjmqweB6n9uV2quXQFn9+hixHMA/Whl1r
cntsvYPECle9DFcCF18Fs1OJ+6a8cgdu/SNwUyL7FOj7iO8YDkqDc72Q4DlYY5/U1g4W4REupVma
OUrvvxRNe57w41HU12wYRwyj9cG8wTNccclVqkM8wbNTXSFvIstO9cX1rFfutnPqNwvfvE32JcSs
c3sqBJOR3zCl89xlcbC2dtAymL3NVt5v66FF7x0QO0jVB3CWxEbGI2vByg/YtBz74iP9oc8TtbQr
F0O9cnojNVhbKh5pNI6skFerIDU1z/GHuJo1X1O70oi/eQyQI1uDI40BnKuIebCqPj4IwLkBCOQI
AjmCQI4gNh8Ys+J9zUpxO3KkiuF1Ow62ebzWIDAeQSBHEMgRBHIEgRxpCKAcAjlSDpoisnxYf8an
uxYhGVogtiFHun7jPUt/rhvgV5XrpfDt37Ycyd0cAOU/f81FWKospGkeLZHl2OrgE2htmW0BZBRR
vgqQFkS5C8mwjThij5F/tyQu+FqaSB0GSMxa0quktPlzVkOduMwnOh7XLeVZwpY268o9JEMZ3I/z
0PjcVp4uKfm2RhdUPEML3maTVuli6GxAHh5vurQ3MJ01OldxWz6L3/C8nBsKlsPG1cvwt/5ryWSy
4G3Rxd/zO5/2l6lob7ZwuAevNdvpWiP+Jvn3jVBeg+GQ3gts97b44R0/dXJhKfNIhm3EETmbhXRu
OCjDetkGNe7XaIdPeJquZWGUfvItp7VfLCEZyqAZlPvuNS3e03b8XP8JeetjS7vHAcjfh53HbsYX
6RrF7l/90eiVZro13zw13jMOnU3a/14LSCtyTZGgbfthWQkcDJwDXgyMWe/3mBVRX+A8tNIjbYUt
5AgCUIN1/9/XIJAjCOQIAjmCQI4gkCMI5AgCgRxBIEfWCmOT2zdWB8gRBI4jCOQIYr2B80fW5Wp+
HwC/e7PaA1Qjx9Z64jVAB3itQWA8gkCOIDBmRTROAI8xa9mQTWULtfr4z2vDlqtq6seJam22/ThT
rdoDvsv3upxR5EjZw0f+2G/VFHGPrupsVd80dDtVi22/uQHVemBEXmlZoxiP1Pt+ufa7TkOtG7nr
ag3Hkbq/c0bNdDGiD2ZWb1ut2gO16heMHKk4NBj016g6rncvNWS52qbgtazRdlE/NXlQqg1yZOUr
vLqq81mtuam6Zttr9aB0G4xH6nipMdZ4pVj7ZU5de4RT3AY5Um861f55YL0+Saz3J5L4DK1y+Gi4
zxlW9XRitU2LHrDU2oG6GudLPR8p0QbzciJWJB5eaxArATmCQI4gkCMI5AgCOYJodMQi9/cIhAO1
BEfwSQkCSg0ZeK1BYDyCQI4gkCMI5AhiC937VrgLbtQ7HnR00zgSHV2Wt4r7+YZ1NJLepIDXGgTG
IwjkSFWX1DJ7i+oZhl+6Ec/7jZKWjMZz3nO0nP0GOaj10k6spCpt6FBts51XG/ugrv5aYxgO8z0m
G+zH2RM8Q3hNI8J8p5pfe/0GFNdS0HV3YTSO87xjCDnbQAd11eNIKUGpoYb3BLddhbEn7AmLkNeX
JKr/W2zZd6wBnKedhiw10EGt8VqjGs5PZLBTiwbCogFR3bhBUi1pSA0vN9F5I3JMi71piINaRy2n
Gvj+jZWPjGpsfHRSIcbbFOer0Gw1wkGN1fe0pWxfQWFqBL5EZYNJooYc2BrON4BfO2oeNFSIfJlJ
tTfHgWh3fY6qUTQ0GyvcGDeE88Zanjis50GNrfI1qOWHM38PJ0+4pmp4O/me9bvWRLoOWqZrjgON
5XxJpxrkoAa0nEbZzNDLDftRWfTzmoZ1NPp5jbrSQ4/Nd1ktc5ARm/WOQON+FowcaQw08lyB0hzZ
MsnT81vF0cIW5m9sq5EaHd1w4NwABHIEgRxBIEcQyBEEcgSx1RG898Uvl0CswBH8agkEXmsQyBEE
cgSBHEEgRxDIEQRyBIFAIErg/wGm/H5eciozlQAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-06-24 21:20:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-07-17 16:04:20 +0100" MODIFIED_BY="[Empty name]">Earlier search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-24 21:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Biological Abstracts on Ovid (1980 to March 1999) was searched using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>((level$ adj2 (blood or plasma or serum)) or (therap$ adj2 equivalen$) or (dos$ adj2 (high$ or low$ or threshold$ or maxim$ or minim$ or mid$ or medium or standard$ or respon$ or effect$ or rate$ or activ$ or depend$ or schem$ or find$ or calculat$) ) or ( drug$ adj2 (plasma or respon$ or blood or serum) ) ) and ((haloperi$ or R-1625 or haldol$ or alased$ or aloperidi$ or bioperido$ or buterid$ or ceree$ or dozic$ or duraperido$ or fortuna$ or serena$ or serenel$ or seviu$ or sigaperid$ or sylad$ or zafri$))<BR/>
<BR/>2. CINAHL on Ovid (1982 to April 1999) was searched using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>((level$ adj2 (blood or plasma or serum)) or (therap$ adj2 equivalen$) or (dos$ adj2 (high$ or low$ or threshold$ or maxim$ or minim$ or mid$ or medium or standard$ or respon$ or effect$ or rate$ or activ$ or depend$ or schem$ or find$ or calculat$) ) or ( drug$ adj2 (plasma or respon$ or blood or serum)) or exp Dosage-Calculation/ or exp Dose-Response-Relationship-Drug/) and (haloperi$ or R-1625 or haldol$ or alased$ or aloperidi$ or bioperido$ or buterid$ or ceree$ or dozic$ or duraperido$ or fortuna$ or serena$ or serenel$ or seviu$ or sigaperid$ or sylad$ or zafri$ or explode HALOPERIDOL/)</P>
<P>3. <I>The Cochrane Library</I> (1999, Issue 2) was searched using the Cochrane Schizophrenia Group's terms for schizophrenia combined with the phrase:</P>
<P>((level* near (blood or plasma or serum)) or (therap* near equivalen*) or (dos* near (high* or low* or threshold* or maxim* or minim* or mid* or medium or standard* or respon* or effect* or rate* or activ* or depend* or schem* or find* or calculat*) ) or ( drug* near (plasma or respon* or blood or serum)) or DOSE-RESPONSE-RELATIONSHIP-DRUG*:ME) and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or HALOPERIDOL*:ME))]</P>
<P>4. The Cochrane Schizophrenia Group's Register (December 1999) was searched using the phrase:<BR/>(dosage-effect or dose-activity or dose-dependence or dose-effect or dose-rate or dose-response or dosage-scheme or drug-response or effective-dose or dose-finding or dose-calculation or therapeutic-equivalency or blood-level or blood-drug or serum-level or serum-drug or plasma-level or plasma-drug or high-dose or low-dose or medium-dose or standard-dose or middle-dose or maximum-dose or minimum-dose or threshold-dose) and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or #42 = 14))</P>
<P>#42 being the intervention field and 14 the code for haloperidol.</P>
<P>5. EMBASE on Ovid (January 1980 to April 1999) was searched using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>((level$ adj2 (blood or plasma or serum)) or (therap$ adj2 equivalen$) or (dos$ adj2 (high$ or low$ or threshold$ or maxim$ or minim$ or mid$ or medium or standard$ or respon$ or effect$ or rate$ or activ$ or depend$ or schem$ or find$ or calculat$) ) or ( drug$ adj2 (plasma or resp$ or blood or serum) ) or ("dose-response"/ all subheadings or "blood-level"/ all subheadings or "dose-calculation"/ all subheadings or "drug-blood-level"/ all subheadings)) and (haloperi$ or R-1625 or haldol$ or alased$ or aloperidi$ or bioperido$ or buterid$ or ceree$ or dozic$ or duraperido$ or fortuna$ or serena$ or serenel$ or seviu$ or sigaperid$ or sylad$ or zafri$ or explode HALOPERIDOL /)</P>
<P>6. MEDLINE on Silver Platter (January 1966 to July 1999) was searched using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>((level* near2 (blood or plasma or serum)) or (therap* near2 equivalen*) or (dos* near2 (high* or low* or threshold* or maxim* or minim* or mid* or medium or standard* or respon* or effect* or rate* or activ* or depend* or schem* or find* or calculat*) ) or ( drug* near2 (plasma or resp* or blood or serum) or explode "dose-response relationship, drug"/ all subheadings) and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or explode "HALOPERIDOL" / all subheadings))</P>
<P>7. PsycLIT on Silverplatter (January 1887 to April 1999) was searched using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>((level* near2 (blood or plasma or serum)) or (therap* near2 equivalen*) or (dos* near2 (high* or low* or threshold* or maxim* or minim* or mid* or medium or standard* or respon* or effect* or rate* or activ* or depend* or schem* or find* or calculat*) ) or ( drug* near2 (plasma or resp* or blood or serum) ) ) and (haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri)</P>
<P>All citations identified in this way were inspected for additional relevant search terms, and if found, they were added to the above search strategies and the search was repeated.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-05-11 16:51:40 +0100" MODIFIED_BY="[Empty name]">Methods of 2002 version of this review</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Criteria for considering studies for this review</P>
<P>Types of studies: all relevant randomised controlled trials were included. Where a trial was described as 'double-blind' but it was implied that the study was randomised and the demographic details of each group were similar, it was included. Quasi-randomised studies, such as those allocated by using alternate days of the week, were excluded. The duration of studies included in this review needed to be a minimum of three days.<BR/>
<BR/>Types of participants: anyone with schizophrenia or similar serious, non-affective psychosis diagnosed by any criteria irrespective of gender, age, or race was included. If a trial included people with other mental illnesses, it was accepted for inclusion if greater than 50% of participants had serious functional psychotic illnesses such as schizophrenia, but studies were excluded if greater than 33% of people were experiencing an affective psychosis. People were considered be in the acute phase of schizophrenia if they were experiencing an exacerbation in their baseline level of symptoms, or if they had active symptoms and were currently hospitalised. This review excluded studies where greater than 50% of people were considered to be healthy, or were described as undergoing maintenance, or dose reduction treatment.<BR/>
<BR/>Types of interventions</P>
<P>Drug dosages<BR/>1. Haloperidol: dose greater than 0.25 mg/day to 1.5 mg/day (ultra low dose).<BR/>2. Haloperidol: dose greater than 1.5 mg/day to 3 mg/day (low dose).<BR/>3. Haloperidol: dose greater than 3 mg/day to 7.5 mg/day (standard-lower dose).<BR/>4. Haloperidol: dose greater than 7.5 mg/day to 15 mg/day (standard-higher dose).<BR/>5. Haloperidol: dose greater than 15 mg/day to 35 mg/day (high dose).<BR/>6. Haloperidol: dose greater than 35 mg/day (very high dose).<BR/>
<BR/>Plasma levels<BR/>1. Haloperidol: plasma level greater than 1.4-3.5 ng/mL (very low plasma levels).<BR/>2. Haloperidol: plasma level greater than 3.5-7 ng/mL (low plasma levels).<BR/>3. Haloperidol: plasma level greater than 7.0-16.5 ng/mL (medium plasma levels).<BR/>4. Haloperidol: plasma level greater than 16.5 ng/mL (high plasma levels).<BR/>
<BR/>Any means of administration except depot was included.<BR/>
<BR/>Types of outcome measures</P>
<P>Outcomes were divided into the following time periods: 3 days to less than 2 weeks, 2 weeks to 10 weeks *, greater than 10 weeks to 6 months, greater than 6 months. If data on more than one time point within these time periods was available, the duration closest to the middle of the time period was used. For the greater than 6 month period, the longest available time period was used.<BR/>
<BR/>* Primary outcomes of interest. Other outcomes not falling into the above categories were reported in this review if reported regularly within the trials, but were not of pre-stated interest. Where possible, outcomes were dichotomised into 'clinically significant change' or 'no clinically significant change' - as defined by each of the included studies.<BR/>
<BR/>Primary outcomes</P>
<P>1. Leaving the study early<BR/>
<BR/>2. Clinical response<BR/>2.1 No clinically significant response in global state<BR/>
<BR/>3. Extrapyramidal adverse effects<BR/>3.1 No clinically significant extrapyramidal adverse effects<BR/>
<BR/>4. Behaviour<BR/>4.1 Clinically significant agitation<BR/>
<BR/>Secondary outcomes</P>
<P>1. Mortality, any cause<BR/>
<BR/>2. Clinical response<BR/>2.1 Mean score/change in global state<BR/>2.2 No clinically significant response in psychotic symptoms<BR/>2.3 Mean score/change in psychotic symptoms<BR/>2.4 No clinically significant response in positive symptoms<BR/>2.5 Mean score/change in positive symptoms<BR/>2.6 No clinically significant response in negative symptoms<BR/>2.7 Mean score/change in negative symptoms<BR/>2.8 Relapse<BR/>
<BR/>3. Extrapyramidal adverse effects<BR/>3.1 Use of any antiparkinsonism drugs<BR/>3.2 Mean score/change in extrapyramidal adverse effects<BR/>3.3 Tardive dyskinesia<BR/>3.4 Acute dystonia<BR/>
<BR/>4. Other adverse effects, general and specific<BR/>
<BR/>5. Hospital and service utilisation outcomes<BR/>5.1 Hospital admission<BR/>5.2 Mean change in days in hospital<BR/>5.3 Improvement in hospital status (e.g. change from formal to informal admission status, use of seclusion, level of observation)<BR/>
<BR/>6. Economic outcomes<BR/>6.1 Mean change in total cost of medical and mental health care<BR/>6.2 Total indirect and direct costs<BR/>
<BR/>7. Quality of life/satisfaction with care for either recipients of care or carers<BR/>7.1. No significant change in quality of life/satisfaction<BR/>7.2 Mean score/change in quality of life/satisfaction<BR/>
<BR/>8. Behaviour<BR/>8.1 Use of adjunctive medication for sedation<BR/>8.2 Aggression to self or others<BR/>
<BR/>9. Cognitive response<BR/>9.1 No clinically important change<BR/>9.2 No change, general and specific<BR/>
<BR/>
<BR/>Data collection and analysis</P>
<P>1. Study selection<BR/>All abstracts were inspected by PW. PW used a random number generator programme to randomly select a sample of 10% of all abstracts. This sample was then re-inspected by CEA in order to allow selection to be reliable. The initial proportion agreement/disagreement is reported (see 'Results'). Any disagreement was resolved by discussion, or where there was still doubt, the full article was acquired for further inspection. Full articles of relevant reports were obtained and PW and CEA independently decided whether they met the review criteria. Again, the proportion agreement/disagreement is reported (see 'Results'). Any disagreement was resolved by discussion, and when this was not possible, further information was sought. These trials were added to the list of those awaiting assessment pending acquisition of further information. Studies which appeared to meet all inclusion criteria but which had no extractable outcomes were excluded pending further information from the study authors.<BR/>
<BR/>2. Blinding<BR/>JM, MR and KH removed journal name, author name, results, and conclusions from all abstracts of studies identified as above before submitting them to CEA or PW for inspection. After it was decided which full reports needed to be obtained, PW was unblinded but CEA remained blinded to the 10% of reports he was analysing as well as all reports in the included/excluded studies list (see above). CEA was unblinded after this list was completed.<BR/>
<BR/>3. Assessment of methodological quality<BR/>The methodological quality of the trials included in this review was assessed using the criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Clarke-2002" TYPE="REFERENCE">Clarke 2002</LINK>) and the Jadad Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The former is based on the evidence of a strong relationship between the potential for bias in the results and the allocation concealment (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and is defined as below:<BR/>
<BR/>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)<BR/>
<BR/>The Jadad Scale measures a wider range of factors that impact on the quality of a trial. The scale includes three items:<BR/>
<BR/>1. Was the study described as randomised? (scored 0-2)<BR/>2. Was the study described as double blind? (scored 0-2)<BR/>3. Was there a description of withdrawals and dropouts? (scored 0-1)<BR/>
<BR/>Each item receives one point if the answer is positive. The trial can be awarded an additional point if the answers to questions 1 or 2 indicate that it is clearly of high quality. In addition, a point can be deducted if either the randomisation or the blinding/masking procedures described were inadequate.<BR/>
<BR/>For the purpose of the analysis in this review, trials were included if they met the criteria A or B of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. Additionally, a cut-off of a total Jadad score of 2 points was used to validate the assessment made by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> criteria. However, the Jadad scores were not used to exclude trials in this review.<BR/>
<BR/>4. Data extraction<BR/>PW and CEA independently extracted data from selected trials. When disputes arose, resolution was attempted by discussion among the authors. If agreement could not be reached, the issue was forwarded to the editorial board of the Cochrane Schizophrenia Group for a final decision.<BR/>
<BR/>5. Data management<BR/>[For clarification of terms please see <I>The Cochrane Library</I> <A HREF="http://www.cochrane.org/glossary">glossary</A>]<BR/>
<BR/>5.1 How data were managed in general<BR/>Data were extracted and entered into RevMan for statistical analysis. With the exception of the outcome of 'leaving the study early', if greater than 50% of people allocated to either treatment were lost to follow-up at the end of the trial, data for that outcome were not reported in the review. Such data were considered to be too prone to bias.<BR/>
<BR/>5.2 Management of dichotomous and continuous data<BR/>5.2.1 Dichotomous (yes/no) data<BR/>Analysis of dichotomous data involved calculating a standard estimation of the risk ratio (RR) and the 95% confidence interval (CI).<BR/>
<BR/>5.2.1.1 Management of losses<BR/>Dichotomous data were analysed on an intention-to-treat basis. This means everyone allocated to treatment was counted irrespective of whether he or she completed follow-up. Where a person did not complete treatment, it was assumed they did not have a good outcome, with the exception of the outcome of death and with the exception of dropouts that were clearly attributable to clinical improvement. Data were not extracted if it was impossible to determine the intention-to-treat values, or if it was clear it was completer data only.<BR/>
<BR/>5.2.1.2 Management of deaths<BR/>When analysing loss of contacts in studies where deaths had occurred, the 'type' of death affected analysis. Deaths as a result of 'natural causes' were not counted as losses of contact and the number of deaths reduced the size of treatment or control groups. However, suicides or suspicious deaths were counted as loss to follow-up and their data were incorporated into the analysis.<BR/>
<BR/>5.2.2 Continuous (including scale) data<BR/>Analysis of continuous data involved calculation of weighted mean differences (WMD) and the 95% CI.<BR/>
<BR/>Continuous data needed to meet several criteria before entry into RevMan. The criteria were that if rating scales were used these should be valid and data should be, to a degree, normally distributed.<BR/>
<BR/>5.2.2.1 Valid scales<BR/>Validity of a scale was determined by ensuring (a) the psychometric properties of the instrument had been described in a peer-reviewed journal; (b) the instrument was either self reported, or completed by an independent rater or relative (not the therapist); and (c) the instrument measured a global assessment of an area of functioning. Outcome measures were selected if they provided global estimations of functioning. Highly specific outcomes such as 'sense of safety' were not included. Such outcomes are rarely reported in more than one study and it is difficult to assess their relevance to the effectiveness of the treatment.<BR/>
<BR/>5.2.2.2 Normally distributed data<BR/>RevMan analyses of continuous data are based on the assumption that the data are, at least to a reasonable degree, normally distributed. Mental health continuous data are often skewed, skewed data are non-parametric, and parametric tests used by RevMan must be applied with caution. To ensure data presented are not very skewed, standard deviations and means are needed. If none were reported or obtainable from the trialists, the data were not used in the review.<BR/>When standard deviations were presented and the continuous data started from a finite number (such as zero), if the standard deviation, when multiplied by two, was less than the mean (otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>), data were presented in 'Other data types' tables.<BR/>Data measuring a mean change (endpoint minus baseline) is even more problematic. In the absence of individual patient data it is impossible, even after applying the above test, to know if change data are skewed. After consulting the ALLSTAT electronic statistics mailing list, it was decided that change data could be entered into RevMan. In doing this it was assumed the analyses within RevMan could cope with the unknown degree of skew. However, when both change and endpoint data were available for the same outcome, only endpoint data were presented as it was considered that this type of data was less prone to bias and closer to being clinically interpretable.<BR/>
<BR/>5.2.2.3 Intention-to-treat data only<BR/>Data were not extracted if it was impossible to determine the intention-to-treat values or if it was clear that data were from 'completers' only.<BR/>
<BR/>6. Management of dose-response studies other than fixed-dose studies<BR/>Careful consideration was given to determining a methodology on how to combine studies that used alternate methods of dose allocation, for example plasma studies, neuroleptic threshold studies. The thresholds for dosage groups were translated into plasma thresholds using data from positron emission tomography (PET) research (<LINK REF="REF-Kapur-1996" TYPE="REFERENCE">Kapur 1996</LINK>). These indicated that a 2.1 mg oral dose is approximately equivalent to a 1 ng/mL plasma level. The thresholds for plasma study dose ranges in nanograms per millilitres are as outlined in 'types of interventions' (see above). This approach was affirmed using data from another study (<LINK REF="STD-Volavka-1995" TYPE="STUDY">Volavka 1995</LINK>), which reported both oral dose and plasma levels, and it was found there was 100% correspondence between oral dose range allocation and plasma dose allocation using this method.<BR/>Treatment arms from neuroleptic threshold and other flexible dose range studies were classified in the same dose ranges as fixed-dose studies. The criteria used were: if the mean dose plus or minus the 50% CI fell within the predefined fixed-dose range, or if at least 50% of people in a dose arm had received doses within the prespecified ranges, the flexible treatment arm was considered equivalent to the corresponding fixed-dose treatment arm. If the dose range from a treatment arm met none of the above criteria, then data related to that arm of the study was not extracted.<BR/>
<BR/>7. Management of co-interventions<BR/>Studies that involved randomisation to combined treatments of neuroleptic with additional known psychoactive treatments were excluded. Studies that allowed for use of other forms of intervention on an 'as needed' basis, or as part of routine clinical practice were not excluded.<BR/>
<BR/>8. Management of multiple time periods<BR/>If data on more than one time point within prespecified time periods were available, the duration closest to the middle of the time period was used. For the greater than six month period, the longest available time period was used.<BR/>
<BR/>9. Management of multiple doses<BR/>If data were available for more than one dose within the prespecified dosage ranges, the data from these two doses were pooled.<BR/>
<BR/>10. Clinically significant outcomes<BR/>Several outcomes were prefixed by the term 'clinically significant'. Wherever possible we utilised the definition of the authors of the study to define this concept. Where the authors were not specific, we determined that any circumstance that would have led to a significant change in clinical management (e.g. intolerable adverse effects, use of adjunctive medication) was considered clinically significant. For continuous outcomes, a 40% change was considered clinically significant.<BR/>
<BR/>11. Testing for heterogeneity<BR/>The review authors checked whether the differences between the results of trials were greater than could be expected by chance alone. They examined the graphical display of the results to achieve this and used the Chi<SUP>2</SUP> test of heterogeneity. The threshold value for heterogeneity was P value = 0.1. When data were not homogeneous, if the reason for this was not clear, heterogeneous studies were re-inspected to try to identify the cause. If the cause was apparent and justified, separate analyses of these studies were undertaken and presented. If the cause was not apparent and their inclusion did not substantially change the overall result, a random-effects model of analyses was used, and their effect on the overall analyses discussed. Finally, if the cause was not apparent and their inclusion did substantially change the overall result, then they were removed from the analysis and presented separately.<BR/>
<BR/>12. Assessment of publication bias<BR/>For the primary outcomes, data were entered into a funnel graph (trial effect versus trial size - <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) in an attempt to investigate the likelihood of overt publication bias.<BR/>
<BR/>13. Sensitivity analysis<BR/>PW and CEA selected trials that involved people whose illnesses were diagnosed using operational criteria. The review authors also selected trials that involved people whose illnesses were defined as first episode or treatment resistant at the data extraction stage of the review.<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-06-24 21:20:50 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-07-17 15:53:00 +0100" MODIFIED_BY="[Empty name]">Risk of bias</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-24 21:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment of methodological quality<BR/>The methodological quality of the trials included in this review was assessed using the criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Clarke-2002" TYPE="REFERENCE">Clarke 2002</LINK>), and the Jadad Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The former is based on the evidence of a strong relationship between the potential for bias in the results and the allocation concealment (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), and is defined as below:</P>
<P>A. low risk of bias (adequate allocation concealment);<BR/>B. moderate risk of bias (some doubt about the results);<BR/>C. high risk of bias (inadequate allocation concealment).</P>
<P>The Jadad Scale measures a wider range of factors that impact on the quality of a trial. The scale includes three items:</P>
<P>1. was the study described as randomised? (scored 0-2);<BR/>2. was the study described as double blind? (scored 0-2);<BR/>3. was there a description of withdrawals and dropouts? (scored 0-1).</P>
<P>Each item receives 1 point if the answer is positive. The trial can be awarded an additional point if the answers to questions 1 or 2 indicate that it is clearly of high quality. In addition, 1 point can be deducted if either the randomisation or the blinding/masking procedures described were inadequate.</P>
<P>For the purpose of the analysis in this review, trials were included if they met the criteria A or B of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. Additionally, a cut-off of a total Jadad score of 2 points was used to validate the assessment made by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> criteria. However, the Jadad scores were not used to exclude trials in this review.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-12-11 13:47:47 +0000" MODIFIED_BY="[Empty name]">Results of 2002 version of this review</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-26 10:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Excluded studies<BR/>A total of 548 papers were inspected in hardcopy. PW was blinded to all the authors, sources and results of electronic citations, however at the stage of examining hard copies he was unblinded. Of all 1249 citations identified in the search, 1005 were excluded because they were not controlled (41%), not randomised or quasi-randomised (9%), did not primarily involve people with schizophrenia (14%), did not include acutely ill people (4%), were not studies of antipsychotics (6%), involved only one dose of medication (26%), or were of too short duration (&lt; 1%). The remaining 245 citations met all of the above inclusion criteria, but a further 118 were excluded because they were comparing two doses of antipsychotic drugs, but not haloperidol. A further 95 studies were excluded as they were additional reports of the same clinical trial. This left 32 studies for the final stage of inclusion/exclusion. A 10% random sample of the original 1249 citations was submitted to CEA for independent assessment for inclusion/exclusion. CEA was blinded to author, source and results of the study. PW and CEA were in complete agreement on inclusion/exclusion for this 10% sample.</P>
<P>Sixteen studies were entered in the excluded studies section of the review. Several reported outcomes in such a way that made inclusion impossible. Either data did not have clear clinical implications, for example electroencephalogram recordings, or relevant clinical data were inadequately reported. Frequently the numbers of participants in each group were not specified, means or standard deviations were not given, or data were not reported from individual arms of cross-over studies.</P>
<P>2. Included studies<BR/>Sixteen studies were included in the review, dating between 1967 and 2000.</P>
<P>2.1 Methods<BR/>All studies were stated to be randomised and double blind (see Methodological quality of included studies). The longest study was 10 weeks (<LINK REF="STD-Liang-1987" TYPE="STUDY">Liang 1987</LINK>), the shortest was only six days (<LINK REF="STD-Neborsky-1981" TYPE="STUDY">Neborsky 1981</LINK>). Most were between three and six weeks.</P>
<P>2.2 Participants<BR/>The largest study involved 132 people (<LINK REF="STD-Volavka-1992" TYPE="STUDY">Volavka 1992</LINK>), the smallest only 20 people. Only two of the included trials did not report stringent criteria for the diagnosis of schizophrenia (<LINK REF="STD-Donlon-1980" TYPE="STUDY">Donlon 1980</LINK>; <LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK>). In the other studies, diagnoses were either established by structured interviews or clinical examination by a psychiatrist and the diagnostic criteria applied included RDC (Research Diagnostic Criteria), ICD and DSM.</P>
<P>Although sometimes demographic data were missing, participants tended to be acutely ill men or women in their 20s or 30s. People had often been recently admitted to hospital, although some studies included acutely ill people who had been in hospital for months or years. Most studies involved people who had been ill before and for some time.</P>
<P>2.3 Interventions<BR/>Doses of haloperidol varied from a low of 1 mg/day (<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK>) to a high of up to 100 mg/day (<LINK REF="STD-Donlon-1980" TYPE="STUDY">Donlon 1980</LINK>). Doses were commonly fixed (8/13), perhaps preceded by a titration up to the final dose, and were given orally (13/13). The most common comparison (5/13) was standard higher dose (&gt; 7.5 to 15 mg/day) versus high dose (&gt; 15 to 35 mg/day). Three out of 16 randomised trials were plasma studies.</P>
<P>2.4 Outcomes<BR/>Every included study reported on leaving the study early and most reported usable data on global state (11/16). Definitions of 'no clinically significant improvement' differed across studies. It was difficult to decide whether the results concerning clinical improvement were comparable. However, it seemed unlikely that those judging improvement would have applied such dramatically differing criteria as to make summation inappropriate, especially given that analysis was restricted to randomised comparisons only. Further, if convergence of effects occurs despite differing methods, this may enhance the applicability of findings.</P>
<P>Mental state was reported in a form that was useful for this review in only half the included studies, but some adverse effects were clearly reported in 10 of 16 studies.</P>
<P>All scale data that we were able to present were from the single study (<LINK REF="STD-Rifkin-1991" TYPE="STUDY">Rifkin 1991</LINK>).</P>
<P>2.4.1 Clinical Global Impression (CGI) (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. Generally, a seven-point scoring system is used with low scores indicating decreased severity or greater recovery, or both.</P>
<P>2.4.2 Schedule for Affective Disorders and Schizophrenia (SADS) (<LINK REF="REF-Endicott-1978" TYPE="REFERENCE">Endicott 1978</LINK>)<BR/>The scale makes use of collateral information and past history. It rates symptoms at their highest level of severity over the previous week. Used serially, it provides a detailed record of the individual's progress. Greater scores indicate more severe symptoms.</P>
<P>2.4.3 Simpson and Angus Scale (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>A standard physical examination that measures parkinsonism symptoms. This scale is comprised of a 10-item rating scale, each item rated on a five-point scale with zero meaning the complete absence of condition and four meaning the presence of condition in extreme. Adding the items and dividing by 10 obtains the total score.</P>
<P>3. Awaiting assessment<BR/>There are no studies currently awaiting assessment.</P>
<P>4. Ongoing<BR/>The review authors know of no ongoing studies.</P>
<SUBSECTION>
<HEADING LEVEL="3">Risk of bias in included studies</HEADING>
<P>1. Randomisation<BR/>All studies were described as 'randomised'. However, none reported adequate concealment of randomisation and, therefore, could not be designated 'category A' studies. All studies met criteria for unclear (category B) concealment of randomisation. Most studies simply reported randomisation and presented baseline data that were equivalent for the different comparator groups. Further information regarding concealment has yet to be obtained from study authors.</P>
<P>2. Blinding of assessment<BR/>All studies were reported as 'double-blind' but none tested this by asking rater or participants to guess the allocated treatment.</P>
<P>3. Description of people leaving early<BR/>For all studies, it was difficult to determine the number of people who dropped out because of poor reporting at each stage of the studies. Use of a flow-diagram would have been helpful. Three studies did not report detailed information on people who dropped out. It was nevertheless possible to perform intention-to-treat analyses by assuming people who left early had negative outcomes. This procedure could introduce a bias that would make the treatment arms similar if they have an equal number of dropouts, or exaggerate their divergence if they have a differential dropout rate.</P>
<P>Of the 15 included studies that reported continuous outcomes, only one reported no people leaving early, and the remaining 14 either reported completer analyses, did not specify whether they were completer or intention-to-treat analyses, or presented data that was highly skewed. Continuous data may subsequently be biased by excluding analysis of those who left the study early. Assuming these individuals were mostly not doing well or had significant adverse effects, and that they mostly dropped out from higher dose arms, if the completer data were included it would bias the results of high dose study arms towards improved efficacy and reduced adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effects of interventions</HEADING>
<P>After eliminating duplicate citations, 1249 publications were generated from all searches. Of these, 701 citations could be excluded by examining electronic abstracts, leaving 548 to be inspected in hardcopy. All the studies included in the review so far had outcomes assessed before 10 weeks, so no data could be presented for longer periods (greater than 10 weeks to six months, greater than six months). For several of the comparisons the same data from a specific study were re-presented several times. For example one study may have compared low dose and high dose haloperidol. Therefore, we considered it was appropriate to present these data in both comparison number 1, where low dose is the 'experimental intervention' and high the 'control' and comparison number 5, where the opposite applies.</P>
<P>1. DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg/day) versus OTHER DOSES</P>
<P>The review authors found one small study (n = 26) comparing low dose haloperidol with ultra low doses (&gt; 0.25 to 1.5 mg/day) (<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK>). No other studies were identified.</P>
<P>1.1 Leaving the study early<BR/>There was good compliance in this study with few leaving before completion and no clear difference in acceptability (n = 26, 1 RCT, RR 3.5, 95% CI 0.4 to 29).</P>
<P>1.2 Global state<BR/>More people in the ultra low dose group showed a significant response during the study than in the low dose group. This did not reach conventional levels of statistical significance (n = 26, 1 RCT, RR no clinically important response 0.53, 95% CI 0.3 to 1.1). Another measure of global state was 'use of sedative medication'. This too was used less frequently in the ultra low group, but again not to a statistically significant degree (n = 26, 1 RCT, RR 1.75, 95% CI 0.4 to 9).</P>
<P>1.3 Mental state/behaviour<BR/>
<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK> also reported on agitation. This was infrequent and there was no difference between groups (n = 26, 1 RCT, RR 1.75, 95% CI 0.4 to 9).</P>
<P>1.4 Adverse effects<BR/>Extrapyramidal adverse effects were less frequent for people allocated the ultra low doses, but not to a statistically significant degree (n = 26, 1 RCT, RR clinically significant extrapyramidal adverse effects/needing to use antiparkinsonism drugs 1.94, 95% CI 0.6 to 6.5)</P>
<P>2. DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg/day) versus OTHER DOSES</P>
<P>2.1 Leaving the study early<BR/>Two small studies found that standard lower dose was no more acceptable than standard higher dose (&gt; 7.5 to 15 mg/day) (n = 64, 2 RCTs, RR leaving the study early 0.12, 95% CI 0.01 to 2.1) (<LINK REF="STD-McEvoy-1991" TYPE="STUDY">McEvoy 1991</LINK>; <LINK REF="STD-Stone-1995" TYPE="STUDY">Stone 1995</LINK>). When the standard lower dose was compared with high dose (&gt; 15 to 35 mg/day) the small studies did not conclusively show that the lower of the two doses was more acceptable. This did not reach a statistically significant level (n = 144, 3 RCTs, RR 0.61, 95% CI 0.4 to 1.1). There also was no discernible difference in the numbers leaving the groups early when the standard lower dose was compared with very high dose (&gt; 35 mg/day) (n = 86, 2 RCTs, RR 0.7, 95% CI 0.3 to 1.6).</P>
<P>2.2 Global state<BR/>Approximately the same numbers of people allocated to standard lower dose showed no clinically important improvement in global state compared with standard higher dose (n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.8) and with high dose (n = 81, 2 RCTs, RR 0.95, 95% CI 0.8 to 1.2). One study reported on the need for additional sedative medication. This was evenly balanced between groups (n = 65, 1 RCT, RR 0.93, 95% CI 0.7 to 1.3).</P>
<P>2.3 Mental state/behaviour<BR/>One small study (n = 65) reported on agitation. There was no difference for those allocated standard lower dose compared with high dose (RR 0.93, 95% CI 0.7 to 1.3).</P>
<P>2.4 Adverse effects<BR/>Compared with standard higher dose, the standard lower dose did not reduce clinically significant extrapyramidal adverse effects (n = 64, 2 RCTs, RR 0.12, 95% CI 0.01 to 2.1). Compared with high dose, people allocated the standard lower dose had fewer adverse effects (n = 144, 3 RCTs, RR clinically significant extrapyramidal adverse effects/use of any antiparkinsonism drugs 0.59, 95% CI 0.5 to 0.8, NNT 3, 95% CI 2 to 6). However, when the same standard lower dose was compared with yet higher doses (&gt; 35 mg/day), this finding was not replicated (n = 86, 2 RCTs, RR clinically significant extrapyramidal adverse effects/use of any antiparkinsonism drugs 0.7, 95% CI 0.5 to 1.1).</P>
<P>3. DOSES: 3. STANDARD HIGHER DOSE (&gt; 7.5 to 15 mg/day) versus OTHER DOSES</P>
<P>3.1 Mortality<BR/>Only one small study (n = 20), comparing standard higher dose with very high dose (&gt; 35 mg/day), reported on death stating that none had occurred (<LINK REF="STD-Neborsky-1981" TYPE="STUDY">Neborsky 1981</LINK>).</P>
<P>3.2 Leaving the study early<BR/>Two studies comparing standard higher dose with very high dose reported early study attrition (between 3 and 14 days). There was no clear difference between groups (n = 83, 2 RCTs, RR 0.72, 95% CI 0.3 to 2).</P>
<P>Several studies reported study attrition between 2 and 10 weeks. There was no clear difference between the standard higher dose group and standard lower dose (&gt; 3 to 7.5 mg/day) (n = 64, 2 RCTs, RR 8.31, 95% CI 0.5 to 146), high dose (&gt; 15 to 35 mg/day) (n = 208, 5 RCTs, RR 0.78, 95% CI 0.4 to 1.4), or very high dose (&gt; 35 mg/day) (n = 74, 2 RCTs, RR 0.62, 95% CI 0.3 to 1.5).</P>
<P>3.3 Global state<BR/>One study comparing standard higher dose with very high dose reported early appraisal of global state (between 3 and 14 days). There was no clear difference between groups (n = 20, 1 RCT, RR no significant global improvement 3.0, 95% CI 0.4 to 24).</P>
<P>A series of small trials, even when combined, showed no difference for the outcome of 'no significant global improvement' when standard higher dose was compared with standard lower dose (n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.7), high dose (n = 126, 3 RCTs, RR 1.17, 95% CI 0.8 to 1.8), or very high dose (n = 58, 1 RCT, RR 1.29, 95% CI 0.8 to 2). Mean change scores were equally equivocal. The numbers of people needing additional sedation were essentially the same when standard higher dose was compared with high dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high dose (n = 58, 1 RCT, RR 1.43, 95% CI 0.6 to 3).</P>
<P>3.4 Mental state/behaviour<BR/>Early appraisal of psychotic symptoms (between 3 and 14 days) was undertaken in the one study that compared standard higher dose with very high dose. There was no clear difference between groups (n = 20, 1 RCT, RR no significant response in psychotic symptoms 3.0, 95% CI 0.4 to 24).</P>
<P>
<LINK REF="STD-Rifkin-1991" TYPE="STUDY">Rifkin 1991</LINK> reported on agitation between 2 and 10 weeks, but showed no differences between standard higher dose and high dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high dose (n = 58, 1 RCT, RR 1.43, 95% CI 0.6 to 3).</P>
<P>3.5 Adverse effects<BR/>None of the comparisons found differences in the few adverse effects reported. Acute dystonia was no more common in those allocated standard higher dose than in people given very high dose (n = 63, 1 RCT, RR 0.69, 95% CI 0.4 to 1.2). Neither were clinically significant extrapyramidal effects clearly more common for people taking standard higher dose than those given standard lower dose (n = 64, 2 RCTs, RR 8.3, 95% CI 0.5 to 146). Mean change scores for extrapyramidal effects were also equivocal.</P>
<P>Finally, only one study reported on postural hypertension (n = 63) (<LINK REF="STD-Donlon-1980" TYPE="STUDY">Donlon 1980</LINK>). It found no difference between people taking standard higher dose compared with people taking very high dose (RR 0.7, 95% CI 0.03 to 16).</P>
<P>4. DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES</P>
<P>4.1 Leaving the study early<BR/>No differences were apparent when high dose was compared with standard lower (&gt; 3 to 7.5 mg/day) (n = 144, 3 RCTs, RR 1.63, 95% CI 0.9 to 2.8), standard higher (&gt; 7.5 to 15 mg/day) (n = 208, 5 RCTs, RR 1.28, 95% CI 0.7 to 2.4), and very high doses (&gt; 35 mg/day) (n = 312, 5 RCTs, RR 1.04, 95% CI 0.7 to 1.6).</P>
<P>4.2 Global state<BR/>Even combination of several studies found no differences when high dose was compared with standard lower dose (n = 81, 2 RCTs, RR 1.06, 95% CI 0.8 to 1.3), standard higher dose (n = 126, 3 RCTs, RR 0.85, 95% CI 0.6 to 1.3), and very high dose (n = 255, 4 RCTs, RR 0.92, 95% CI 0.8 to 1.1). Change scores also found no clear differences when high dose was compared with standard higher dose and very high dose. The risk of needing additional sedation was greater for people given high dose compared with standard lower dose (n = 144, 3 RCTs, RR 1.40, 95% CI 1.1 to 1.8, NNTH 3, 95% CI 2 to 6). No differences were apparent when high dose was compared with standard higher dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), and very high dose (n = 115, 2 RCTs, RR 1.07, 95% CI 0.7 to 1.7).</P>
<P>4.3 Mental state/behaviour<BR/>For the outcome of 'no clinically important change in psychotic symptoms' there were no differences for those given high doses compared with people allocated either standard higher dose (n = 20, 1 RCT, RR 0.71, 95% CI 0.3 to 1.5), or very high dose (n = 92, 1 RCT, RR 1.57, 95% CI 0.8 to 3.1). Agitation was equally common for people given high doses versus those allocated standard lower dose (n = 65, 1 RCT, RR 1.08, 95% CI 0.8 to 1.5), standard higher dose (n = 20, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high doses (n = 115, 2 RCTs, RR 1.07, 95% CI 0.7 to 1.7). Mean scores were also equivocal. Although sustained high doses of haloperidol are extensively used to treat agitation in acute phases of schizophrenia (<LINK REF="REF-Baldessarini-1988" TYPE="REFERENCE">Baldessarini 1988</LINK>), there were no statistically significant differences between the dose ranges in studies that reported on this important outcome. However, there were few studies that examine this outcome.</P>
<P>It should be emphasised that this review does not have any information regarding the benefits and tolerability of 'as needed' doses of antipsychotics. For this, readers should examine the findings from a complementary Cochrane review (<LINK REF="REF-Whicher-2002" TYPE="REFERENCE">Whicher 2002</LINK>).</P>
<P>4.4 Adverse effects<BR/>High doses resulted in more extrapyramidal adverse effects than standard lower dose (n = 144, 3 RCTs, RR 1.7, 95% CI 1.3 to 2.2, NNTH 3, 95% CI 2 to 6), but the same levels as very high doses (n = 134, 2 RCTs, RR 1.03, 95% CI 0.7 to 1.4). Change scores in ratings of extrapyramidal effects were, compared with standard higher dose and very high doses, equivocal and uninformative. More people allocated to high doses needed drugs to counter parkinsonism symptoms compared with standard lower dose (n = 144, 3 RCTs, RR 1.7, 95% CI 1.3 to 2.2, NNTH 3, 95% CI 2 to 6). Compared with very high doses people given high dose did not need more antiparkinsonism drugs (n = 114, 2 RCTs, RR 1.13, 95% CI 0.9 to 1.4). Akathisia was as common for people allocated to high dose as people allocated to very high dose (n = 57, 1 RCT, RR 0.71, 95% CI 0.4 to 1.4).</P>
<P>5. DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES</P>
<P>5.1 Mortality<BR/>Only one small study (n = 20), comparing standard higher dose (&gt; 7.5 to 15 mg/day) with very high dose, reported on mortality, stating that none had occurred (<LINK REF="STD-Neborsky-1981" TYPE="STUDY">Neborsky 1981</LINK>).</P>
<P>5.2 Leaving the study early<BR/>Two studies comparing very high dose with standard higher dose reported on early study attrition (between 3 and 14 days). There was no clear difference between groups (n = 83, 2 RCTs, RR 1.4, 95% CI 0.5 to 4).</P>
<P>Several studies reported study attrition between 2 and 10 weeks. There was no clear difference between the very high dose group and standard lower dose (&gt; 3 to 7.5 mg/day) (n = 86, 2 RCTs, RR 1.42, 95% CI 0.6 to 3.2), standard higher dose (n = 74, 2 RCTs, RR 1.62, 95% CI 0.7 to 4), or high dose (&gt; 15 to 35 mg/day) (n = 312, 5 RCTs, RR 0.96, 95% CI 0.6 to 1.5).</P>
<P>5.3 Global state<BR/>One study comparing very high dose with standard higher dose reported early appraisal of global state (between 3 and 14 days). There was no clear difference between groups (n = 20, 1 RCT, RR no significant global improvement 0.33, 95% CI 0.04 to 3).</P>
<P>For the outcome of 'no global improvement between 2 and 10 weeks', no clear differences were found when very high dose was compared with standard higher dose (n = 58, 1 RCT, RR 0.78, 95% CI 0.5 to 1.3), and high dose (n = 255, 4 RCTs, RR 1.09, 95% CI 0.9 to 1.3). Mean change scores comparing very high dose with standard higher dose and high dose were equally equivocal. The numbers of people needing additional sedation were essentially the same when very high dose was compared with standard higher dose (n = 58, 1 RCT, RR 0.7, 95% CI 0.3 to 1.6) or high dose (n = 115, 2 RCTs, RR 0.94, 95% CI 0.6 to 1.5).</P>
<P>5.4 Mental state/behaviour<BR/>Very high doses were no different to any other doses for various measures of mental state/behaviour. For the outcome of 'no clinically important change in psychotic symptoms between three days and two weeks', very high doses were not clearly different to standard higher doses (n = 20, 1 RCT, RR 0.33, 95% CI 0.04 to 2.7). This applied equally well to later changes in psychotic symptoms when very high doses were compared with high dose (n = 92, 1 RCT, RR 1.18, 95% CI 0.9 to 1.5). Mean change scores on rating of mental state were also equivocal for a comparison of very high dose versus high dose. Finally, agitation was equally common for people given very high dose when compared with both standard higher dose (n = 58, 1 RCT, RR 0.7, 95% CI 0.3 to 1.6) and high dose (n = 115, 2 RCTs, RR 0.94, 95% CI 0.6 to 1.5).</P>
<P>5.5 Adverse effects<BR/>Acute dystonia was as common for people allocated very high dose as for people given standard higher dose (n = 63, 1 RCT, RR 1.45, 95% CI 0.9 to 2.5). However, when compared with standard lower dose, very high doses did not cause more clinically significant extrapyramidal adverse effects (n = 86, 2 RCTs, RR 1.42, 95% CI 0.9 to 2.2). When very high dose was compared with high dose, studies found no clear difference (n = 114, 2 RCTs, RR clinically significant extrapyramidal adverse effects 0.97, 95% CI 0.7 to 1.4). Mean scores where very high doses were compared with standard higher dose or high dose, were equivocal and uninformative. Use of drugs to counter parkinsonism symptoms was as common for people allocated very high dose as for people given standard lower doses (n = 70, 1 RCT, RR 1.25, 95% CI 0.8 to 2) and high dose (n = 114, 2 RCTs, RR 0.89, 95% CI 0.7 to 1.1). Akathisia was common, but no more so for people taking very high dose compared with high dose (n = 57, 1 RCT, RR 1.4, 95% CI 0.7 to 2.7). Finally, postural hypotension was not common and had the same risk of occurrence for people taking very high dose and those given standard higher dose (n = 63, 1 RCT, RR 1.43, 95% CI 0.1 to 34).</P>
<P>6. PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS</P>
<P>6.1 Leaving the study early<BR/>Low plasma levels resulted in fewer people leaving the studies early when compared with medium plasma levels (&gt; 7.0 to 16.5 ng/mL), but this did not quite reach conventional levels of statistical significance (n = 138, 2 RCTs, RR 0.61, 95% CI 0.4 to 1.1). There was no difference when low plasma levels were compared with high levels (&gt; 16.5 ng/mL) (n = 70, 1 RCT, RR 0.96, 95% CI 0.4 to 2.4).</P>
<P>6.2 Global state<BR/>One study monitored 'no clinically significant improvement in global state' (n = 65) and, when low plasma levels were compared with medium levels, the trialists found no difference (RR 0.8, 95% CI 0.3 to 1.9) (<LINK REF="STD-Volavka-1995" TYPE="STUDY">Volavka 1995</LINK>).</P>
<P>6.3 Adverse effects<BR/>Low plasma levels resulted in fewer clinically significant extrapyramidal effects than medium levels (n = 138, 2 RCTs, RR 0.63, 95% CI 0.5 to 0.8, NNTH 3, 95% CI 2 to 7). When low plasma levels were compared with high plasma levels, no differences were found (n = 70, 1 RCT, RR 0.8, 95% CI 0.5 to 1.2).</P>
<P>7. PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS</P>
<P>7.1 Leaving the study early<BR/>Compared with very low plasma levels (&gt; 1.4 to 3.5 ng/mL), medium levels did not clearly promote study attrition (n = 128, 2 RCTs, RR 1.63, 95% CI 0.9 to 3). This also applied to comparisons with high plasma levels (&gt; 16.5 ng/mL), although results were heterogeneous (n = 149, 2 RCTs, RR 1.1, 95% CI 0.6 to 2.1, heterogeneous P value = 0.074).</P>
<P>7.2 Global state<BR/>Medium plasma levels did not produce different rates of global improvement when compared with either very low plasma levels (&gt; 1.4 to 3.5 ng/mL) (n = 65, 1 RCT, RR 0.80, 95% CI 0.3 to 1.9) or high plasma levels (n = 92, 1 RCT, RR 1.57, 95% CI 0.8 to 3.1).</P>
<P>7.3 Adverse effects<BR/>Clinically significant extrapyramidal adverse effects were more common for people with medium plasma levels compared with people with very low plasma levels (n = 128, 2 RCTs, RR 1.59, 95% CI 1.2 to 2.1, NNTH 3, 95% CI 2 to 7). There was no clear difference for those in a medium plasma level group compared with the high plasma level group (n = 59, 1 RCT, RR 1.28, 95% CI 0.9 to 1.8).</P>
<P>8. PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS</P>
<P>8.1 Leaving the study early<BR/>Compared with very low plasma levels (&gt; 1.4 to 3.5 ng/mL), high plasma levels did not affect study attrition (n = 70, 1 RCT, RR 1.04, 95% CI 0.4 to 2.6). There was no difference between medium plasma levels (&gt; 7 to 16.5 ng/mL) and high plasma levels (n = 149, 2 RCTs, RR 0.91, 95% CI 0.5 to 1.7, heterogeneous P value = 0.074).</P>
<P>8.2 Global response<BR/>One small study (n = 92) reported that there was no difference for those allocated to high levels compared with medium plasma levels (RR 1.18, 95% CI 0.9 to 1.5).</P>
<P>8.3 Adverse effects<BR/>Over half of those given haloperidol, irrespective of plasma level, had significant extrapyramidal effects (high levels versus very low levels: n = 70, 1 RCT, RR 1.25, 95% CI 0.8 to 2; high levels versus medium levels: n = 59, 2 RCTs, RR 0.8, 95% CI 0.5 to 1.1).</P>
<P>9. Sensitivity analyses<BR/>We stated that we would undertake a sensitivity analysis on diagnostic criteria and quality as measured by the Jadad Scale. These are not as yet complete, but are unlikely to change the results. There are no data to undertake analyses separately for people in their first episode of illness.</P>
<P>10. Publication bias<BR/>There were an insufficient number of trials per comparison (maximum of five trials) to conduct a valid funnel plot to examine for possible publication bias.</P>
<P>11. Funnel plots<BR/>Meaningful plots could not be created with so few trials in each outcome.</P>
<P> </P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-06-24 21:42:45 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-01-29 12:25:29 +0000" MODIFIED_BY="[Empty name]">Past differences between protocol (2002) and full review of same year</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-24 21:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>Aspects of the protocol were altered during the course of completing the review,<BR/>
<BR/>1. We added more clarification regarding how to combine plasma dose studies with oral dose studies (see Methods Section 6).<BR/>
<BR/>2. We added an additional search strategy to increase the probability of identifying relevant studies by considering other Cochrane reviews involving haloperidol for potential studies for inclusion. We contacted authors of these reviews for any other potential studies identified in their search strategies.<BR/>
<BR/>3. At the time of formulation of the study protocol there were limited data regarding an oral dose range that reflected 60% to 80% blockade of dopamine D<SUB>2</SUB> receptors, a range thought to be both efficacious and relatively free of side effects (<LINK REF="STD-Kapur-2000" TYPE="STUDY">Kapur 2000</LINK>). An additional dose range was inserted (&gt; 1.5 to 3 mg/day) to reflect this new research and to enable testing of this hypothesis using data from randomised trials included in this review.<BR/>
<BR/>4. We changed the minimum duration of a study to be included in this review from any duration to at least 3 days to minimise overlap with another Cochrane review (<LINK REF="REF-Whicher-2002" TYPE="REFERENCE">Whicher 2002</LINK>). This review is examining these short term outcomes in more detail. We also considered that studies of very short duration may have systematically different dose response relationships when compared with studies with longer durations due to their focus on the dimension of acute agitation. Thus, it was not logical to pool them with studies of longer duration.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 of studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;548 of full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1249 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 of records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1249 of records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 of additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;701 of records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;532 of full-text articles excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 of studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;73 of full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1494 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1494 of records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;1494 of records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1421 of records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;6 full-text articles were excluded, a further 64 were found to be either included or excluded in origional study. &lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>